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Kaposi’s sarcoma-associated herpesvirus (KSHV), a gamma-herpesvirus with a particularly high 
seroprevalence in Sub-Saharan Africa (SSA), is the etiological agent of the endothelial tumour Kaposi’s 
sarcoma (KS), the most common acquired immunodeficiency syndrome (AIDS)-related malignancy 
worldwide and particularly in SSA. It also causes primary effusion lymphoma (PEL), multicentric 
Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KICS). AIDS-related deaths have 
declined, due to global scale-up of antiretroviral therapy (ART). However, the vast majority of these 
occurred in SSA, where tuberculosis (TB) is the leading cause of mortality among human 
immunodeficiency virus (HIV)-infected individuals, accounting for a third of all AIDS-related deaths. 
The exceptionally high burden of suspected TB in SSA causes misdiagnosis or delayed diagnosis of 
diseases mimicking TB, such as several pathologies associated with KSHV. KSHV infection is essential 
but insufficient for the development of KS and other KSHV-associated pathologies; precipitating 
factors, such as HIV-related immune suppression and potentially genetic predisposition, are required. 
The erythropoietin-producing hepatocellular carcinoma (Eph) receptor A2 protein (EPHA2) tyrosine 
kinase receptor is a promising candidate for studies on genetic variants as it potentially acts on two 
levels: susceptibility to KSHV infection (being one of the key receptors utilised by KSHV for cell entry 
and intracellular trafficking) and susceptibility to KS development (being implicated in oncogenesis). 
Despite the high seroprevalence in SSA, the contribution of dysregulated KSHV lytic replication 
or host KSHV receptor variations to disease outcome in HIV-infected patients is unknown. We 
hypothesised that KSHV lytic reactivation plays yet unrecognised roles for morbidity and mortality in 
high HIV settings and to this end, we conducted a cohort study of 682 HIV-positive critically ill patients 
admitted to Khayelitsha Day Hospital, South Africa, investigated for TB, and followed for 12-weeks to 
ascertain vital status. We demonstrated that elevated blood KSHV viral load (VL) was a strong 
predictor of death in hospitalised HIV-infected patients without microbiologically proven TB. Further, 
we identified and validated variants in the EPHA2 protein tyrosine kinase and sterile alpha motif 
domains that were significantly associated with susceptibility to infection, KS development and/or 
KSHV VL in 300 South African HIV-infected patients, by aggregate by-gene analysis. In order to 
elucidate the functional significance of the identified EPHA2 missense mutations, we knocked out 
endogenous EPHA2 by CRISPR/Cas9 in the human endothelial cell line, HuARLT2, and reintroduced 
the wild type and mutant EPHA2 open reading frames by lentiviral transduction. These engineered 
cells were assessed for baseline EPHA2 phosphorylation levels and susceptibility to KSHV infection 
utilising recombinant KSHV in binding, internalisation and infection assays. We found that the EPHA2 




cohort, was deficient in tyrosine phosphorylation and less permissive to rKSHV infection when 
introduced as a single mutation or as a double mutant together with c.2257A>C (p.Asp701Ala) which 
was found to be in linkage disequilibrium with it. Another tyrosine kinase domain variant, c.2688G>S 
(p.Ala845Pro), found to be overrepresented among KS patients, had enhanced baseline tyrosine 
phosphorylation levels. These findings validated the patient-derived data on the molecular level by 
assigning functional consequences to some mutants which might have implications for the 
development of future biomarkers predicting KS susceptibility in high-risk populations.   
In summary, this novel research contributes to the understanding of KSHV-associated pathology 
and disease outcome. It identified KSHV VL as a potential biomarker to predict KSHV-associated 
diseases and mortality and assessed the contribution of KSHV entry receptor EPHA2 variations to 
KSHV-associated pathologies, with potential clinical implications, by facilitating the development of 






1. Introduction  
Kaposi’s sarcoma-associated herpesvirus (KSHV, or human herpesvirus-8) is a gamma-herpesvirus 
with a particularly high seroprevalence (30–50%) in Sub-Saharan Africa (SSA). It is the etiological agent 
of the most common acquired immunodeficiency syndrome (AIDS)-related malignancy, Kaposi’s 
sarcoma (KS) [1], as well as the rare (although most certainly under-reported [2]) primary effusion 
lymphoma (PEL), multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome 
(KICS) which all primarily occur in human immunodeficiency virus (HIV)-infected patients (see 1.3) [3–
8]. Exposure to and infection with KSHV is thought to occur early in life via saliva [9], whereupon the 
virus establishes long-term persistent infection which can, particularly in the context of HIV co-
infection, lead to the development of KSHV-associated pathologies (see 1.2.3 and 1.2.4) [10]. 
The increasing number of HIV-infected individuals on long-term antiretroviral therapy (ART) 
has led to a global shift in the proportion of deaths from AIDS-defining malignancies, such as KS, and 
communicable conditions, such as tuberculosis (TB), towards chronic non-communicable conditions, 
such as cardiomyopathy (see 1.1.1) [11,12]. Yet, in SSA, TB is still the leading cause of mortality among 
HIV co-infected individuals, claiming more than a third of all AIDS-related deaths [13]. Unsurprisingly, 
the high number of patients presenting with suspected TB in South Africa has led to overdiagnosis and 
overtreatment, and associated delay in diagnosis of cancers such as lymphoma and lung cancer given 
their clinical similarities to TB (see 1.1.2) [14–17]. These include nonspecific symptoms such as 
lymphadenopathy, fever, weight loss, chest pain and night sweats [15].  
KSHV-associated diseases may also mimic TB symptoms. While primary infection among 
immunocompetent individuals is often asymptomatic, the development of KSHV-related malignancies 
is generally associated with immunosuppression [1]. KS often presents as cutaneous disease, with 
KSHV-infected endothelial cells as the predominant cell type [18], but advanced visceral disease with 
limited or no cutaneous involvement may occur (see 1.3.1) [19]. Both PEL and MCD are 
lymphoproliferative disorders caused by KSHV-infected B-cells (see 1.3.2 and 1.3.3) [18]. The cell type 
implicated in KICS is unknown and the syndrome presents with nonspecific and severe inflammatory 
symptoms characterised by high KSHV viral load (VL) and host and viral interleukin-6 (IL-6) (see 1.3.4) 
[20]. KSHV can exhibit latent and lytic infection phases which are characterised by distinct viral gene 
expression patterns in both cell types (see 1.2.3) [21,22]. In KS and PEL, KSHV predominantly expresses 
a limited number of latent phase genes [18,23,24], and KS patients generally do not have elevated 
KSHV VL in the blood [8,25]. In contrast, lytically active KSHV in MCD and KICS leads to a broader range 
of viral gene expression [23] that contributes to pathogenesis [5,8]. Indeed, KSHV VL is significantly 




characterised by an overproduction of host IL-6, KSHV-encoded viral IL-6 (vIL-6) and other cytokines, 
giving rise to severe inflammatory symptoms such as fever, wasting, hypoalbuminemia, cytopenia, 
hyponatremia and elevated C-reactive protein (CRP) [7,8]. 
Untreated MCD and KICS have high mortality [6–8,26], and a working case definition of KICS 
has been proposed that may serve as a surveillance tool for individuals with HIV/KSHV co-infection 
[6]. While KICS is a proposed clinical diagnosis requiring exclusion of MCD [6] and other serious 
intercurrent infections [6,8], MCD is diagnosed by histologic confirmation of KSHV-positive staining of 
plasmablastic cells in the mantle zone of lymph nodes (see 1.3.3.3) [27]. It has been proposed that 
KICS contributes to the inflammatory symptoms seen in some patients with severe KS or PEL [6]. KICS 
in the absence of a KSHV-associated malignancy has also been reported [6,8]. Rituximab is a highly 
effective therapy for MCD, while management of KICS is primarily directed at treating associated 
malignancies (see 1.3). More research on dysregulated KSHV lytic reactivation is urgently needed in 
order to better understand these conditions and to identify additional treatments to improve 
outcomes [2]. 
Although HIV-related immune suppression is important for the development of KSHV-
associated pathologies, not all co-infected individuals develop a disease pointing to a potential 
underlying genetic predisposition which has been particularly discussed in the context of KS 
development (see 1.5) [28–30]. While studies have primarily focused on association with immune-
modulatory genes [31–33], we recently identified variants in the erythropoietin-producing 
hepatocellular carcinoma (Eph) receptor A2 protein (EPHA2) receptor tyrosine kinase (RTK) that were 
associated with KSHV infection and KS development, respectively, in HIV-infected South Africans (see 
1.6.6) [34,35]. EPHA2 is a major receptor for KSHV entry and intracellular trafficking (see 1.6.4) [36]. 
Moreover, EPHA2 signalling plays a role in oncogenesis (see 1.6.3) [36–38], thus potentially acting at 
the level of both susceptibility to KSHV infection and susceptibility to KS development. Research into 
altered host factors modulating KSHV infection is still in its infancy, and EPHA2 may be a potential 
novel biomarker to predict the development of KSHV-associated diseases.  
While KS has been well established as an independent risk factor for death in HIV-infected 
people, a broader range of KSHV-associated diseases with lytic syndromes, particularly in the context 
of a high-burden HIV/TB setting, may play a yet unrecognised role in HIV-associated morbidity and 
mortality in SSA. It is therefore important that KSHV research continues, both due to the overlapping 
clinical features of KSHV-associated diseases with TB as well as their persistent occurrence in the era 
of ART. Correct diagnosis and identification of patients at risk for development and/or progression of 




preventative and therapeutic interventions and to predict the development of clinical disease. 
Furthermore, it is imperative to identify and evaluate biomarkers for KSHV-associated diseases, in 
order to accelerate the development of relevant tools for this most at-risk population.  
 
1.1. The HIV epidemic in the age of ART 
The burden of the HIV epidemic falls disproportionately on SSA where 63.5% of global new infections 
occurred in 2018. The World Health Organisation (WHO) estimates that 37.9 million (32.7 million–44.0 
million) people are HIV-positive, 15% more than the 33 million estimated a decade ago [39,40]. 
However, the number of HIV-infected people progressing to AIDS, the most advanced stage of HIV 
infection defined by the appearance of AIDS-defining diseases (such as toxoplasmosis of the brain, 
candidiasis of the oesophagus and KS) or a cluster of differentiation (CD)4-positive T-cell count less 
than 200 cells/µl, has concomitantly decreased [40,41]. This represents the lives saved due to the 
introduction of ART, and particularly highly active antiretroviral therapy (HAART) [41], which has 
drastically reduced AIDS-related mortality and shifted HIV from a terminal to a chronic disease [42]. 
However, the improved HIV survival rate has resulted in increased prevalence of HIV-associated 
malignancies, other non-communicable diseases and co-infections, again particularly burdening SSA 
[43–46]. 
HIV-associated malignancies include the AIDS-defining cancers, KS, non-Hodgkin lymphoma 
and cervical cancer, caused by KSHV, Epstein-Barr virus (EBV) and human papillomaviruses (HPV), 
respectively. Other cancers caused by oncogenic infectious agents have additionally increased in 
prevalence, such as Hodgkin’s lymphoma caused by EBV, anogenital, oral and oropharyngeal cancers 
caused by HPV, hepatitis B virus and hepatitis C virus-related liver cancer and stomach cancer caused 
by Helicobacter pylori infection, in developed countries [43] however this increased risk is less clearly 
established in studies from Southern Africa [46,47]. HIV co-infection with the mentioned infectious 
agents likely enhances the risk of cancer as immune suppression is a promoting factor for oncogenesis. 
Therefore, cancers caused by infectious agents have become an important public health concern in 
the ART era as a complication of chronic HIV infection [10,43,47–49].  
HIV infection, as well as ART, are known to exacerbate a number of non-communicable 
diseases such as cardiovascular and pulmonary diseases and diabetes in the context of certain lifestyle 
factors linked to urbanisation and ageing [50,51]. Cardiomyopathy (prevalence of 5–29%) and 
hypertension (prevalence of 11–28%) are highlighted as the most important cardiovascular diseases 




have hindered thorough epidemiological assessment of other cardiovascular and pulmonary diseases 
such as coronary artery disease, stroke, obstructive lung disease and pulmonary arterial hypertension, 
all of which are proposed to have an increased risk in HIV-positive populations [51]. HIV-positive 
patients have increased likelihood of dysglycaemia, especially those on efavirenz and protease 
inhibitors [52,53], and it has been postulated that type 2 diabetes in the context of HIV infection may 
further increase the risk for the development of pathogen-associated malignancies [12]. 
The introduction of ART has led to a reduction of risk for all HIV-related opportunistic 
infections, the key reason for the worldwide decline in HIV-related deaths, but pulmonary and 
extrapulmonary TB, cryptococcal meningitis and oral candidiasis remain the most common HIV-
related opportunistic infectious diseases in SSA in the ART era [54].  
 
1.1.1. Mortality in the context of HIV 
Most recent data from The Joint United Nations Programme on HIV and AIDS (UNAIDS) indicates that 
while AIDS-related deaths have declined from an estimated 1.7 million (1.3 million–2.4 million) in 2004 
to 770,000 (570,000–1.1 million) in 2018, due to global scale-up of ART, the vast majority of these 
(61%) occurred in SSA [40]. In the ART era, TB is still the leading cause of mortality among HIV co-
infected individuals, claiming more than a third of all AIDS-related deaths [13,40]. HIV-associated TB 
case fatality rates in hospitalised patients in high-burden settings are between 11–32% [55–61]. 
However, diagnosis of HIV-related TB, particularly disseminated TB, remains a challenge despite 
improved diagnostic assays such as urine Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF) 
and urine lipoarabinomannan (LAM) assays [60,61] and approximately 18–25% of patients treated for 
TB have microbiologically unconfirmed diagnoses (see 1.1.2) [57,62]. 
 
1.1.2. Misdiagnosis of TB 
In 2017, 10 million people were diagnosed with active TB while about 23% of the global population 
(1.7 billion) is estimated to have latent TB and 5–10% of those latently infected will develop active TB 
at some point in their lives. In the context of HIV infection, people living with latent TB are up to 
20-times more likely to fall ill [63]. About one-third of the 37.9 million HIV-positive people worldwide 
are co-infected with TB, the major burden of this falling on SSA: in 2018, the incidence of HIV-positive 
TB in Africa was 615,000 cases, accounting for 71% of HIV-positive TB incidence globally [64]. 




diagnosis has led to overdiagnosis and overtreatment, and associated delay in diagnosis of cancers 
such as lymphoma and lung cancer given their clinical similarities to TB [14–17]. These include 
nonspecific symptoms such as lymphadenopathy, fever, weight loss, chest pain and night sweats [15]. 
Studies conducted in HIV-burdened countries (South Africa, Malawi and Uganda) on misdiagnosis of 
lymphoma as TB indicate that mean delay in correct diagnosis while on TB treatment is 3.5–5 months 
[14,15,17] and a significant proportion of patients die without a confirmed diagnosis [55].  
 
1.2. KSHV  
1.2.1. Epidemiology 
KSHV prevalence varies geographically with the highest prevalence in general adult populations in SSA 
(seroprevalence 30–50%) and the Mediterranean region (20–30%) and low prevalence in Western and 
Northern Europe, Asia and North and South America (5–10%) [65–67]. Higher prevalence has been 
noted in people who have certain behavioural risk factors, such as men who have sex with men (20–
40%) in the United States of America (USA) and Northern Europe [68,69], or people of specific 
ethnicities regardless of HIV infection, such as Uganda (14–86%) and the Ivory Coast (43–100%) where 
there is risk for endemic KS, and the Mediterranean region (20–30%), at risk for classic KS (see 1.3.1.1) 
[67,70]. In HIV-infected people in the USA on ART, prevalence was 38% [71].  
KSHV prevalence in South Africa has been investigated in only a few epidemiological studies. 
Sitas et al. [72] reported KSHV seroprevalence of 32% among black patients with cancers other than 
KS and similarly high levels among black blood donors but not white blood donors (5%) in Soweto and 
Johannesburg. Similarly, another study reported 35% KSHV seroprevalence among a rural black 
population in Kwa-Zulu Natal province in which adult medical ward patients were found to have 
extremely elevated KSHV seroprevalence (58%) [73]. Both studies found that KSHV seroprevalence 
increased with age with as high as a two-fold increase in seroprevalence in the >65 age group 
compared to the 15–24 age group but did not differ between sexes [72,73].  
  Of particular public health concern in South Africa are these elevated levels of KSHV together 
with high HIV prevalence which ranges from 13% in the Western Cape province to 27% in KwaZulu-
Natal province [74]. A cross-sectional study in HIV-infected patients initiating ART in Johannesburg 
reported an even higher incidence (42%) [75]. Our previous study found KSHV seroprevalence among 





1.2.2. Structure and classification of KSHV 
KSHV is a γ2 herpesvirus of the genus Rhadinovirus [76]. KSHV virions, with an average diameter of 
100 nm, consist of a double-stranded deoxyribose nucleic acid (DNA) genome encased in a capsid, a 
tegument and a glycoprotein containing lipid envelope (Figure 1A), resembling the structure of other 
herpesviruses like EBV [10,77–79]. The KSHV envelope contains unique glycoproteins K8.1A, ORF4, 
ORF45 and ORF68 in addition to herpesvirus conserved gB, gH, gL, gM and gN [80–83]. In particular, 
K8.1, gB and a gH-gL complex play essential roles in KSHV entry (see 1.2.3.2) [84–87]. The 
approximately 140 kb DNA genome encodes 87 open reading frames (ORF), the majority of which are 
common to herpesviruses while 20 so-called ‘K genes’ are unique. KSHV encodes at least 14 cellular 
orthologues pirated from human genes, characteristic of rhadinoviruses, and 17 viral microRNAs 
(miRNAs) [67,85]. The KSHV episome contains a latency-associated region encoding transcripts that 
characterise the KSHV latent cycles, while lytic transcripts are encoded on the remainder of the 
episome (see 1.2.3 and Figure 1B) [67]. A number of latency-associated genes are oncogenes, such as 
latency-associated nuclear antigen (LANA), viral-encoded Cyclin (vCyclin) and viral FADD-like 
interleukin-1-converting enzyme (FLICE) inhibitory protein (vFLIP) (see 1.2.4) [67]. 
Based on variability in the KSHV K1 gene sequence, KSHV has been classified into 7 major 
subtypes: A, B, C, D, E, F and Z [88]. The different subtypes have been shown to have variable 
penetrance in various population groups and are distributed along broad geographic and ethnic lines, 
and it has been proposed that different genotypes may have different pathogenic and tumorigenic 
properties [89]. Subtypes B and A5 have been suggested to predominate in SSA [88,90,91] while 
subtypes F and E are found particularly in Uganda and Brazil, respectively. Subtypes A, C and D are 
found more broadly in the Americas and Northern Europe, the USA and Eurasia and Asia, respectively 
[89,92,93].  
 
1.2.3. KSHV lifecycle 
1.2.3.1. Transmission  
KSHV transmission primarily occurs via infection-capable virions shed in saliva with the major routes 
of infection thought to be from mother to child [9,94–96]. KSHV isolated from throat wash samples is 
capable of productively infecting oral epithelial cells in vitro, likely representing initial infection 
following exposure [97]. Other body fluids may also contain detectable KSHV, such as blood, breast 






Figure 1: KSHV structure. A) The KSHV virion consists of its linear, double stranded DNA genome, 
encapsulated by a capsid, tegument and lipid envelope. Glycoproteins are embedded in the 
envelope and those essential for KSHV entry are depicted here. B) In the host nucleus following 
KSHV infection, the KSHV genome occurs as an episome as depicted. Latent genes are indicated 
in green, early lytic genes in red, late lytic genes in blue, miRNAs in purple and cellular 








1.2.3.2. KSHV entry 
KSHV entry is schematically represented in Figure 2. Initially, envelope glycoproteins gB, K8.1A and 
gH-gL interact with heparan sulphate proteoglycans (HSPG) which occur ubiquitously on the target 
cell surface [10,86,87,104,105]. This initial attachment facilitates concentration of the virus on the cell 
surface and is thought to occur in a redundant manner as HSPGs are not essential but do enhance viral 
entry [105].  
Subsequently, KSHV binds to various cellular entry receptors dependent on the target cell type 
which allows KSHV its wide host cell tropism. There is evidence that KSHV-HSPG binding triggers 
formation of a lipid raft in the host cell membrane consisting of the cell-dependent combination of 
entry receptors, including HSPG, various integrins and receptors and the glutamate/cysteine exchange 
transporter xCT [10,106,107]. KSHV gB binds the integrins α3β1, αVβ3, αVβ5 and αVβ1 [106,108–112] 
and/or dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) [112–
114] dependent on target cell type (Table 1). The dimeric complex of viral gH-gL interacts with Eph 
receptors: EPHA2 on endothelial cells (Figure 2) and fibroblasts [36,115–117]; EPHA2, EPHA4 and 
EPHA5 on epithelial cells [36,115,116,118,119] and EPHA7 and to a lesser extent EPHA5 on B-cells 
(Table 1) [120]. Both gH-gL and EPHA2 have been shown to be essential for KSHV entry into endothelial 
cells while EPHA2 is not necessary for attachment, specifically mediating entry [121,122]. The viral 
binding partner of xCT is yet unknown [106,123]. Further, an integrin-independent route of infection 
requiring HSPG and the ectodomain of EPHA2 has been described in endothelial cells [119]. As 
infection is drastically reduced but not completely abrogated using EPHA2-binding-deficient mutant 
virus or upon inhibition of any specific binding receptors, it is likely that KSHV may further make use 
of alternative Eph receptors [107,115,119]. The functions of several glycoproteins have not yet been 
elucidated, but it is speculated that these have regulatory functions in vivo that are undetectable in 
vitro [107].  
Following specific binding of KSHV glycoproteins to target cell entry receptors, KSHV binding 
activates host signalling pathways extracellular signal-regulated kinase (ERK)/mitogen-activated 
protein kinase (MAPK) and focal adhesion kinase (FAK)/phosphoinositide 3-kinase (PI3K)/protein 
kinase C (PKC) which facilitate KSHV entry [124–126]. The downstream effector of ERK/MAPK, p90 
ribosomal S6 kinase 1 (RSK), has been shown to phosphorylate EPHA2 at Ser897, vital for KSHV 
infection, and it has been suggested that the androgen receptor (AR), via recruitment of Src, promotes 
this pathway and enhances KSHV infection [127]. KSHV enters cells utilising diverse endocytic 
pathways including clathrin- and caveolin-mediated endocytosis, macropinocytosis and undefined 




lineage lymphoma (c-Cbl) signalling via its tyrosine kinase domain (see 1.6.2.1) enabling endocytosis 
of KSHV via actin-dependent, dynamin-independent macropinocytosis [129]. Entry into fibroblasts is 
by clathrin-mediated endocytosis [117,129,130], into monocytes by clathrin- and caveolin-mediated 
endocytosis [112] while epithelial cell endocytosis is not clathrin-dependent [131] and B-cell 
endocytosis mechanisms have not been fully defined [114]. Thereafter, the viral envelope fuses with 
the membrane of the endosome, likely triggered by low pH as in other herpesviruses, and the capsid 
is released into the perinuclear region. The KSHV genome enters the nucleus via nuclear pores where 





Figure 2: A schematic representation of the entry mechanism of KSHV into endothelial cells. 
Viral entry consists of three stages. 1) Binding: initial attachment is mediated by the interaction 
of K8.1 and gB with heparan sulphate proteoglycans (HSPG). gB binds integrins which associate 
with xCT in a lipid raft. Subsequently, gH-gL binds EPHA2 which triggers 2) Entry: KSHV binding 
to EPHA2 triggers actin-dependent macropinocytosis of the virus into an endosome, the 
membrane of which subsequently fuses with the viral envelope releasing the capsid into the 






Table 1: Interaction of KSHV glycoproteins with cellular receptors on KSHV-susceptible cell types. 





Endothelial α3β1, αVβ3, αVβ5 
[106,108]  
EPHA2 [36,115,116] Actin-dependent, dynamin-
independent, macropinocytosis 
[129] 
Epithelial α3β1, αVβ3, αVβ5 
[106,109,110] 






Fibroblasts α3β1, αVβ3, αVβ5 
[106,108] 
EPHA2 [117] Clathrin-mediated endocytosis 
[117,129,130] 
Monocytes α3β1, αVβ3, αVβ5, 
αVβ1, DC-SIGN 
[112,113] 
 Clathrin- and caveolin-mediated 
endocytosis [112] 
Macrophages DC-SIGN [113]   
Dendritic 
cells 
DC-SIGN [113]   




1.2.3.3. Latent infection 
Characteristic of herpesviruses, KSHV soon establishes latency following initial, acute infection which 
allows KSHV to evade the immune system and establish a viral reservoir. The latency programme 
prioritizes host cell survival and proliferation. Latent proteins such as LANA, vCyclin, vFLIP, Kaposin A 
and B and viral miRNAs are expressed from the KSHV episome (Figure 1B) which persists in the host 
cell nucleus [67]. The episome is replicated during cell division, facilitated by LANA which directly links 
the KSHV episome to cellular chromosomes during mitosis [22,134]. Latency-associated genes 
facilitate KSHV persistence and are essential for oncogenesis (see 1.2.4). 
 
1.2.3.4. Lytic infection 
Expression of the KSHV lytic switch, replication and transcription activator (RTA), which is encoded by 




such as hypoxia, inflammation, oxidative stress and temporary or chronic immune suppression 
[22,135,136]. The lytic cycle facilitates the production of infectious KSHV virions and as such is 
cytopathic and no longer hidden from the host immune system. Early lytic transcripts (Figure 1B), such 
as DNA polymerase, drive KSHV episome replication into a linear, double-stranded DNA molecule that 
is packaged into a capsid during virion maturation [22,67]. Late lytic transcripts (Figure 1B) encode 
proteins necessary for structural assembly of the produced virions, such as capsid and tegument 
proteins [67]. In KS tumours, some spindle cells are lytically infected and express lytic transcripts, such 
as K1, K15, vIL-6, viral G protein-coupled receptor (vGPCR), viral-encoded B-Cell lymphoma 2 (vBCL-2), 
viral-encoded interferon response factors (vIRF) 1, 2 and 4 (vIRF3 is latently expressed) and 
viral-encoded C-C chemokine ligands (vCCL) that promote oncogenesis and thereby KS development 
(see 1.2.4).  
 
1.2.4. Oncogenesis 
KSHV infection in an immune-competent host is insufficient to induce oncogenesis but in the context 
of HIV infection and immune suppression, the interplay of latent and lytic infection can promote 
oncogenesis and lead to the development of KS and other KSHV-associated malignancies [21,137,138]. 
The majority of KS spindle cells express latent genes, but some are lytically infected [139,140]. After 
acute infection, KSHV establishes latent infection in endothelial cells during which the virus will persist 
but remain immune silent. Similarly, while cytopathic, lytic infection following a reactivation event will 
usually be controlled by an immunocompetent host [28]. However, immune suppression favours 
oncogenesis and results in loss of immune control of lytically infected cells [137]. Expression of lytic 
transcripts K1 and K15 drives a microenvironment of inflammation and angiogenesis that favours 
recruitments of target cells for re-infection [28].  
Following reactivation, KSHV-infected cells express lytic transcripts in endothelial cells (see 
1.2.3.4) leading to genomic instability and inhibition of DNA-damage response pathways. KSHV vIRFs 
1–4 inhibit interferon signalling (a vital host immune response to viral infection) and apoptotic 
pathways and disrupt a number of cell cycle regulatory pathways [141–146]. Importantly, vGPCR 
induces inflammatory and pro-angiogenic cytokines, IL-6, IL-8, angiopoietin 2 and vascular endothelial 
growth factor (VEGF) and also inhibits apoptosis via activation of the Akt/TSC/mammalian target of 
rapamycin (mTOR) pathway, MAPKs and nuclear factor kappa B (NFκB) [147–150]. Growth factors 
together with KSHV-expressed vIL-6 drive proliferation of latently infected cells in a paracrine manner 




proliferation and angiogenesis, inhibit apoptosis and drive the cancer phenotype. KSHV vCyclin 
counteracts cyclin-dependent kinase inhibitors, p21 and p27, to override the cell cycle restriction 
checkpoint before S phase [151]. LANA represses retinoblastoma protein and p53, thereby promoting 
proliferation and inhibiting apoptosis [152]. Additionally, vFLIP through constitutive activation of 
NFκB, inhibits apoptosis and induces the characteristic spindle cell morphology in endothelial cells and 
also leads to the further secretion of chemokines and cytokines [153–155].  
Further, HIV-related chronic inflammation promotes KSHV reactivation through inflammatory 
cytokines and associated pathways (such as Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT)) [156]. More directly, HIV trans-activator of transcription (tat) protein has been 
shown to enhance entry of KSHV into endothelial cells and transmission [138]. HIV has also been 
shown to potently induce lytic replication of KSHV via activation of the KSHV RTA in a tat-independent 
manner [157]. HIV tat promotes the KS phenotype via secretion of the pro-angiogenic interferon-γ 
(IFN-γ) and activation of VEGF receptor 2 (VEGFR-2), thereby stimulating the growth of KS lesions 
[158–160]. Angiogenesis is further enhanced by the synergistic effect of tat and KSHV K1 on NFκB 
activation via induction of miR-891a-5p [161]. Similarly, HIV negative factor (nef) and K1 synergistically 
induce miR-718 which inhibits phosphatase and tensin homolog (PTEN) thereby activating the 
PI3K/AKT/mTOR pathway and enhancing angiogenesis [162]. Tat further enhances cell adhesion via 
interaction with integrin receptors and via mimicry of matrix proteins which additionally promotes 
migration and cellular invasion and activation of the basic fibroblast growth factor (bFGF) which has 
angiogenic properties [163,164]. The effects of KSHV vGPCR are synergistically enhanced by HIV-1 tat 
which accelerates tumorigenesis in vGPCR transgenic mice [165,166]. Taken together, the oncogenic 
mechanisms of KSHV promoted by HIV co-infection activate many of the cancer hallmarks and 
culminate in carcinogenesis [167,168]. 
 
1.3. KSHV-associated diseases 
Primary KSHV infection, while often silent, may sometimes be associated with nonspecific symptoms 
including fatigue, rash, diarrhoea and lymphadenopathy [169]. In immunocompetent individuals, the 
lifelong course of KSHV infection is clinically silent even during intermittent lytic activation, likely 
controlled by T-cell responses [7,169,170]. However, with a decline in T-cell immunity, most markedly 
due to HIV immunosuppression, KSHV-infected patients become more likely to develop KSHV-




KS was first described by a Hungarian dermatologist, Moritz Kaposi, in 1872 in a case 
description of six elderly men with angioproliferative tumours [171]. Over a century later, prompted 
by the peculiar geographic distribution of KS and the massive explosion of KS prevalence during the 
early AIDS epidemic, KSHV was discovered as the etiological agent of Classic, Endemic, Iatrogenic and 
AIDS-related KS (see 1.3.1.1) [3]. Soon after, two additional diseases caused by KSHV were identified: 
PEL, a body-cavity-based B-cell lymphoma [4]; and a KSHV-associated plasmablastic form of MCD 
(KSHV-MCD) [172]. Recently, an IL-6 related inflammatory syndrome without an MCD diagnosis 
termed KICS was described [6]. These KSHV-associated diseases often present simultaneously in 
patients co-infected with KSHV and HIV which has implications for diagnosis and treatment strategies 
[2,173]. While all of these KSHV-associated diseases have been reported in other immunosuppressed 
and elderly people [174–176], HIV-related immune suppression (i.e. CD4 count <200 cells/µl) is one of 
the most important mechanisms that favours KSHV-driven pathogenesis [1]. 
 
1.3.1. Kaposi’s sarcoma 
1.3.1.1. Epidemiology 
KS is the most common AIDS-related malignancy globally and incidence rates are still increasing in SSA 
[177]. Before the AIDS epidemic, KS occurred in particular epidemiological groupings specific to 
geographical locations. Classic KS primarily occurred in elderly men from the Mediterranean and 
Eastern European region while Endemic KS was found in Central Africa mostly in younger males 
[176,178]. Further, Iatrogenic KS was associated with transplant-related immunosuppression and 
therefore regressed with immune reconstitution [179,180]. With the onset of the AIDS epidemic, the 
incidence of an AIDS-related or Epidemic KS variant, the most clinically aggressive, burgeoned, driven 
by HIV/AIDS-related immune suppression and HIV itself (see 1.2.4) [43]. All four epidemiological 
variants of KS are histologically identical and are all caused by the oncogenic KSHV (see 1.2) [3,181]. 
The rollout of ART, particularly the HAART strategy, has substantially reduced AIDS-related KS 
incidence predominantly in resource-rich regions, while this has been less successful in low-income 
regions [48,182]. KS incidence is the highest in SSA (Figure 3) [177,183]. KS age-standardised incidence 
rates in South Africa have increased 50-fold in women and 20-fold in men concomitant with the 
HIV/AIDS epidemic [19,184]. ART coverage in Uganda and South Africa was particularly expanded from 
1998 to 2006 but there were no significant declines in KS incidence [48]. On the African continent, 
there were an estimated 32,446 new cases and a staggering 17,659 deaths in 2018 [185]. Age-







Figure 3: Epidemiology of KS. Geographic representations of A) incidence and B) mortality of KS 
are summarised by region in C). Data are from GLOBOCAN 2018 and maps and graph were 





represented in Figure 3) show that Eastern, Southern and Middle Africa have substantially higher KS 
incidence rates (>2.0 per 100,000 persons per year) and mortality rates (>1.2 per 100,000 persons per 
year) compared to the global incidence rate of 0.50 per 100,000 persons per year and global mortality 
rate of 0.24 per 100,000 persons per year [185,186]. Indeed, the SSA KS incidence in HIV-infected 
individuals on ART is estimated to be 286/100,000 person-years [187]. Furthermore, a steady increase 
in the proportions of HIV-infected KS patients with CD4 counts >300 cells/µl has been observed [71]. 
This might be due to senescence resembling classic (HIV-unrelated) KS as the life expectancy of HIV-
infected patients on ART has significantly increased; or due to HIV-related effects independent of T-cell 
immunosuppression [1]. 
KS incidence correlates with KSHV seroprevalence [176] and the burden of disease falls 
predominately on SSA (see 1.2.1). Geographically, high KS-risk areas, such as eastern, central and 
southern Africa, concomitantly have the highest reported rates of KSHV seroprevalence (>50%) 
[67,188]. Further, HIV incidence has an overlapping geographical picture. AIDS-related KS is driven by 
HIV-related immune suppression, and HIV is considered a potent risk factor for KS development 
following the observation that the incidence of KS in HIV-positive patients is 20,000-fold higher than 
in the general population in developed countries [138,189–191]. Due to high background of Endemic 
KS pre-dating the AIDS epidemic, these risks are lower, although still substantial, in Africa [46,192]. 
Stein et al. reported HIV-positive patients aged between 18 and 34 to have 58.6-times greater risk of 
developing KS than HIV-negative patients [46]. Additionally to HIV-induced immune suppression which 
creates an environment favourable for carcinogenesis, HIV infection itself supports KSHV-driven 
pathogenesis beyond just immune suppression; the incidence of KS in HIV-positive patients is 300-fold 
higher than in patients with alternative forms of immunosuppression (see 1.2.4) [168,191]. Within the 
context of KS, these numbers clearly show the enormous impact of HIV on clinical outcome in KSHV-
infected individuals.  
Mortality rates are reported (GLOBOCAN 2018) to be highest in SSA (Figure 3), supported by 
clinical reports that AIDS-KS is more aggressive than the other KS variants. AIDS-KS is characterised by 
multifocal presentation and visceral involvement which complicates treatment, resulting in death 
[193,194]. The introduction of HAART has resulted in decreased KS mortality, but SSA mortality rates 
are still majorly elevated compared to the rest of the world (Figure 3) [195]. This is postulated to be 





1.3.1.2. KSHV is the etiological agent of KS 
Research into an infectious etiological agent of KS was prompted by its peculiar epidemiological 
presentation leading to the discovery, in 1994, of KSHV in an AIDS-related tumour by representational 
difference analysis [3]. Since then, polymerase chain reaction (PCR) has been utilised to detect KSHV 
DNA sequences in blood and tissue of patients with all KS variants [197–203]. The in vitro oncogenic 
properties of KSHV have been well established. KSHV infection was sufficient to induce transformation  
in primary human endothelial cells and immortalised dermal microvascular endothelial cells (DMVEC), 
indicated by morphological alteration toward the spindle cell phenotype characteristic of KS, 
decreased growth factor dependence, loss of contact inhibition and anchorage-independent growth 
[204–206]. Likewise, KSHV infection of human umbilical vein endothelial cells (HUVEC) inferred a 
survival advantage under serum-starvation and apoptotic stress conditions via activation of the 
PI3K/Akt/mTOR pathway [207]. Finally, KSHV-infected immortalised endothelial cells formed tumours 
in nude mice [208]. As such, these data informed the International Agency for Research on Cancer 
(IARC) in its classification of KSHV as a class I human carcinogen [209]. Like other oncogenic pathogens, 
KSHV-induced transformation of endothelial cells is driven by the expression of viral proteins in 
conjunction with precipitating factors, most importantly HIV infection and related 
immunosuppression (see 1.2.4) [210].   
1.3.1.3. Clinical presentation and diagnosis 
KS is a multicentric, highly vascularised tumour comprising of hyperproliferating spindle cells and 
infiltrating monocytes, T-cells and plasma cells [181,210]. KS commonly presents as a multifocal, flat, 
red/purple patch of variable size on the skin and progresses to cutaneous plaques and nodules usually 
on the head, neck or lower limbs [29,210]. Alternative presentation sites are the oral mucosa, the 
lungs, gastrointestinal tract or the lymph nodes, often accompanied with marked lymphoedema 
[29,211]. KS spindle cells express endothelial and lymphatic cell markers leading to debate over their 
lineage [181]. One theory is that transformation of spindle cells results in their evolution from blood 
vasculature to lymphatic endothelium with loss of cell junctions and the vascular phenotype, resulting 
in leakage of red blood cells into the stroma giving lesions their florid appearance [181].  
 Diagnosis of KS skin lesions is made by biopsy. Characteristic microscopic features of KS lesions 
are spindle-shaped cells and abnormal blood vessels described as vascular slits, often accompanied by 
fibrosis, inflammatory infiltrates and hemosiderin together with positive immunohistochemical 
staining for CD31 and KSHV LANA [2,212]. Pulmonary KS is diagnosed by chest X-ray, computerized 
tomography or visualisation of typical lesions by bronchoscopy, while biopsy of endobronchial lesions 




microcytic anaemia and, in severe cases (faecal blood loss), is visualised by endoscopy or colonoscopy 
[2].  
1.3.1.4. Treatment 
HAART is an effective treatment for KS, and in ART-naïve patients who have limited KS disease, up to 
80% of patients may have regression in three to nine months [2,213,214]. However, patients with 
extensive oral KS, gastrointestinal or non-nodal visceral KS or tumour-associated oedema or 
ulceration, are considered high-risk and do not show substantial response to HAART [2]. Furthermore, 
some patients started on HAART develop immune reconstitution inflammatory syndrome (IRIS) and 
may develop or have an exacerbation of KS [215].  
 Systemic chemotherapy including doxorubicin, vincristine, vinblastine and bleomycin is used, 
especially in low-resource settings, in cases where a patient has not responded to HAART or has 
extensive or advanced KS, but approximately 30% of patients do not have adequate response and 
long-term use is associated with cumulative toxicity [213].  
 
1.3.2. Primary effusion lymphoma 
1.3.2.1. Epidemiology 
PEL is considered to be a rare disease, estimated to account for approximately 4–9.8% of AIDS-related 
lymphomas, and was originally thought to occur in patients with advanced AIDS (CD4 count 
<200 cells/µl) [4,216,217]. Recent reports, however, suggest that PEL may occur in patients with 
higher CD4 counts, for example, a median CD4 count of 204 cell/µl was reported in 51 patients with 
PEL by Guillet et al. [4,173,218]. Nonspecific presentation, in the context of high TB prevalence (see 
1.1.2), and technically-difficult diagnosis (see 1.3.2.3) likely indicate that PEL is highly underreported, 
especially in low-resource settings. The prognosis for PEL is poor and median survival, in the era of 
HAART, is less than a year [173].  
1.3.2.2. KSHV is the etiological agent of PEL 
Suspecting that body-cavity-based lymphomas in HIV-patients which formed as effusions in the 
pleural, pericardial and peritoneal cavities may constitute a distinct subgroup with unique clinical, 
immune and genetic characteristics, Cesarman et al. [4] investigated 193 lymphomas from 42 AIDS 
patients and 151 patients without AIDS and identified the KSHV DNA sequence by Southern blot 
hybridization, PCR and sequencing in all 8 AIDS-related body-cavity-based lymphomatous effusions in 




DNA sequences were detected in and restricted to 4 cases of body-cavity-based effusions [219]. In 
2001, PEL was recognized and classified by the WHO as a distinct neoplastic disease [220].  
1.3.2.3. Clinical presentation and diagnosis 
PEL presents in HIV-infected patients as an effusion in a body cavity — the pleura, peritoneum, or 
pericardium — together with inflammatory symptoms, such as fever and malaise, and laboratory 
abnormalities of hypoalbuminemia, thrombocytopenia, anaemia, elevated IL-6 and elevated KSHV VL 
[218]. 
Diagnosis of PEL requires pathological examination and identification of tumour cells which 
have positive expression of CD45, CD138, CD30, CD38 and human leukocyte antigen (HLA)-DR as well 
as demonstration of KSHV infection (usually latent genes are expressed) and often EBV co-infection 
[24,221].   
1.3.2.4. Treatment 
PEL does not have an established therapy but is most commonly treated with anthracycline-based 
chemotherapy regimens, similarly to other non-Hodgkin lymphomas, along with ART. A CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisone)-based regimen in combination with 
HAART has been shown to achieve remission in 43% of patients [173]. In a series of 20 patients with 
PEL, treatment with ART and modified EPOCH (etoposide, prednisone, vincristine, cyclophosphamide 
and doxorubicin) resulted in three-year cancer-specific survival of 47% [218].  
 
1.3.3. Multicentric Castleman disease 
1.3.3.1. Epidemiology 
KSHV-MCD is considered a rare disorder. In a prospective HIV database (the Chelsea and Westminster 
HIV cohort) with 56,202 patient-years of follow-up, the incidence of biopsy-proven KSHV-MCD was 
4.3/10,000 years of patient follow-up (compared to KS incidence of 210.1/10,000 patient-years) [222]. 
Unlike KS, MCD patients often display relatively preserved immune functions [26,222]. Indeed, there 
is evidence that its incidence may have increased in the ART era: when stratified by pre-HAART (1983–
1996), early-HAART (1997–2001) and later HAART (2002–2007) eras, KSHV-MCD in the Chelsea and 
Westminster HIV cohort showed an increase from 2.3 to 2.8 to 8.3/10,000 patient-years [222]. 
Furthermore, KSHV-MCD is very likely underreported [2]. Despite the high prevalence of HIV and KSHV 
co-infection in SSA, KSHV-MCD is scarcely reported: a pathology review of 64 reactive lymph nodes 




specimens that were suggestive of MCD [223], and a single case of MCD was described in a 
retrospective evaluation of reactive lymphoid tissue specimens from Tanzania [224]. Not only is KSHV-
MCD diagnosis technically difficult requiring experienced and vigilant physicians, limited diagnostic 
pathology in SSA and inadequate surgical capabilities to obtain biopsies for diagnostic assessment 
further hinders KSHV-MCD diagnosis [2,225]. In Malawi, improved pathology infrastructure led to the 
first clinical case series of KSHV-MCD being reported from SSA in 2015 and demonstrated late 
diagnosis and frequent misdiagnosis as lymphadenitis due to HIV or TB [26,225]. Diagnosis of KSHV-
MCD in African immigrants in the USA in contrast to few to no diagnoses in Africa is further evidence 
of underdiagnosis in SSA [2,226,227].  
1.3.3.2. KSHV is the etiological agent of MCD 
Following the identification of KSHV as the etiological agent of KS and due to the close association of 
MCD with KS, which were noted to frequently co-occur in the context of HIV, Soulier et al. [172] 
published the first description of KSHV-MCD, in which KSHV sequences were detected in all of 14 HIV-
associated MCD cases and in 7/17 HIV-negative MCD cases. Since then, a long list of studies has 
corroborated that KSHV infection is the cause of MCD in HIV-positive patients [e.g. 173,176–178].  
1.3.3.3. Clinical presentation and diagnosis 
KSHV-MCD is clinically characterized by inflammatory symptoms including fevers, night sweats, weight 
loss, cachexia, oedema and effusions with lymphadenopathy and splenomegaly and often, respiratory, 
dermatologic and neurologic symptoms [2,231]. Laboratory abnormalities include anaemia, 
decreased albumin, hyponatremia, thrombocytopenia, elevated CRP and elevated KSHV VL in both 
plasma and peripheral blood mononuclear cells (PBMC) [2,231,232]. The clinical course is 
characterised by flares during which CRP is highly elevated and has been suggested as a screening 
marker together with KSHV VL [2,218]. This clinical presentation may mimic plasmablastic leukaemia, 
lymphoma, TB or bacterial sepsis which may delay diagnosis [2,26,225,232].  
MCD is diagnosed by lymph node biopsy and histologic confirmation of KSHV-infected 
plasmablastic cells (identified by LANA staining) in the mantle zone of lymphoid organs that express 
IgM and are lambda restricted. KSHV-MCD lymph nodes characteristically have regressed germinal 
centres with vascularised core and mantle zone expansion [27].  
1.3.3.4. Treatment 
Rituximab (a monoclonal antibody targeting CD20) is a highly effective therapy for MCD and is now 
considered the first-line treatment option. It has greatly improved KSHV-MCD outcomes, resulting in 




limited in patients with low CD4 counts, organ dysfunction and co-existing KS as rituximab may 
exacerbate KS [227,233,235]. Severe symptoms or MCD flare-ups require supportive treatment in an 
intensive care unit [2]. Advanced KSHV-MCD is treated with cytotoxic chemotherapy (liposomal 
doxorubicin or etoposide) in addition to rituximab and one study found that treating concurrent KSHV-
MCD and KS with the combination of rituximab and liposomal doxorubicin resulted in KS improvement 
in five of six patients and overall survival of 81% [227]. Another study found that virus-activated 
cytotoxic therapy (high dose zidovudine plus valganciclovir, a pro-drug of ganciclovir) resulted in 86% 
survival at 12 months [226].  
Without treatment, KSHV-MCD is fatal with observed survival of less than two years [231]. In 
a Malawian study, late diagnosis, inadequate supportive care and inappropriate therapies (neither 
rituximab, zidovudine nor ganciclovir are available in Malawi) were attributed to poor survival of 
KSHV-MCD patients (median survival <6 months) [26]. In resource-limited SSA, even 
chemotherapeutic agents included in the WHO Model Lists of Essential Medicines (which rituximab is 
not) are limited in their availability [236]. In Malawi and much of SSA, KSHV-MCD is treated with the 
chemotherapeutics available — etoposide, cyclophosphamide, vincristine and prednisone — with 
unsatisfactory results [26,236]. 
 
1.3.4. KSHV inflammatory cytokine syndrome 
1.3.4.1. Epidemiology 
KICS is a newly described inflammatory syndrome that was first reported in a retrospective analysis of 
six patients in the USA [8] and has since been described in a prospective study of ten patients in the 
USA [6]. Since, a handful of cases have been described: one patient in Italy [174]; seven patients in the 
USA [237]; and another patient in the USA [238]. While KICS is likely undiagnosed in the majority of 
cases, it is considered a very rare but serious, high-risk diagnosis [2].  
1.3.4.2. KSHV is the etiological agent of KICS 
The first description of the syndrome that would be named KICS arose from the observation of patients 
with KSHV infection and a symptom profile resembling KSHV-MCD in which pathological diagnosis of 
KSHV-MCD, or any alternative conditions, could not be made [8]. These patients were found to have 
high KSHV VL and elevated vIL-6 as well as human IL-6, IL-10 and other cytokines and the authors 
postulated that the syndrome observed was a result of direct or indirect cytokine activation by KSHV 




characterise the clinical, laboratory, virological and immunological features of KICS, culminating in a 
working case definition (Table 2 [6,7]). 
1.3.4.3. Clinical presentation and diagnosis 
KICS is a proposed clinical diagnosis requiring pathological exclusion of MCD [6] and other serious 
intercurrent infections [6–8]. Like MCD, KSHV is lytically active in KICS and VL is elevated resulting in 
an overproduction of host and viral IL-6 and other cytokines giving rise to inflammatory symptoms 
such as fever, wasting, hypoalbuminemia, cytopenia, hyponatremia and elevated CRP [8]. The working 
case definition for the diagnosis of KICS (Table 2) stipulates that a patient has: at least two clinical 
manifestations from at least two of the lists of symptoms, laboratory abnormalities and radiographic 
abnormalities; evidence of systemic inflammation measured by CRP; elevated KSHV VL above 100 
copies/106 cells; and exclusion of MCD and other serious infections [6,7]. The implicated cell type in 
KICS is unknown, but it commonly occurs in conjunction with KS or PEL tumours [2]. KICS in the 
absence of KS or PEL has also been reported [6,8].  
 
Table 2: Working case definition of KICS defined by Polizzotto et al. [6,7]. 
1. Clinical manifestations 





Respiratory symptoms C. Radiographic abnormalities 
Neuropathy with or without pain Lymphadenopathy 
Arthralgia and myalgia Splenomegaly 
Altered mental state Hepatomegaly 
Gastrointestinal disturbance Body cavity effusions 
2. Evidence of systemic inflammation 
Elevated CRP 
3. Evidence of KSHV lytic activity 
Elevated KSHV VL in peripheral blood mononuclear cells (>100 copies/10
6
 cells) 
4. No evidence of KSHV-associated MCD 





As a recently described syndrome with which there is little clinical experience, it is still unclear how 
KICS should best be treated. Current management strategies are directed at treating any associated 
malignancy [2,7]. However, KS in the context of KICS does not respond well to standard therapy, and 
overall, KICS patients have shown a poor prognosis with high mortality, often from progressive 
KSHV-related tumours [6–8]. Additionally, approaches developed for KSHV-MCD (high dose 
zidovudine, valganciclovir and liposomal doxorubicin) showed some promise in the original series of 
six KICS patients [8]. One case report described treatment of a patient diagnosed with KICS and KS 
with rituximab and liposomal doxorubicin who died and attributed this to delay in diagnosis due to 
time spent on differential diagnoses [238], while another describing the first reported case of a 
KICS-like syndrome in an HIV-negative post-transplant patient had success using rituximab, cidofovir 
and foscarnet [174]. 
 
1.3.5. Clinical management of KSHV infection 
Regardless of the individual KSHV-associated pathology, treatment of KSHV infection with anti-
herpesvirus therapy to reduce viral replication has been examined in the HIV setting to prevent and 
treat disease. Prophylactic ganciclovir used to prevent cytomegalovirus retinitis in HIV-positive 
patients was shown to concomitantly reduce KS incidence [239]. Use of cidofovir in KS patients with 
KS lesions resistant to ART and chemotherapy treatment led to clinical improvement correlated with 
reduction in KSHV viremia [240] and similarly, treatment with foscarnet led to a reduction in KSHV 
DNA in PBMCs to an undetectable level in an HIV-positive patient with disseminated KS [241] and in 
an HIV-negative patient with primary KSHV infection post-transplant [242]. In a case series of three 
patients with KSHV-MCD treated with oral and intravenous ganciclovir, reduction in KSHV viral 
replication was observed along with the resolution of symptoms [243]. Valganciclovir has been 
successfully used in combination with rituximab [235] or zidovudine [226] to control KSHV viremia.  
 
1.4. KSHV VL as a potential diagnostic and monitoring tool 
KSHV DNA levels in peripheral blood differ between KSHV-associated diseases, with highest levels 
evident in lytically-associated syndromes MCD and KICS and lower levels in PEL and KS [20,25,244]. 
Further, KSHV VL in blood and oral fluids has been shown to be associated with KS disease status 




and proposed as a clinical tool for assessment of risk of KS progression [7,25,244–247]. KSHV VL has 
been characterised as a virological parameter, together with vIL-6, to monitor KSHV-MCD treatment 
progress and outcome in combination with immunological parameters, such as CRP, haemoglobin, 
albumin, sodium, platelets and host IL-6, to characterise a profile corresponding to best clinical 
response [25,226,233]. KSHV VL elevated above 100 copies/106 cells is included in the working case 
definition of KICS [6,7]. KSHV VL may be a useful biomarker for KSHV-associated disease risk, to inform 
diagnosis and to manage KSHV-associated diseases. This study further assessed the applicability of 
KSHV VL as a surveillance tool for KSHV-associated pathologies in a high HIV/TB setting.    
 
1.5. Host genetic factors in KSHV infection and KS development 
KSHV infection is necessary but insufficient for KS development. Precipitating factors such as HIV 
infection or immune suppression are required for KSHV-associated oncogenesis (see 1.2.4). Even so, 
HIV-KSHV co-infection does not strictly result in cancer development. Furthermore, exposure to KSHV 
does not always result in KSHV infection; seroconversion even in areas of high exposure is 30–50% 
[94]. An epidemiological population-based study on 1,337 individuals of African origin in French 
Guinea where KSHV is endemic, showed strong correlation of KSHV seroprevalence between mother-
child and sibling-sibling pairs, suggestive of familial aggregation, although a plateau in seroprevalence 
rates with age led the authors to suspect genetic resistance may be present in the population [9]. 
These observations in addition to the geographic and population-specific incidence of KS suggest a 
potential role for host genetic factors in KSHV infection following exposure and/or progression to KS 
[28,29,67,248].  
Various groups have investigated host genetic factors in relation to KSHV susceptibility and 
subsequent KS development. Plancoulaine et al. [30] identified, by segregation analysis of KSHV 
seroprevalence among the aforementioned French Guinean population, the presence of a recessive 
major gene that affects, in combination with age, susceptibility to KSHV seroconversion in children 
under ten years of age. This was mapped to chromosome region 3p22 which encodes PDCD6IP, UBP, 
FBXL2, ARPP-21, LRRFIP2 and CCR4 [249].   
Thus far, immune-modulatory genes have been the focus of investigations of candidate 
susceptibility genes. In particular, published studies have reported significant associations with KS or 
KSHV-infection of single nucleotide polymorphisms (SNPs) in genes encoding interleukins (IL-6, IL-8 
and IL-13) [32,250–252], VEGF [252,253], NFκB [254], mannose-binding lectin (MBL)-2 [255], Fc 




their HLA ligands and linked genes [31,257–262] and homologues of human genes mimicked by KSHV, 
namely cyclin D1 (CCND1), IL-6, C-C chemokine ligand 2 (CCL2) and FADD-like apoptosis regulator 
(CFLAR) [263]. We have conducted a preliminary assessment into the KSHV entry receptor EPHA2 in 
relation to KSHV infection and KS development [34]. The above-mentioned studies are summarised in 
Table 3. Further, tumour necrosis factors (TNFα and TNFβ) [32,252], IFN-γ [252], stromal-derived 
factor 1 (SDF1), C-C chemokine receptor type 5 (CCR5) [32] and caspase 8 (CASP8) [263] have been 
investigated in relation to KS and KSHV but have not yielded statistically significant results.  
From these studies, several notable associations have been identified in genes encoding 
proteins that are known to be pro-inflammatory (Table 3). A SNP in the IL-6 promoter (c.-174G>C, 
reference SNP (rs)1800795) which is associated with increased levels of IL-6 was noted in a familial 
clustering of Classic KS and was further associated with KS in HIV-infected men and renal transplant 
recipients [32,248,250]. IL-6 potently promotes the growth of KS spindle cells in an autocrine and 
paracrine manner [264] and is mimicked by KSHV-encoded vIL-6 [67,263]. A SNP in the IL-13 promoter 
region (c.-1069C>T, rs20541) was associated with Classic KS in patients latently infected with KSHV 
[252]. Similarly, an IL-8 promoter SNP (c.-251A>T, rs4073), linked to below normal IL-8 expression, was 
identified in a cohort of patients with Classic KS [252]; however, it was conversely found to decrease 
the risk of AIDS-KS in HIV-positive patients [251]. The combination of two SNPs (c.1235T>C, rs1126579 
and c.-1010G>A, rs1126580) in the human homolog to the KSHV-encoded vGPCR, IL-8RB, were found 
to be protective against the development of Classic KS [252]. The angiogenesis-related VEGF was 
found to harbour a promotor region SNP (c.-172C>A, rs59260042) associated with KSHV viremia in 
kidney transplant recipients, and a SNP in the 5’ untranslated region (UTR, c.405C>G, rs2010963) was 
likewise associated with KSHV viremia but in females only [253]. Polymorphisms in the NFκB1 
promoter (NFkB1 -94 ins/del ATTG, rs28362491) and the 3’UTR region of the NFκB1 inhibitor alpha 
(NFκBIA c.2758G>A, rs696) were found to be associated with the presence of antibodies to KSHV lytic 
antigens [254]. The innate immune system protein MBL haplotype (based on combinations of 
genotypes of two promoter region SNP (c.-550 H/L and c.-221 Y/X) and three coding SNPs in exon 1 
(codon positions 52, 54 and 77)) was associated with intermediate expression of MBL and was found 
to be associated with lower CD4 count in KSHV co-infected patients compared to HIV mono-infected 
patients [255].   
Immunoregulatory genes have also been implicated in KS development and/or KSHV 
susceptibility. A polymorphic form of the immunoglobulin G (IgG) binding receptor, FcγRIIIA, was 
associated with AIDS-KS in a cohort of HIV-positive men and was found to enhance  IgG affinity in vitro 
and promote natural killer (NK) cell activation [33,265]. Inflammation mediated by NK cell activation 




Table 3: Summary of SNPs associated with KS development, KSHV infectivity or KSHV serumpositivity in the studies detailed in 1.5. SNP mRNA position is 
given where appropriate (a + value indicates a position within the coding region, while a - value indicates a position in the promotor region). Reference SNP 
identification (rsid) numbers correspond to the SNP database. Alternatively, the haplotype is given where appropriate. HLA haplotypes are named according 
to the naming convention determined by the WHO Nomenclature Committee for Factors of the HLA System. The base referred to in the corresponding table 
entry is in bold. Odds ratio (OR), confidence interval (CI) and P values are extracted from papers referenced in the table or calculated from the published data 
as required. An OR>1 is indicative of increased risk; OR<1 indicates decreased risk. Table is adapted and updated from [35]. 
Gene SNP (rsid)/ haplotype OR (95% CI) P value Associated with Description of study cohort 
Cases vs. 
controls Ref. 
IL-6 G-174C (rs1800795) 
2.11 (1.2-3.7) 0.0046 AIDS-related KS HIV+ male patients with or without KS  115 vs. 126 [32] 
5.3 (1.5 to 18.9) 0.008 
Iatrogenic KS Renal transplant recipients with or 
without KS 
15 vs. 40 [250] 
IL-8 A-251T (rs4073) 0.49 (0.25-0.97) 0.039 
AIDS-related KS HIV+/KSHV+ male patients with or 
without KS  
84 vs. 154 [251] 
IL-8RB 
T+1235C (rs1126579) + 
G-1010A (rs1126580) 
0.49 (0.30-0.78) 0.003 
Classic KS 
HIV-/KSHV+ patients with or without KS 133 vs. 172 [252] 
IL-13 C-1069T (rs1800925) 1.88 (1.15-3.08) 0.01 Classic KS HIV- KSHV+ patients with or without KS 133 vs. 172 [252] 
VEGF 
C-172A (rs59260042) 4.8 (1.4-17.1) 0.005 
KSHV viremia Renal transplant recipients, KSHV+ or 
KSHV- after transplant  
44 vs. 128 [253] 
C+405G (rs2010963) 3.98 (1.5-11.1) 0.004 
KSHV viremia Female only renal transplant recipients, 
KSHV+ or KSHV- after transplant 
18 vs. 50 [253] 
NFκB1 
-94 ins/del ATTG 
(rs28362491) 




HIV+/KSHV+ patients  63 vs. 69 [254] 
NFκBIA G+2758A (rs696) 
Het: 12.3 (4.3–34.9) 






HIV+/KSHV+ patients 63 vs. 69 [254] 
MBL2 
HYA/HXA, HYA/ HYO, 
HYA/LXA, HYA/LYO, 
LXA/LXA, LYA/LXA and 
LYA/LYO (intermediate 
expression haplotypes) 
3.1 (1.2-7.6) 0.02 
CD4 count 
response 






HLA-A*11:01 0.4 (0.2-0.7) 0.002 Classic KS HIV- patients with or without KS 248 vs. 855 [257] 
HLA-C*07:01 1.6 (1.2-2.1) 0.002 Classic KS HIV- patients with or without KS 250 vs. 846 [257] 
HLA-B*1401 
4.2 (1.1-15.5) 0.03 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
4.27 (1.67-10.91) 0.033 AIDS-related KS HIV+ patients with or without KS.  157 vs. 523 [258] 
HLA-B*2702/5 
0.37 (0.15-0.94) 0.04 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
0.39 (0.16-0.94) 0.04 
AIDS-related KS HIV+ CD4 decline matched patients with 
or without KS 
96 vs. 96 [259] 
HLA-CW4 
4.96 (2.9-8.12) 0.03 
Iatrogenic KS HIV- renal transplant recipients with or 
without KS  
44 vs. 15 [260] 
HLA-A30 0.48 (0.25-0.90) 0.48 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-CW5 0..32 (0.16-0.65) 0.0006 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-CW7 2.48 (1.27-4.72) 0.01 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 





6.12 (1.29-28.9) 0.02 
AIDS-related KS HIV+, CD4 decline matched patients with 
or without KS 
96 vs. 96 [259] 
HLA-DRB1*F13 2.24 (1.19-4.20) 0.016 AIDS-related KS AIDS patients with or without KS 122 vs. 94 [262] 
HLA-DRB1*1104 2.12 (1.05-4.25) 0.047 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-DRB1*1302 5.83 (1.73-19.83) 0.004 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-DRB1*1601 0.50 (0.26-1.0) 0.043 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-DQA1*0302 11.97 (1.27-103.36) 0.019 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-DQB1*0502 0.52 (0.27-0.97) 0.047 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-DQB1*0604 7.75 (2.02-29.70) 0.0017 Classic KS HIV- patients with or without KS 62 vs. 220 [261] 
HLA-DMB  A>G (rs6902982) 4.09 (1.90-8.80) 0.0003 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
TAP1 
A+ 2090G (rs1135216)  1.54 (1.09-2.18) 0.014 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
A+ 1177G (rs1057141)  1.45 (1.05-1.99) 0.024 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 






A-127G (rs2071541) 1.6 (1.11-2.32) 0.012 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
GPANK1 A+1846G (rs7029) 1.55 (1.17-2.05) 0.002 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
TRIM31 G+1261A (rs1116221) 0.74 (0.56-0.96) 0.033 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
LT-α A-90G (rs909253) 0.75 (0.58-0.96) 0.022 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
LY6G6C G+298A (rs1065356) 1.60 (1.18-2.16) 0.002 
AIDS-related KS HIV+/KSHV+ patients with and without 
KS 
348 vs. 318 [31] 
KIR KIR3DS1 4.0 (1.4-11.4) 0.006 
Classic KS Patients with or without KS (those 
without KS were KSHV+ or KSHV-) 
32 vs 51 [256] 
HLA and 
KIR 
HLA-B Bw4-80I + 
KIR3DS1 
0.6 (0.4-0.9) 0.01 KSHV viremia HIV-/KSHV+ or KSHV- patients  277 vs. 562 
[257] 
2.1 (1.3-3.4) 0.002 Classic KS HIV-/KSHV+ patients with or without KS 248 vs. 277 








AIDS-related KS HIV+/KSHV+ patients with or without KS 
 
50 vs. 50 [34] 
C+2727T 6.4 (1.4-28.4) 0.03 
KSHV 
serumpositivity 










activated by interaction with HLA molecules. Goedert et al. [257] reported that the combination of 
KIR3DS1 (an activating haplotype of KIR) and HLA-B Bw4-80I (the Bw4 haplotype with an isoleucine at 
position 80) was protective against KSHV viremia but increased the risk of Classic KS among KSHV-
positive patients in a cohort of HIV-negative patients without KS although this was not corroborated 
in a smaller cohort of Italian Classic KS patients [256]. Additionally, the KIR3DS1 haplotype was found 
to be associated with Classic KS [256]. 
Several HLA class I and II haplotypes have been thoroughly investigated. KS development post 
kidney transplant was associated with HLA-CW4 in a small study [260]. In a study of Classic KS in a 
Sardinian population (high risk for Classic KS), a number of Class I and Class II HLA haplotypes were 
identified as increasing (Class I: HLA-CW7; Class II: HLA-DRB1*1104, HLA-DRB1*1302, HLA-
DQA1*0302, HLA-DQB1*0604) or decreasing (Class I: HLA-A30, HLA-CW5, HLA-B58; Class II: HLA-
DRB1601, HLA-DQB1*0502) risk of Classic KS [261]. HLA-C*07:01 has also been associated with Classic 
KS, while HLA-A*11:01 was found to decrease risk [257]. HLA-B*1401 is a risk allele for AIDS-related 
KS [31,258] and HLA-B*2705 is protective [31,259]. HLA-DRB1*1302 in linkage disequilibrium with 
DQB1*0604 was identified as a risk haplotype for AIDS-related KS [259] as were HLA-DRB1 alleles with 
a phenylalanine residue at position 13 [262]. Several variants identified in a SNP screening of the HLA-
DMB gene region were found to increase AIDS-KS risk. Most significantly, a SNP in the HLA-DMB 
intronic region (rs6902982) was associated with a four-times higher risk of AIDS-KS in HIV-KSHV 
coinfected men [31]. Non-synonymous SNPs in TRIM31 and LT-α were observed to be protective 
whereas SNPs within HLA-DMB linked genes, TAP1, TAPSAR1 microRNA, GPANK and LY6G6C, were 
associated with increased risk of AIDS-KS [31]. While certainly indicative of an association with KS, 
particularly in Class I and II HLA types, the heterogeneity of studied populations and different HLA 
genotyping techniques used has led to numerous but inconsistent reports that require validation 
[258]. 
Recently, human genes that are mimicked by KSHV have been investigated hypothesising that 
virally expressed homologues, which promote immune-silent proliferation, may be advantaged by 
genetic SNPs in their cellular homologues [263]. A SNP screening in AIDS-KS patients including several 
cellular homologues identified SNPs in CCND1, IL-6, CCL2 and CFLAR (homologues of KSHV-encoded 
vCyclin, vIL-6, vFLIP and vCCL, respectively). Various combinations of these SNPs (but not the SNPs 
alone) were associated with AIDS-KS [263].  
Key molecules involved in the initial stages of KSHV entry (see 1.2.3.2) are interesting 
candidate genes for KSHV and KS association studies. We investigated sequence variants in the KSHV 




analysis revealed two novel, non-synonymous heterozygous variants (c.2254T>C and c.2990G>T) 
significantly associated with KS and a novel heterozygous transition (c.2727C>T) associated with KSHV 
in a cohort of HIV-infected South African patients stratified by KS and KSHV status (see 1.6.6) [34,35]. 
  
1.6. The KSHV entry receptor EPHA2 
Eph receptors are important in KSHV entry processes through their direct binding with the KSHV 
glycoprotein complex gH-gL (see 1.2.3.2, Table 1). EPHA2, in particular, is essential for KSHV entry into 
endothelial cells (see 1.2.3.2, Figure 2), facilitating KSHV infection (see 1.6.4) and subsequent KS 
development through oncogenic mechanisms (see 1.6.3). 
 
1.6.1. The Eph and ephrin families 
The family of Eph receptors, which bind Eph receptor-interacting proteins (ephrins), are classified as 
RTKs. The generally conserved structure of Eph receptors consists of an intracellular kinase domain at 
the C-terminal end, adjacent to a region for binding of interacting proteins, and an extracellular region 
containing a ligand binding domain, a cysteine-rich domain and two fibronectin type-3 (Fn-3) repeats 
at the amino-terminal end [267]. Eph receptors, like classical RTKs, are monomeric and dimerize upon 
ligand binding. Eph receptors are classified based on homology of the extracellular domain either as 
EphA receptors that bind ephrin A (1–5) ligands or EphB receptors that bind ephrin B (1–3) ligands 
[268,269]. Unique among RTK ligands, ephrins are situated in the cell membrane and on binding to 
Eph receptors, elicit both ‘forward signalling’ in the Eph-expressing cell through activation of the Eph 
receptor and ‘reverse signalling’ through the ephrin in the cells on which they are expressed [270–
272]. This signalling functions in developmental tissue organization, for example in vasculature 
organisation and axon guidance via contact adhesion or repulsion, and therefore Ephs and ephrins are 
expressed at high levels during development [273]. In adult tissue, Ephs and ephrins are expressed in 
a wide variety of tissues at low levels and function in regulating cell proliferation, dynamics and 
angiogenesis via signalling cascades [269,273,274]. Eph receptors, additionally, regulate oncogenesis 
[275] and have been found to be expressed aberrantly in various tumour tissues, correlating with 




1.6.2. The EPHA2 receptor 
1.6.2.1. Gene and protein structure 
The EPHA2 RTK is a transmembrane receptor consisting of 976 amino acids (AA) encoded by a 31,773 
base pair (bp) gene (chromosome 1p36, National Center for Biotechnology Information (NCBI) 
Accession number NG_021396) [276]. EPHA2 is comprised of 17 exons and several domains conserved 
among the Eph receptor family (Figure 4).  
 The extracellular region consists of an ephrin ligand-binding domain (Eph-lbd, AA position 
28–201); a cysteine-rich epithelial growth factor-like (EGF-like) domain (AA position 260–273); and 
two Fn-3 domains (AA positions 329–424 and 436–519). The G-H loop (a 15 AA loop region) on Ephrin-
A ligands binds EPHA2 promiscuously at the Eph-lbd [277].  
 The transmembrane domain (Tm-1, AA positions 536–558) connects the extracellular 
domain to the intracellular region, comprised of the functionally important juxtamembrane region, 
protein tyrosine kinase (Pkinase-Tyr) domain (AA position 613–871) and sterile alpha motif (SAM) 
domain (position 902–966) [278,279]. The juxtamembrane region and the Pkinase-Tyr domain are 
important in activation of the EPHA2 receptor, containing multiple tyrosine, serine and threonine 
residues that are phosphorylated upon receptor activation thereby creating binding sites for signalling 
proteins that contain Src homology (SH)2/SH3 domains such as Src, Ras GTPase activating protein 
(RasGAP), Phosphoinositide 3-kinase (PI3K), Fyn, Nck, Crk, Grb2, Grb10, Src-like-adaptor protein 
(SLAP), Vav2, Vav3 and low molecular weight protein tyrosine phosphatase (LMWPTP). Signalling 
mediated through the recruitment of these signalling proteins to the phosphorylated sites of EPHA2 
is functionally important, regulating actin dynamics, cellular adhesion, vascular assembly, 
angiogenesis and cell migration (see 1.6.2.2) [280–282]. For example, phosphorylated tyrosine 
residues at positions 587 and 593 bind guanine nucleotide exchange factors Vav2 and Vav3 and 
phosphorylated Tyr734 binds the p85 regulatory subunit of PI3K, and without these interactions, 
EPHA2 is defective in Rac1 activation and cell migration, and vascular assembly [282]. Additionally, 
phosphorylation sites Tyr772 and Ser897 in the intracellular region have been highlighted as key to 
the EPHA2’s oncogenic potential (see 1.6.3) [283–286] and phosphorylation of Ser897 is essential in 
KSHV entry (see 1.2.3.2) [127]. The SAM domain facilitates functionally important protein-protein 
interactions to regulate receptor dimerization and is the docking site for a number of interacting 
proteins that mediate downstream signalling [287,288]. A recent report indicates that the EPHA2 SAM 
domain is an inhibitor of kinase activity by reducing receptor oligomerization as SAM deletion led to 




been obtained from the crystal structure of the ectodomain (Protein Data Bank (PDB) ID: 3fl7), the 
Pkinase-Tyr domain (PDB ID: 5ek7) and the SAM (PDB ID: 3kka).  
1.6.2.2. Physiological function 
EPHA2 is an epithelial and endothelial cell receptor, with mRNA expression detected in tissues with a 
high turnover of epithelium such as intestinal, bladder, skin and lung tissue, but the extent of protein 
expression in tissues is not yet known [36,269,290]. Ephrin-A ligands are membrane-bound through 
glycosylphosphatidylinositol linkage [271,277,291]. All ephrin-A ligands, but in particular ephrin-A1 
which is encoded by the EFNA gene, bind EPHA2 to trigger canonical contact-dependent signalling in 
the Eph receptor expressing cell and the ephrin expressing cell [271,272,277]. EPHA2 plays a role in 
the development processes of the optic lens, inner ear, mammary gland and kidney and in ischemia-
reperfusion injury repair in the kidney, angiogenesis, cellular stress  response and bone remodelling.  
During foetal development, Eph-receptor-ephrin contact-induced attraction and repulsion 
results in pattern formation, or topographical mapping in tissues. The interaction of EPHA2 and one 
of its ligands, ephrin-A5, both of which are expressed and co-localised in the pre-natal optic lens, 
mediates lens transparency and organisation of the refractive fibre cells [292,293]. EPHA2 
homozygous knockout animal models demonstrate the importance of this interaction in the 
prevention of cataracts and EPHA2 mutations have been associated with congenital and age-related 
Figure 4: The EPHA2 gene structure showing conserved domains and structural models. Green 
boxes represent exons and black lines are intronic regions. Depicted as 3D structural models are 
the ectodomain (PDB ID: 3fl7) including the Eph-lbd (pink), the EGF-like domain (dark green) and 
the two Fn-3 domains (blue); the Pkinase-Tyr domain (5ek7, orange) and the SAM domain (3kka, 
light green). Italics indicates regions; non-italics indicates conserved domains. SP, signal peptide; 
Eph-lbd, Eph-receptor ligand binding domain; EGF-like, epithelial growth factor-like region; Fn-3, 
Fibronectin type-III domain; Tm-1, transmembrane domain type-I; Pkinase-Tyr, protein tyrosine 





cataract pathogenesis (see 1.6.5) [279,292–298]. EPHA2 is also expressed in the otic placode which 
likely has an important but currently unknown function in the development of the inner ear [299]. 
EPHA2 in mammary epithelial tissue is regulated by oestrogen and c-myc, and receptor knockout 
impaired mammary gland development via reduced proliferation and branching [38,300]. Branching 
morphogenesis, important for kidney development from the foetal ureteric bud is similarly regulated 
by EPHA2 [301].  
On the level of cellular dynamics, the EPHA2-ephrin-A1 interaction is essential in the 
regulation of postnatal angiogenesis via cellular migration and vascular assembly facilitated through 
the EPHA2 canonical pathway [290]. EPHA2 further facilitates the trafficking of T-cells via integrin-
mediated adhesion to endothelial cells [302]. Additionally, EPHA2 functions as a regulator of injury 
and stress response [303], for example, by regulating actin dynamics in the cytoskeleton following 
renal ischemia-reperfusion injury studied in in vitro and in vivo models [304]. Furthermore, ultraviolet 
(UV)-mediated apoptosis is dependent upon EPHA2 upregulation in response to UV in human and 
mouse melanocytes, keratinocytes and fibroblasts [305]. Remodelling of bone is dependent on the 
interaction of EPHA2 with ephrin-A2 which drives osteoclastogenesis and suppresses 
osteoblastogenesis [306]. Canonical signalling through ligand activation of EPHA2 is tumour 
suppressive while EPHA2 has also been found to induce signalling pathways through a noncanonical 
ligand-independent pathway that promotes oncogenesis (see 1.6.3 and Figure 5) [285]. 
 
1.6.3. Association of EPHA2 with oncogenesis  
Several cancer cell lines and cancer tissues have upregulated EPHA2 mRNA and protein expression 
and EPHA2 signalling has been shown to mediate cellular transformation, angiogenesis and metastasis 
[267]. EPHA2 was found to be overexpressed in 75.9% of invasive ovarian carcinomas studied by 
immunohistochemistry [37]. Similarly, EPHA2 was overexpressed in breast cancer tissue compared to 
normal breast tissue by immunohistochemistry and Western blot and overexpression of EPHA2 in 
mammary epithelial cells was sufficient to induce transformation, morphological changes and loss of 
cell-to-cell contact [307]. Prostate cancer cell lines were also shown to have high levels of EPHA2 
expression by Western blot and this was associated with metastatic potential [308], while EPHA2 
overexpression in ovarian tumours was linked to advanced disease and poor survival [37]. Moreover, 
EPHA2 was exclusively expressed in a metastatic melanoma cell line, not in a poorly invasive 
melanoma cell line [309]. EPHA2 was found to be overexpressed in NSCLC cell lines and tumour 




showed EPHA2 overexpression in malignant pleural mesothelioma (MPM) cell lines by 
immunoblotting and in MPM and non-small cell lung cancer (NSCLC)-squamous cell carcinoma (SCC) 
tumour specimens by immunohistochemistry. Further, the invasive tumour edge and NSCLC 
metastatic sites had higher EPHA2 expression than the primary tumour [286]. Importantly, EPHA2 
protein expression was upregulated in KS skin tissue compared to uninvolved skin by 
immunohistochemistry [36]. 
EPHA2 has been shown to exhibit opposing roles in potentiating oncogenesis (Figure 5) via 
two key phosphorylation sites in its cytoplasmic region (see 1.6.2.1). EPHA2 inhibits cancer cell survival 
and trans-endothelial migration via a ligand and tyrosine kinase-dependent signalling mechanism (the 
canonical pathway) reliant on phosphorylation of Tyr772 [274,283,285,310–312]. Ephrin-A1 activation 
of EPHA2 via Tyr772, concomitant with dephosphorylation of phosphor-Ser897, and subsequent 
EPHA2 dimerization similarly inhibited cell migration in glioma and prostate cancer cells [311] and cell 
proliferation in malignant mesothelioma cells [312]. Accordingly, dephosphorylated EPHA2 at position 
Tyr772 functions as an oncoprotein [283,313,314]. Locard-Paulet et al. [283] found that Tyr772 was 
rapidly dephosphorylated in breast cancer cells upon endothelial cell contact and a comparison of 
breast cancer cell lines with differing metastatic potential showed dephosphorylated Tyr772 to be 
selectively associated with higher lung metastatic potential. Kikawa et al. [315] identified LMWPTP to 
be responsible for EPHA2 dephosphorylation in cancer cells. Overexpression of LMWPTP in epithelial 
cells was sufficient to confer transformation and enhance cellular adherence and proliferation 
[313,315]. However, in exception to this, sustained Tyr772 phosphorylation was observed upon 
ephrin-A1 stimulation in a parental breast cancer cell line, indicating that Tyr772 dephosphorylation 
may act as a molecular switch by which cancer cells can aggressively overcome ligand-dependent 
EPHA2 inhibition of oncogenesis [283].  
Paradoxically, EPHA2 promotes tumour progression via ligand- and tyrosine kinase-
independent activation (noncanonical pathway) and phosphorylation, predominantly albeit not 
exclusively, of Ser897 by Akt, RSK or protein kinase A (PKA)-dependent on the cellular context and 
induced by inflammatory cytokines and growth factors [285,311,316,317]. Ser897 mutant is sufficient 
to abolish cell migration [311]. In addition, Tyr772 phosphorylation in association with other tyrosine 
sites in the EPHA2 juxtamembrane region, such as Tyr588, has been noted in kinase- and ligand-
independent mechanisms to modulate trans-endothelial migration [283]. The noncanonical pathway 
of unliganded activation of EPHA2 explains the enhanced tumorigenesis seen when EPHA2 is 
overexpressed in malignant cell lines or tissue (as above) which is often accompanied with low ephrin 
ligand expression [307,318–320]. Zelinski et al. [307] showed that failure of overexpressed EPHA2 to 






Figure 5: Schematic of the canonical and noncanonical oncogenic mechanisms of EPHA2. Tyrosine 
dephosphorylation promotes oncogenesis via the canonical pathway when the ligand is bound. In the 
absence of ligand binding, serine phosphorylation drives oncogenesis via the noncanonical pathway. 
Red circles indicate phosphorylated residues named by their IUPAC one-letter amino acid codes. 
Figure created with BioRender.  
 
1.6.4. EPHA2 is a major KSHV entry receptor on endothelial cells 
Hahn et al. [36] identified EPHA2 as the KSHV entry receptor on endothelial cells with an elegant series 
of experiments founded on co-precipitation of EPHA2 with KSHV virions and gH-gL. The authors 
showed that overexpression of EPHA2 proportionally increased KSHV infection (measured by green 
fluorescent protein (GFP) expression as a proxy for recombinant KSHV (rKSHV) that harboured the GFP 
gene) which closely correlated with EPHA2 expression levels in several primary cell lines. Conversely, 
blocking EPHA2 with antibodies or short interfering RNA (siRNA) or pre-treating KSHV with soluble 
EPHA2 inhibited KSHV infection. These findings were independently corroborated by 
immunoprecipitation of the lipid raft fraction using antibodies to α3β1 and mass spectrometry to 
identify EPHA2 in the multi-protein complex composed additionally of c-Cbl and myosin [122]. Similar 
to Hahn et al. [36], Chakraborty et al. [122] showed that attenuation of EPHA2 with tyrosine kinase 
inhibitors, short hairpin RNA (shRNA) or antibodies abolished KSHV entry into dermal endothelial cells. 




the EPHA2 Eph-lbd (bp position 237–756, AA position 28–201), the same binding region as ephrin-A 
ligands which inhibited the interaction [321]. The intracellular Pkinase-Tyr domain (see 1.6.2.1) is 
important for KSHV infection, as overexpression of full-length EPHA2 but not a mutant EPHA2 with a 
deleted intracellular domain, enhanced infection by >70% [36]. This is due to the presence of tyrosine 
residues in the intracellular domain (see 1.6.2.1) that are phosphorylated upon KSHV treatment and 
signal activation of the receptor [36]. It has been suggested that phosphorylation of EPHA2 may 
facilitate KSHV infection by organising cell surface receptors on the membrane, as has been described 
for hepatitis C virus [36,322]. While EPHA2 is clearly a major KSHV entry receptor in endothelial cells, 
there is evidence that KSHV may further make use of alternative entry receptors [36,115]. 
 
1.6.5. Genetic variation in EPHA2  
The majority of studies investigating sequence variants in EPHA2 have been in relation to cataract 
formation [279,294–298]. Age-related cortical cataract formation has been associated with a missense 
heterozygous transversion (c.2842G>T, SNP database ID: rs137853199) in an Italian cohort [279], two 
intronic EPHA2 variants (rs477558 and rs7548209) in a Han Chinese cohort [296], two variants in the 
3’ region (rs7543472 and rs11260867) in an Indian cohort [295] and a synonymous variant in the 
Eph-lbd (c.573G>A, rs6678616) in a meta-analysis of patients from three Caucasian populations [294]. 
Congenital cataract formation has similarly been linked to EPHA2 sequence variants. A non-
synonymous mutation (c.2353G>A, rs766078852) was identified in a consanguineous Pakistani family 
with autosomal recessive congenital cataracts [297], while autosomal dominant posterior polar 
congenital cataracts in a Han Chinese family was linked to an EPHA2 missense mutation (c.2819C>T, 
rs137853200) [298], and a two bp deletion (c.2915delTG) and a splicing variant (c.2826-9G-A) were 
identified in affected British and Australian families, respectively [298]. Few of these studies have 
corroborated the others, which may indicate that associations are population group-specific and that 
EPHA2 is genetically heterogenous amongst different ethnicities. 
Few studies have investigated EPHA2 SNPs in relation to cancer. Rare SNPs located in Eph-lbd 
and Pkinase-Tyr domains were found to be prognostic of worse survival in multiple myeloma, such as 
c.2080A>G [323]. A non-synonymous EPHA2 mutation (p.Gly391Arg in the Fn-3 domain was detected 
in a SCC cell line and in 2/28 lung SCC patient samples [286]. Overexpression of this variant resulting 
in p.Gly391Arg in a human immortalised bronchial epithelial cell line revealed a phenotype of 
constitutive EPHA2 activation and increased invasiveness, focal adhesions and cell survival mediated 
by the phosphorylation of Src, cortactin, p130Cas and mTOR [286]. Another study similarly identified 




p.Arg159Gly, a Fn-3 domain mutant p.Pro350Thr, and Pkinase-Tyr domain mutations p.Met631Thr, 
p.Arg876Cys/His and p.Arg890Gln. Additionally, in MPM tumour tissues, the authors identified 
p.Thr140Ile, p.Asp184Tyr, p.Arg195Cys and p.Asp232Gly in the Eph-lbd and p.Thr647Met, 
p.Ala859Asp and p.Arg876His in the Pkinase-Tyr domain [310]. In particular, expression of the Pkinase-
Tyr domain mutant p.Ala859Asp, which exhibited low levels of Y772 phosphorylation, in HEK293 cells 
resulted in increased proliferation and cell migration in wound healing assays mediated by 
upregulation of the STAT3 and platelet-derived growth factor (PDGF) pathways and suppression of 
CBL signalling [310]. Additionally, HEK293-EPHA2-p.Ala859Asp showed resistance to doxazosin 
treatment while BEAS2B cells expressing the EPHA2 Gly391Arg mutation were sensitive to a small 
molecule tyrosine-protein kinase Met (c-Met) inhibitor, SU11274 [310]. 
 
1.6.6. Association of EPHA2 sequence variation with KSHV and KS 
Although vital in the uptake mechanism of KSHV [36] and significantly involved in oncogenesis 
[36,37,307], little was known about the pathological consequences of EPHA2 sequence variants on 
KSHV infection and/or KS development. We, therefore, performed a retrospective candidate gene 
association study on 150 HIV-infected South African patients who were grouped according to their KS 
status and KSHV serodiagnosis [34,35]; namely Group 1: KS+/KSHV+; Group 2: KS-/KSHV+; Group 3: 
KS-/KSHV-. Mutation analysis revealed two novel, non-synonymous heterozygous single nucleotide 
variants (SNV) (c.2254T>C and c.2990G>T) in the Pkinase-Tyr and SAM domains, respectively, to be 
significantly associated with KS; and a novel heterozygous transition (c.2727C>T) in Pkinase-Tyr to be 
significantly associated with KSHV (Table 3) [34,35]. These variants were designated a ‘probably 
damaging’ annotation when assessed for functional impact using the in silico PolyPhen-2 prediction 
tool (see 3.2.1, Table 23), thereby possibly predisposing affected individuals to KSHV infection and KS 
oncogenesis, respectively [34,35]. To frame the context of the current study, details of this previous 
association analysis are provided in section 3.2.1. In the present study, these variants were subjected 
to functional validation.  
 
1.7. Rationale and aims  
KSHV has a particularly high seroprevalence in SSA and in the context of HIV co-infection, can lead to 
the development of KSHV-associated pathologies (see 1.2.1 and 1.3), which likely represent a 




KS, KSHV-MCD and PEL, late and incorrect diagnosis limit the applicability of these in the SSA context 
where these conditions have high mortality if left untreated (see 1.3). Appropriate implementation of 
blood KSHV VL testing may offer a potential approach to improving diagnostic accuracy in HIV-infected 
populations with competing infectious co-morbidities (see 1.4), such as TB which is highly prevalent 
in South Africa and whose symptoms are often unspecific at presentation and mimic KSHV-associated 
diseases (see 1.1.2). Since testing for KSHV is not yet included in routine diagnostic workup, research 
is urgently needed to advance the differential diagnostic capabilities of KSHV-associated pathologies 
and link results to earlier implementation of appropriate treatments to improve outcomes. Therefore, 
we aimed to evaluate KSHV VL in the context of KICS-related symptoms and laboratory abnormalities 
in a cohort of HIV-infected patients presenting with suspected TB and assess the contribution of KSHV 
and KSHV associated pathologies to mortality in the context of TB and HIV infection.  
Peculiar geographical epidemiology of KSHV seroprevalence and population-specific incidence 
of KS outside the setting of HIV (see 1.2.1 and 1.3.1.1), discrepancies in KSHV exposure and infection 
and KSHV/HIV co-infection and KS development in addition to evidence of familial aggregation of KSHV 
seroprevalence add to a growing body of evidence that points to a potential underlying genetic risk of 
susceptibility to KSHV and KS development (see 1.5). Host factor genetic association studies have 
primarily focused on immune-modulatory genes as risk factors for KS (see 1.5). The endothelial entry 
receptor for KSHV, EPHA2 is another promising candidate for investigation not only due to its key role 
in KSHV entry and intracellular trafficking in endothelial cells (see 1.2.3.2 and 1.6.4) but also its 
implication in oncogenesis (see 1.6.3), thus potentially acting at the level of both susceptibility to KSHV 
infection and susceptibility to KS development. Here, we aimed to validate previously identified EPHA2 
variants associated with KSHV and KS (see 1.6.6) and further assess the functional consequences of 






2. Materials and methods 
2.1. Ethics 
Ethics approval was obtained from the Human Research Ethics Committee (HREC), Health Sciences 
Faculty, University of Cape Town (UCT), for the enrolment of patients and collection of blood samples 
for the purposes of this study (HREC279/2008, HREC057/2013, HREC729/2014 and HREC136/2013). 
 
2.2. Patient recruitment 
Two patient cohorts from two sites were utilised for the purposes of this work: an existing hospitalised 
HIV-associated TB cohort (n=682), referred to as ‘KDHTB cohort’, which was recruited at Khayelitsha 
Day Hospital, Cape Town, South Africa, from January 2014 to October 2016 (UCT HREC Ref: 
057/2013)[58]; and a KS cohort (n=100), referred to as ‘KS cohort’, which was recruited at the 
Radiation Oncology Unit at Groote Schuur Hospital (GSH, UCT HREC Ref: 279/2008) from December 
2014 to February 2018.  
 
2.2.1. KDHTB cohort 
2.2.1.1. Study design 
We conducted a retrospective analysis of an existing hospitalised HIV-associated TB cohort (n=682) in 
South Africa. The primary objective was to evaluate whether elevated KSHV VL, defined as 
>100 copies/106 cells, predicted 12-week mortality in the entire cohort, or in a subset that was culture-
negative for TB. Secondarily, we evaluated associations of KSHV VL and serologic assays with clinical 
features in the cohort, as well as the use of clinical parameters that define KICS to predict mortality. 
Due to the retrospective nature of this study, no prospective sample size calculation was performed. 
 Dependent on KSHV status determined by enzyme-linked immunosorbent assay (ELISA, see 
2.4), KS-negative samples from the KDHTB cohort were randomly selected as KSHV-positive or KSHV-




2.2.1.2. Study cohort 
HIV-infected adults presenting with clinical syndromes compatible with pulmonary or extrapulmonary 
TB were recruited at Khayelitsha Day Hospital, Cape Town, South Africa, from January 2014 to October 
2016 in the context of a study entitled “Defining interventions to reduce mortality in severe 
HIV-associated tuberculosis” lead by Prof Graeme Meintjes (UCT). Emergency room and medical ward 
patients were screened, eligible patients were enrolled, and written consent was obtained. Eligible 
patients with a depressed level of consciousness were enrolled and followed up daily until they 
regained the capacity to consent. If a patient died prior to providing consent, we obtained approval 
from UCT HREC to use the patient’s data. Clinical details, including physical examination with 
evaluation of skin and oral mucosa, and samples were collected at enrolment. CD4 cell count, HIV VL, 
CRP, full blood and differential count, and renal and liver function tests were performed by the 
National Health Laboratory Services (NHLS), as well as serum cryptococcal antigen lateral flow assays 
(IMMY). Citrate whole blood and plasma were stored at -80°C for KSHV VL and immunologic assays. 
The standardized TB diagnostic workup included sputum induction if required. TB blood culture in 
Myco/Flytic bottles (Becton Dickinson Biosciences), sputum Xpert MTB/RIF assay, sputum TB culture, 
urine lipoarabinomannan (LAM), and urine Xpert MTB/RIF on concentrated urine were performed 
during enrolment. Bacterial blood cultures were performed in all patients who had not received 
intravenous antibiotics prior to presentation to hospital. Patients were followed for 12 weeks to 
ascertain vital status. 
2.2.1.3. Definition of patient groups 
Patients were grouped into four overlapping categories based on the presence or absence of 
microbiologically confirmed infections. Group 1 (n=675) consisted of the total patient cohort analysed; 
Group 2 (n=500) included all patients with microbiologically confirmed MTB (on culture or GeneXpert 
on any clinical sample or urine LAM-positive); Group 3 (n=175) included the remainder of the total 
patient cohort without microbiologically confirmed MTB; Group 4 (n=159) consisted of Group 3 
patients without another microbiologically confirmed infection (e.g. bacterial bloodstream infection 
or Cryptococcus species), although this group included some patients who were treated for TB despite 
negative microbiology. These groups are not mutually exclusive.  
2.2.1.4. Definition of “possible KICS” 
We evaluated Group 4 patients for KICS. The working case definition of KICS requires at least two 
clinical manifestations from at least two of three categories (Table 2 [6]): A) symptoms (including 
fever, fatigue, oedema, cachexia, respiratory symptoms, gastrointestinal disturbance, arthralgia and 




thrombocytopenia, hypoalbuminemia, and hyponatremia); and C) radiographic abnormalities 
(lymphadenopathy, splenomegaly, hepatomegaly, and body cavity effusions), together with evidence 
of systemic inflammation (elevated CRP), evidence of KSHV lytic activity (elevated [>100 copies/106 
cells] KSHV VL in peripheral blood), and exclusion of MCD. As this analysis was done retrospectively, 
MCD could not be excluded for all patients, hence the designation “possible KICS” patients.  
 
2.2.2. KS cohort 
2.2.2.1. Study design 
Further to our previous study [34,35], in which we identified significant associations of EPHA2 variants 
with KS development or KSHV seroprevalence with a sample size of n=150 powered to detect variants 
with minor allele frequency (MAF) >3%, we recruited a validation cohort of the same sample size 
(n=150) to supplement and validate the original cohort. Statistical association testing was designed as 
three analyses: 1) to assess susceptibility to KSHV infection by comparing KSHV seropositive cases to 
KSHV seronegative controls; 2) to assess KS development by comparing KS cases to KS-negative 
controls; and 3) to assess detectable KSHV VL in the blood by comparing KSHV seropositive patients 
with detectable KSHV VL to those with no detectable VL.  
2.2.2.2. Study cohort 
Patients with KS were recruited from the Radiation Oncology Unit, GSH, where they were receiving 
treatment for KS, under the supervision of radiation oncologist, Dr Zainab Mohamed. Patients with no 
KS were identified within the KDHTB study (see 2.2.1) in collaboration with Prof Graeme Meintjes [58] 
and KSHV serostatus was determined by ELISA (see 2.4). HIV-positive males and females over the age 
of 18 who were living in South Africa, irrespective of population group, were recruited to the study. 
Clinical diagnosis of KS was recorded in addition to demographic information (sex, age and population 
group) and appropriate clinical information (HIV status, latest CD4 count and ART treatment status) 
was sourced from patient records. KS treatment was recorded but not used as an exclusion criterion.  
Enrolment was contingent on the patient giving their informed consent. Recorded patient 
information and collected samples were anonymised with numerical labelling that did not disclose 
patient identity. Information was recorded only if necessary for the study purposes and stored on a 
password-protected computer and in a locked office in accordance with the Protection of Personal 




2.2.2.3. Definition of patient groups 
Patients were recruited into three groups determined by KS diagnosis and KSHV serostatus. The newly 
recruited validation cohort (n=150, 50 patients per group as below) was recruited from the same 
clinics as the original cohort (n=150, 50 patients per group [34]) to supplement the sample sizes: 
 
Group 1 (KS+/KSHV+): patients with KS who were KSHV seropositive (n=100) 
Group 2 (KS-/KSHV+): patients without KS who were KSHV seropositive (n=100) 
Group 3 (KS-/KSHV-): patients without KS who were KSHV seronegative (n=100) 
 
All patients had a thorough clinical examination by experienced clinicians to document the occurrence 
of typical KS cutaneous lesions, mucosal lesions and lymphoedema. When indicated, skin biopsy and 
chest X-ray supported the diagnosis of KS. KSHV serostatus was determined by KSHV ELISA (see 2.4). 
 
2.3. Sample collection, preparation and storage 
2.3.1. Sample collection 
A nurse practitioner drew 10 ml of peripheral blood from the arm of each patient during their routine 
visit and, when possible, at the same time as drawing blood for medical purposes to reduce the 
patient’s discomfort. Samples obtained for the KS cohort were collected in 
ethylenediaminetetraacetic acid (EDTA)-tubes and initially stored at room temperature preceding 
plasma preparation (see 2.3.2); then at 4°C prior to DNA extraction (see 2.3.3); and thereafter at -20°C 
at the Institute for Infectious Diseases and Molecular Medicine (IDM), UCT. KDHTB study samples were 
stored at -20°C after being allowed to settle. 
 
2.3.2. Plasma preparation and storage 
Plasma was prepared as soon as possible and within 4 hours (h) after collection of KS cohort samples 
(see 2.3.1) by centrifugation (Eppendorf 5810 R, 2237 x g for 10 minutes (min) at room temperature) 
to separate plasma from blood cells. Stored samples from the KDHTB cohort that had been allowed 




were opened in a Biosafety Level 2 laboratory safety cabinet. Plasma was pipetted off the top layer of 
the separated blood and used immediately or stored in 500 μl aliquots at -20°C to avoid freeze-
thawing.  
 
2.3.3. DNA extraction, quality assessment and storage 
Following removal of plasma, blood samples containing a leukocyte enriched buffy coat fraction and 
an erythrocyte fraction were immediately used for genomic DNA extraction using the QIAamp DNA 
Blood Mini or Midi kits (Qiagen) according to the manufacturer’s protocol for DNA purification from 
blood (spin protocol). Following DNA isolation, DNA quantity and quality were assessed by nanodrop 
analysis and eluted DNA of good quality (ratio of absorbance at 260 nm to absorbance at 280 nm in 
the range 1.8–2.0) was stored in Buffer AE (Qiagen) at -20°C. 
 
2.4. KSHV K8.1 and LANA ELISAs 
KSHV ELISAs were performed for all patients to determine KSHV serostatus. Cryopreserved plasma 
(see 2.3.2) was tested by ELISA kits generously provided by Dr Denise Whitby (Frederick National 
Laboratory for Cancer Research, USA) [324] for antibodies against LANA (ORF73) and K8.1, following 
established specifications [324]. Briefly, ELISA plates coated either with recombinant K8.1 or LANA and 
stored at -80°C were thawed in a 37°C incubator. Once thawed, the plates were washed three times 
with at least 350 µl ELISA wash buffer (see Appendix 7.1) per well, inverted and patted dry on paper 
towel. Plasma samples stored at -20°C were thawed on ice, vortexed and diluted 1:10 with ELISA assay 
buffer (see Appendix 7.1). Samples were added to the K8.1 plate and the LANA plate at final dilutions 
of 1:20 and 1:100, respectively, as determined previously [324]. Only ELISA assay buffer was added to 
wells as blank controls. Ten pooled KS patient samples at a 1:10 dilution in ELISA assay buffer were 
used as a positive control, while a pool of ten samples from patients without KSHV served as our 
negative control. Sealed plates were incubated at 37°C for 90 min. Plates were subjected to five 
washes with ELISA wash buffer to remove unbound plasma components and dried on paper. 
ReserveAP Goat anti-Human IgG (H+L) phosphatase labelled antibody (KPL) was diluted with ELISA 
assay buffer (1:5000) and 100 µl per well was added after which the plate was incubated for 30 min 
at 37°C and then washed five times. Next, 100 µl of 1-step p-nitrophenyl phosphate (PNPP) substrate 
solution (Pierce Biotechnologies) was added to each well and the plate was incubated at room 




the reaction was promptly stopped by adding 50 µl ELISA stop solution (see Appendix 7.1). The ELISA 
plates were flamed briefly with a Bunsen burner to remove any bubbles and read on an ELISA plate 
reader (Versa max, with the SoftMax Pro 6.3 software) at a wavelength of 405 nm. The raw values 
were adjusted according to the average optical density (OD) values of the blank controls. The cut-off 
OD values were calculated using the equation previously determined by Mbisa et al. [324]. The cut-
off OD for the K8.1 ELISA was determined as: 
𝑂𝐷𝑐𝑢𝑡 𝑜𝑓𝑓K8.1 = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠K8.1 + 0.95 
 
Similarly, the cut-off OD value for the LANA ELISA was: 
𝑂𝐷𝑐𝑢𝑡 𝑜𝑓𝑓LANA = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠LANA + 0.35 
 
A sample was considered KSHV seropositive if antibodies to either antigen were detected [324]. The 
blank, negative and positive controls were assessed in each assay to determine its validity, as 
summarised in Table 4 below [324]. 
 
 
2.5. KSHV viral load assay  
KSHV VL was determined from the blood samples by quantitative TaqMan PCR to the K6 gene. The 
DNA concentration (see 2.3.3) was adjusted to 25 ng/μl, with 10 μl used per PCR reaction (total volume 
50 μl) to detect KSHV DNA using 100 pmole K6 gene region forward and reverse primers (Table 5), 
5 pmole FAM/TAMRA labelled probe [325] (Table 5), and 2X Universal Master Mix (Applied 
Biosystems). KSHV DNA was quantified against a K6-plasmid (kindly provided by Dr Denise Whitby, 
National Institute of Health (NIH)) standard curve of known concentration of K6 DNA on a LightCycler 
Table 4: Quality control specifications for the K8.1 and LANA ELISAs. 
Control K8.1 ELISA LANA ELISA 
Blank (raw value) <0.20 <0.10 
Negative control (blank adjusted) 0–0.30  
Mean x 0.5 - mean x 1.5 
0–0.20  
Mean x 0.5 - mean x 1.5 




480II System (Roche) as follows: 2 min at 50°C; 8 min at 95°C; and 45 cycles of 15 seconds (s) at 95°C 
and 1 min at 60°C. KSHV DNA concentration was normalised to the number of cellular equivalents in 
the sample, determined using a quantitative assay for human endogenous retrovirus 3 (ERV-3) which 
occurs at two copies per human cell. ERV-3 was similarly quantified using forward and reverse primers 
(Table 5) against a standard curve of known concentration of human ERV-3 DNA (kindly provided by 
Dr Denise Whitby, NIH) [326]. Assays were deemed valid based on several quality controls (Table 6). 
Samples were tested in triplicate, averaged, and reported as viral DNA copies per million cells. 
 
Table 5: Primers and probes used in quantitative Taqman PCR to determine KSHV VL. 
Primer or probe Sequence 5’–3’ 
K6 forward primer CGCCTAATAGCTGCTGCTACGG 
K6 reverse primer TGCATCAGCTGCCTAACCCAG 
K6 probe FAM-CACCCACCGCCCGTCCAAATTC-TAMRA 
ERV-3 forward primer CATGGGAAGCAAGGGAACTAATG 
ERV-3 reverse primer CCCAGCGAGCAATACAGAATTT 
ERV-3 probe FAM-TCTTCCCTCGAACCTGCACCATCAAGTCA-TAMRA 
 
Table 6: Quality control specifications for the KSHV VL assays. 
Control K6 assay ERV-3 assay 
No template control  No amplification  No amplification  
Negative control No amplification  No amplification  
Positive control (Mean copy number range) 10–50,000  10 –100,000  
Standard curve slope range -3.2– -3.7  -3.2– -3.7  
Standard curve R2 value  >0.97 >0.97 
Standard curve Y-intercept (range) 37–43  37–43  
Standard curve average Ct values (range) 
 

















2.6. IL-6 assays 
Plasma IL-6 was measured using the Human IL-6 SimpleStep ELISA kit (Abcam), with a minimum 
detectable dose of 1.6 pg/ml1 quantified against a standard curve of human IL-6 recombinant protein. 
Briefly, standards were prepared by serial dilution of the supplied human IL-6 recombinant protein 
which was reconstituted at 2,000 pg/ml in Sample Diluent NS (proprietary reagent, ab193972 Abcam). 
The blank standard contained only Sample Diluent NS. Plasma samples were thawed on ice and 
vortexed before 50 µl of sample or standard was added undiluted and in duplicate to the provided 
ELISA plates that were pre-coated with an anti-tag antibody. An antibody cocktail (50 µl) consisting of 
Human IL-6 tag-labelled capture antibody and a reporter conjugated detector antibody was added to 
the sample in the ELISA plate and the capture antibody/analyte/detector antibody complex was 
immobilised during 1 h incubation at room temperature on a plate shaker set to 400 revolutions per 
minute (rpm). The plate was washed three times to remove unbound material with 350 µl Wash Buffer 
PT (proprietary reagent supplied with the kit, Abcam) and the plate blotted against paper towel to 
remove excess liquid. Next, 100 µl 3,3′,5,5′-Tetramethylbenzidine (TMB) Substrate (supplied with kit, 
Abcam) was added to each well and the plate was incubated in the dark for 10 min on a plate shaker 
set to 400 rpm at which point 100 µl Stop Solution (proprietary reagent supplied with kit, Abcam 
ab178013) was added to each well. The plate was shaken on a plate shaker for 1 min to ensure 
thorough mixing and the absorbance at 450 nm was immediately read on a fluorometer (Versa max, 
with the SoftMax Pro 6.3 software). The average absorbance for the blank controls was subtracted 
from all absorbance values. A standard curve was constructed by plotting these adjusted standard 
absorbance values against the known protein concentration and the sample concentrations were 
calculated by interpolating the absorbance values onto the standard curve. Samples that were found 
to have absorbance values greater than the highest standard, were diluted and run again and the 
resultant concentrations corrected by the appropriate dilution factor.   
 
2.7. Post-mortem histology 
Post-mortem histology was performed on one patient lymph node to ascertain a diagnosis of MCD or 
KICS by Michael Locketz of the NHLS. After obtaining consent from the family, an excisional cervical 
 





lymph node biopsy was performed two days post-mortem. Tissue was fixed in 10% formal saline for 
48 h, processed overnight in a Tissue-Tek Vacuum Infiltration Processor (Sakura Finetek), and 
embedded in paraffin. Tissue sections were cut at 4 µm thickness and stained with haematoxylin and 
eosin and ORF73 immunoperoxidase (Cell Marque) using the Benchmark XT automated staining 
platform with the Ventana ultraView Universal DAB Detection kit (Roche Diagnostics). 
Immunostaining for kappa and lambda light chains was also performed. Photomicrographs were 
obtained with an Olympus SC30 3.3 megapixel USB digital colour camera attached to an Olympus BX41 
microscope using analySIS getIT 5.1 digital imaging software (Olympus Soft Imaging Solutions). 
 
2.8. Statistical analysis of KDHTB clinical data 
KSHV VL was treated both as a categorical variable (elevated >100 copies/106 cells vs ≤100 copies/106 
cells or nondetectable) and a continuous variable and assessed for association with mortality using 
the χ2, Fisher exact, or Wilcoxon rank-sum test, as appropriate. The relationship between KSHV VL 
and mortality was assessed by binomial logistic regression, controlling for age, sex, CD4 cell count, and 
ART status. Linearity of the continuous variables with respect to the logit of the dependent variable 
was confirmed via the Box–Tidwell procedure [327], and studentized residuals with values <2.5 
standard deviations were accepted. To compare “possible KICS” patients to the remainder of the 
cohort, associations of categorical variables (sex, receiving ART, KSHV seropositivity, presence of skin 
KS) and continuous variables (age, weight, HIV VL, CD4 cell count, KSHV VL, K8.1 and ORF73 antibody 
levels, IL-6, CRP, haemoglobin, white cell count, platelet count, albumin, and sodium) were assessed 
by Fisher exact or Wilcoxon rank-sum test, respectively. To assess the independent associations of 
KSHV seropositivity or KSHV antibody levels with mortality, binomial logistic regression or multiple 
linear regression was performed, respectively. Continuous variables were transformed, where 
appropriate, to approximate normal distributions. Survival analysis was performed using the Kaplan–
Meier method and log-rank sum test. P values were two-tailed and considered significant if <0.05. 
Statistical testing was performed using SPSS version 25 (IBM Corp, 2017). Performance characteristics 
of KICS criteria for predicting death were calculated in R (R Core Team, 2019) using a confusion matrix. 
 
2.9. Validation of EPHA2 SNVs associated with KSHV and/or KSHV  




in exons 12–17, that were significantly associated with KSHV and KS, however, the study was limited 
by the small sample size of only 50 patients per group. Based on this previous work, additional patients 
were now recruited (see 2.2) and a combined analysis of this gene region performed to strengthen 
previous data. 
 
2.9.1. PCR amplification of selected EPHA2 exons  
PCR was performed to amplify the Pkinase-Tyr domain (Exons 12–15) and the SAM domain (Exons 16–
17) of the EPHA2 gene (Figure 4) using a number of gene-specific primers (Table 7) together with the 
FastStart Taq DNA Polymerase kit (Roche) according to the manufacturer’s instructions. PCR reactions 
contained final concentrations of the following reagents: 1X PCR buffer with 2 mM MgCl2; 200 µM 
nucleotide mix; 0.2 µM forward primer; 0.2 µM reverse primer; 1 U FastStart Taq DNA polymerase; 
and 2 ng/µl DNA to a total volume of 25 μl. PCR reactions were cycled on a thermal cycler (Applied 
Biosystems GeneAmp® PCR system 2700 or Perkin Elmer GeneAmp® PCR system 2400) as follows: 4 
min at 95°C; 35 cycles of 30 s at 95°C, 30 s at 60°C (or 62°C for exon 14) and 45 s at 72°C; and 1 min at 
72°C. 
 
Table 7: Primer sequences for PCR of EPHA2 Pkinase-Tyr and SAM domains [34,36]. F and R refer to 
forward and reverse primers, respectively. Amplicon length is calculated based on the EPHA2 NCBI 
reference sequence (ID: NM_004431.3). 
EPHA2 domain Exon Primer sequence (5’–3’) Amplicon length (bp) 
Pkinase-Tyr  12 F TGGTGGTGTAGGTGGCCTCG 602 
R TACCTCTGCCCACTCCTCCG 
13 F CGTCGCTGGCAGAGGTGAAC 600 
R CCCTGGACAAGTTCCTTCGGG 
14 F AACTGTCCTCTGCCCAGCCC 455 
R CGAGGCCACCTACACCACCA 
15 F CTGGGCCATCGTGTCCAGTC 517 
R GGGCAGCTCTGAAGGTTGGG 
SAM 16 F TGGCGGAGTTCTGCCCTTCT 458 
R GACTGGGCTTCCCTGTTGCC 






2.9.2. Agarose gel electrophoresis of DNA 
Following cycling, PCR amplicons (5 μl) mixed with 1 μl 6X gel loading dye (Thermo Fisher Scientific) 
alongside a GeneRuler 1 kb DNA ladder (250-10,000 bp, Thermo Fisher Scientific) were 
electrophoresed on a 1% agarose gel containing SYBRSafe nucleic acid gel stain (Life Technologies, 
1:10,000) in 1X tris-acetate-EDTA (TAE) (see Appendix 7.1) for 1 h at 100 V. Following separation, the 
DNA bands were visualised under UV light to confirm that the individual PCR products were amplified 
successfully and specifically. 
 
2.9.3. Dideoxy DNA sequencing  
PCR products were purified and sequenced using dideoxy sequencing with the gene-specific primers 
used for PCR (Table 7) at the Stellenbosch Central Analytical Facility. Sequencing was performed in 
both the forward and reverse direction to ensure reliable sequence determination. Sequence quality 
was assessed by viewing the sequence chromatograms on the programme BioEdit (version 7.2.5 
©1997–2013). 
 
2.9.4. Bioinformatic processing of sequence data 
Computational processing of the sequence data was performed on the UCT Information and 
Communication Technology Services High Performing Computing Cluster using bioinformatics 
programmes encompassed in the European Molecular Biology Open Software Suite (EMBOSS) [328], 
followed by ClustalW2 multiple alignment (EMBL) [329] to compare the sequences to the EPHA2 
reference sequence (NM_004431.3). DNA sequence variants that were predicted to be non-
synonymous through in silico translation were further assessed for predicted functional consequences 
using the PolyPhen-2 prediction tool [330]. The SNP database was consulted to assess if the identified 
variants had been previously reported [331].  
 
2.9.5. Statistical analysis of EPHA2 SNV data 
Statistical testing of demographic data included Fisher exact tests for categorical variables: sex, 




using in IBM SPSS Statistics (Version 25.0. Armonk, NY: IBM Corp). This analysis was done according to 
the comparisons used for association testing (see 2.9.5.2).  
2.9.5.1. Aggregate analysis of previous data 
In order to determine whether less common variation was associated with KSHV infection and KS 
status, particularly since using a rather small patient cohort of n=150, we performed an aggregate 
analysis on our original cohort as in previous studies [332,333] in which we considered whether each 
participant carried ≥1 or 0 EPHA2 SNV with MAF <5%. Aggregate scores were determined for all SNVs 
across EPHA2 and for missense, synonymous and UTR variants. Additionally, aggregate scores were 
determined by functional domain (Pkinase-Tyr, SAM, 5`-UTR, 3`-UTR and Fn-3 domains). Associations 
between aggregate scores and case-control status were determined using logistic regression. 
2.9.5.2. Association testing  
Identified sequence variants were statistically analysed for association with KSHV serostatus, KS 
prevalence and KSHV VL detection. Contingency tables (2x2) assessed the occurrence of variants on 
the genotypic level in cases versus controls and Fisher Exact association tests were performed in IBM 
SPSS Statistics (Version 25.0. Armonk, NY: IBM Corp), as described [334], using the following 
comparisons, as appropriate: 
 
Association with KSHV serostatus: Groups 1 and 2 (KSHV+) vs. Group 3 (KSHV-) 
Association with KS development: Group 1 (KS+/KSHV+) vs. Group 2 (KS-/KSHV+) 
Association with detectable VL: Detectable VL vs. Non-detectable VL within KSHV+ (Groups 1 
and 2) patient groups.  
 
A P value <0.05 was considered significant. Fisher exact tests were corrected for multiple comparisons 
using the Bonferroni-corrected pairwise technique. 
2.9.5.3. Logistic regression  
With KSHV serostatus, KS status or KSHV VL status as the binomial dependent variable, the relationship 
of SNVs identified through association testing (see 2.9.5.2) were subjected to binomial logistic 





2.10. Plasmids used in this study 
Plasmids used in this study are detailed in Table 8. The pLentiCRISPR v2 into which the CRISPR/Cas9 
guide RNA (gRNA) target sequences (G1, G2 and G3) were cloned (see 2.13.1) was provided by Dr 
Klaus Heger and Dr Marc Supprian (Max Planck Institute of Biochemistry, Germany) and engineered 
by Dr Janina Bruening, Institute for Experimental Virology, Twincore, Hannover Medical School, 
Germany (see 2.13.1). This plasmid contains both puromycin and ampicillin resistance genes. Lentiviral 
packaging vectors pCMV-VSV-G and pCMVR8.74, containing ampicillin resistance genes, were 
received from Dr Janina Bruening and Prof Dr Thomas Pietschmann, Institute for Experimental 
Virology, Twincore, Hannover Medical School, Germany. The lentiviral vector (HIV-1 based) 
RRL.SF.newMCS.i2.Zeo.pre containing ampicillin and zeocin resistance genes was kindly provided by 
Dr Melanie Galla, Prof Dr Christopher Baum and Prof Dr Axel Schambach, Institute of Experimental 
Haematology, Hannover Medical School, Germany. RRL.SF.newMCS.i2.Zeo.pre was engineered to 
carry the synthetic EPHA2 (sEPHA2) coding DNA sequence (see 2.15.1) and subjected to site-directed 
mutagenesis (SDM, see 2.14). The plasmid 17ADD7RP_sEPHA2_pMA consisting of sEPHA2 cloned into 
a pMA backbone with ampicillin resistance was purchased from Geneart, Invitrogen, Thermo Fisher 
Scientific. The human EPHA2 ORF mammalian expression plasmid pCMV3-EPHA2 and the pCMV3-
untagged negative control vector, both containing ampicillin resistance genes, were purchased from 




Table 8: Plasmids used in this study. Affiliations are indicated: 1Max Planck Institute of Biochemistry, Germany, 2Institute for Experimental Virology, Twincore, 
Hannover Medical School, Germany; 3Institute of Experimental Haematology, Hannover Medical School, Germany.  
Plasmid name Source Purpose Selection 
marker 
Plasmid map 
pLentiCRISPR v2 Kindly provided by Klaus Heger and 
Marc Supprian1 
Cas9 containing lentiviral backbone into which 






G1.pLentiCRISPR v2 Engineered by Janina Bruening2 (see 
2.13.1) 
EPHA2-specific gRNA containing CRISPR/Cas9 
lentiviral backbone for production of 




pCMV-VSV-G Kindly provided by Janina Bruening2 Envelope protein for the production of 




pCMVR8.74 Kindly provided by Janina Bruening2 Packaging vector for production of lentiviruses.  Ampicillin Supplementary 
figure 3 
RRL.SF.newMCS.i2.Zeo.pre Kindly provided by Melanie Galla, 
Christopher Baum and Axel 
Schambach3 
Lentiviral backbone into which genes of interest 








Engineered by cloning (see 2.15.1)  sEPHA2 containing lentiviral backbone for 
production of lentiviruses in conjunction with 








Engineered by SDM (see 2.14) sEPHA2 (subjected to SDM) containing lentiviral 
backbone for production of lentiviruses in 
conjunction with envelope and packaging 
vectors. 
17ADD7RP_sEPHA2_pMA Purchased from Geneart, Invitrogen, 
Thermo Fisher Scientific 
Synthetic EPHA2 cloned into standard backbone 
vector for cloning. 
Ampicillin Supplementary 
figure 6 
pCMV3-untagged  Purchased from Sino Biological Inc. Empty negative control vector. Ampicillin Supplementary 
figure 7 
pCMV3-EPHA2 Purchased from Sino Biological Inc. EPHA2 expression vector. Hygromycin/ 
ampicillin 
Supplementary 




2.11. Cell culture  
2.11.1. Established cell lines 
Human embryonic kidney 293 cells (HEK293; Cellonex, C293-C) and HEK293T (derived from HEK293 
cells by stably expressing simian virus 40 (SV40) large T antigen (TAg); DSMZ No.: ACC 305) were 
maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated 
foetal bovine serum (FBS; Sigma). BJAB-rKSHV.219 cells [335], SLK (of epithelial cell origin) and SLK 
EPHA2-KO cells were grown and maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 20% heat-inactivated FBS in the presence of 4.2 μg/ml puromycin and expanded 
in spinner flasks (Lasec, South Africa). These cells were derived from the Burkitt lymphoma-derived B-
cell line BJAB (ACC 757) stably infected with a JSC-1 derived recombinant KSHV.219 (hereafter referred 
to as rKSHV) that expresses both the red fluorescent protein (RFP) under the control of the KSHV lytic 
gene PAN promoter as well as GFP under the control of the cellular EF-1α promoter in addition to the 
puromycin resistance gene as a selectable marker [336]. Lymphatic endothelial cells (LEC) and LEC 
EPHA2-KO cells in addition to HuARLT2 cells which are a derivation of HUVECs conditionally 
immortalised by expressing doxycycline-inducible transgenes SV40 large TAg and human telomerase 
reverse transcriptase (hTert) [337], were grown and maintained in endothelial cell growth basal 
medium (EBM-2, Lonza) containing supplements and growth factors included in the microvascular 
(MV) endothelial SingleQuots kit (Lonza, complete media called EGM-2MV contained 5% FBS, 0.5 ml 
human epidermal growth factor (hEGF), 0.2 ml hydrocortisone, 2 ml basic fibroblast growth factor 
(FGF-B), 0.5 ml VEGF, 0.5 ml arginine 3-insulin-like growth factor (R3-IGF-1), 0.5 ml ascorbic acid and 
0.5ml gentamicin-amphotericin-B (GA-1000) per 500 ml EMB-2) in the presence of 1 μg/ml doxycycline 
(Sigma-Aldrich). HEK293T, BJAB-rKSHV.219 and HuARTL2 cell lines were kindly provided by Prof 
Thomas Schulz (MHH, Hannover, Germany) and SLK, SLK EPHA2-KO cells, LEC and LEC EPHA2-KO cells 
were a kind gift from Dr Frank Neipel, Institute of Clinical and Molecular Virology, University Clinic, 
Erlangen, Germany. 
 
2.11.2. Cell lines engineered in this study 
All engineered cell lines generated in this study are summarised in Table 9. The HuARLT2 cell line was 
subjected to CRISPR/Cas9 knockout (see 2.13) directed towards the EPHA2 gene generating three cell 
lines, namely Hu-G1, Hu-G2 and Hu-G3 (the latter was further referred to as Hu-KO) which were 




CRISPR/Cas9 with lentivirus containing scrambled gRNA was generated as a control cell line. These 
CRISPR/Cas9 engineered cell lines were maintained in EGM-2MV media containing 1 μg/ml 
doxycycline. The Hu-KO cell line was further modified by lentiviral transduction (see 2.15) of the 
RRL.SF.newMCS.i2.Zeo.pre vector alone (empty vector (EV) control) or vector containing wild type 
(WT) sEPHA2 or sEPHA2 having undergone SDM (see 2.14). These transduced cell lines were 
maintained in EGM-2MV media containing 1 μg/ml doxycycline and 200 μg/ml zeocin.  
 
2.11.3. Maintaining cell cultures 
All cells were maintained in the media specified above at 37°C in a humidified incubator with 5% CO2.  
 
Table 9: Engineered cell lines transduced with the indicated lentiviruses.  





parent cell line 
Hu-G1 HuARLT2 G1.pLentiCRISPR v2 gRNA 1 targeting EPHA2 
Hu-G2 HuARLT2 G2.pLentiCRISPR v2 gRNA 2 targeting EPHA2 
Hu-G3/ Hu-KO HuARLT2 G3.pLentiCRISPR v2 gRNA 3 targeting EPHA2 
Hu-Scr HuARLT2 Scr.pLentiCRISPR v2 scrambled gRNA. 
Hu-EV Hu-KO RRL.SF.newMCS.i2.Zeo.pre  Empty vector 
Hu-WT Hu-KO sEPHA2.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 wildtype 
Hu-WT-SDM Hu-KO sEPHA2-SDM.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 wildtype (SDM 
with control primers) 
Hu-SDM1 Hu-KO sEPHA2-SDM1.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 C915T 
Hu-SDM2 Hu-KO sEPHA2-SDM2.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 A2257C 
Hu-SDM3 Hu-KO sEPHA2-SDM3.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 T2254C 
Hu-SDM4 Hu-KO sEPHA2-SDM4.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 A2257C and 
T2254C 
Hu-SDM5 Hu-KO sEPHA2-SDM5.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 G2688C 
Hu-SDM6 Hu-KO sEPHA2-SDM6.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 C2727T 
Hu-SDM7 Hu-KO sEPHA2-SDM7.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 G2990T 
Hu-SDM8 Hu-KO sEPHA2-SDM8.RRL.SF.newMCS.i2.Zeo.pre  sEPHA2 G2844A 




2.11.4. Sub-culturing cells 
Adherent cell lines were grown in 75 cm2 cell culture flasks (SPL Life Sciences) until 80–90% confluency 
before being washed with phosphate-buffered saline (PBS, 1X) and removed from the flask 
enzymatically with 0.025% trypsin/0.01% EDTA or accutase (Biowest, for HuARLT2 and LEC cells). Cells 
were pelleted at 400 x g for 3 min and resuspended in fresh media at the appropriate ratio.  
 
2.11.5. Cell counting and plating 
To count cells, 10 µl of re-suspended cells were added to 90 µl of a 0.4% trypan blue solution (Sigma), 
and 10 µl of this was placed on the Neubauer haemocytometer (Marienfeld) on which a coverslip was 
placed. Trypan blue allows identification of live cells. Using a microscope (Nikon TMS) live cells were 
counted and cell concentration was determined using the following formula: 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑖𝑛 4 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑜𝑓 ℎ𝑒𝑚𝑜𝑐𝑦𝑡𝑜𝑚𝑒𝑡𝑒𝑟 
4
 × 10 × 10,000 = 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 
 
Cell suspensions were diluted to the required density in media and added to the appropriate cell 
culture plate. Cells maintained in selection media were plated in the presence of antibiotics. 
 
2.11.6. Storage of cell lines in liquid nitrogen 
Cell lines were cryopreserved in liquid nitrogen for long term storage. To prepare cells for storage in 
liquid nitrogen, cell pellets were resuspended in media containing 10% dimethyl sulfoxide (DMSO) and 
transferred to cryovials. Cells were frozen in a Mr FrostyTM freezing container (Thermo Fisher Scientific) 
containing isopropanol at -80°C for at least 24 h before being transferred to liquid nitrogen storage. 
To thaw cells after storage in liquid nitrogen, cryotubes were transported on ice before being thawed 
rapidly in a 37°C water bath. Cells were resuspended in 4 ml pre-warmed media before being pelleted 





2.11.7. Mycoplasma testing 
Cell lines were routinely tested for mycoplasma contamination. Cells were plated on glass coverslips 
and, 24 h later, fixed and stained with Hoechst fluorescent DNA-binding stain (Sigma), mounted and 
visualised on a Zeiss Axiovert 200M Fluorescent Microscope (Carl Zeiss, Jena, Germany). 
 
2.12. Transfection of EPHA2 expression constructs into HEK293 cells 
HEK293 cells were plated at a density of 2.5x105 cells/well per transfection in 12-well cell culture plates 
(see 2.11.5). The next day, 1 µg plasmid DNA (pCMV EV control, pCMV-EPHA2-WT or pCMV-EPHA2 
SDM variants) was added to 3 µl Fugene Transfection Reagent (Promega) in 100 µl DMEM (without 
FBS, pre-incubated at room temperature for 5 min) and incubated at room temperature for 15 min. 
The transfection mixture was added to cells and incubated for 48 h at 37°C in a 5% CO2 incubator. Cells 
were lysed for Western blot (see 2.20.1) or further used in infection experiments (see 2.17). 
 
2.13. CRISPR/Cas9 knockout of endogenous EPHA2  
2.13.1. CRISPR/Cas9 gRNA design and plasmid construction 
CRISPR plasmids were engineered by Dr Janina Bruening (Institute for Experimental Virology, 
Twincore, Hannover Medical School, Germany). Three gRNA target sequences were designed to knock 
out EPHA2 using the online tool CHOPCHOP [338,339] targeted to H. sapiens (hg38/GRCh38) EPHA2 
(NM_004431; isoform 1) and selected using the CHOPCHOP ranking and binding site (Table 10). 
Binding sites for gRNAs in the 5’ region were preferred to avoid generation of a truncated protein 
rather than knockout (Table 10). Complementary single-stranded oligonucleotides containing the 
selected gRNA sequences and a scrambled gRNA as a control, appropriate protospacer adjacent motif 
(PAM, “CACC”) sequence and BsmBI restriction sites were synthesised (Institute for Experimental 
Virology, Twincore, Hannover Medical School, Germany). The pLentiCRISPR v2 plasmid and annealed 
double-stranded oligonucleotides were cut with BsmBI and ligated with T4 ligase (Thermo Fisher 










PAM and BsmBI site) 











5 + 70 0 0 
G2 6 GAAGGTAACTCCCAGAG
GGG 
6 - 65 0 0 
G3 14 CGCACCAACTGGGTGTA
CCG 
3 - 65 0 0 
 
 
2.13.2. Transformation and plasmid DNA extraction of CRISPR/Cas9 plasmids 
Ligated plasmid DNA (see 2.13.1) was transformed into E.coli TG2 competent cells that were thawed 
on ice following storage at -80°C. Briefly, 1 µl ligation mixture was added to the thawed competent 
cells and kept on ice for 30 min. Cells were heat-shocked by placing the Eppendorf tubes in a water 
bath at 42°C for 45 s and then immediately back on ice for 10 min. Luria Bertani (LB) media (see 
Appendix 7.1) was pre-warmed to 37°C and 700 µl was added to each tube of transformed cells which 
were incubated at 32°C for 1 h in a shaking incubator. Liquid cultures were centrifuged at 1000 x g for 
3 min and 500 µl supernatant removed to concentrate the cells. 100 µl of the remaining culture was 
spread on agar plates containing ampicillin (75 µg/ml) and incubated at 32°C overnight. The following 
day, colonies were picked into 3 ml LB containing ampicillin (75 µg/ml) and incubated at 32°C 
overnight in a shaking incubator before expanding into a 350 ml LB liquid culture (75 µg/ml ampicillin) 
which was incubated at 32°C overnight in a shaking incubator. Plasmid DNA was isolated from the 
liquid culture the following day using the Endofree Plasmid Maxi kit (Qiagen) according to the 
manufacturer’s instructions. DNA was quantified by nanodrop (see 2.3.3).  
 
2.13.3. Lentivirus production 
HEK293T cells were seeded at a density of 3.5x106 cells per dish in a 10 cm cell culture dish in DMEM. 
The following day, cells were co-transfected with gRNA containing pLentiCRISPR v2 and packaging 
vectors, pCMV-VSV-G and pCMVR8.74 (kindly provided by Prof Dr Thomas Pietschmann and Dr Janina 
Bruening, Institute for Experimental Virology, Twincore, Hannover Medical School, Germany), using 
Lipofectamine (Invitrogen) according to the manufacturer’s instructions. The following day, media 




CRISPR/Cas9 lentiviruses were harvested from the cell culture supernatants by filtering the media 
through 0.45 µm pore size filters and buffered with HEPES (1:50). Polybrene (Sigma-Aldrich, 5 µg/ml) 
was added to the virus preparations. Viruses were used immediately or stored at -80°C. 
 
2.13.4. Virus transduction 
Target cells (HuARLT2) were seeded at a density of 5x105 cells/well in a 6-well plate. One well was 
seeded as a negative control for selection. Four h later, media was removed, and 1 ml lentivirus and 
5 µg/ml polybrene-containing media was added per transduction. Cells were incubated for at least 4 h 
after which 2 ml fresh media was added. Forty-eight hours later, media was removed and selection 
media containing puromycin (4.2 μg/ml) was added to the transduced cells as well as the negative 
control cells. Selection media was changed daily, and cells were expanded once all of the negative 
control cells were dead. The three knockout cell lines were then assessed for EPHA2 knockout by 
Western blot (see 2.20) and sequencing with primers designed to amplify the cut site of transduced 
cells (Table 11).  
 
Table 11: Primers for amplification and sequencing of genomic DNA of CRISPR/Cas9 transduced cells 
to analyse cut site gRNA. Tm=melting temperature of primer.  
Primer name Primer sequence Tm (°C) Amplicon size (bp) 
5’ gRNA1 AGCACTGACTCCTCCTGTCTGT  60.5 
279 
3’ gRNA1 GTGAAGGTGTAGTTCATGTGGG  59.4 
5’ gRNA2  TAGGCAGCTTCTTACCCACTTC  59.9 
234 
3’ gRNA2  GTGATCATCTATGTGACCAGCC  59.4 
5’ gRNA3  CATGAATGACATGCCGATCTAC  60.4 
261 
3’ gRNA3 ATGGTGTCAATCTTGGTGAACA  60.3 
 
2.14. Site-directed mutagenesis 
Point mutations (Table 12) were introduced into the EPHA2-CMV expression plasmid (Sino Biological 
Inc.), the sEPHA2 cloning vector (17ADD7RP_sEPHA2_pMA, Geneart Invitrogen) or the sEPHA2-
RRL.SF.newMCS.i2.Zeo.pre lentiviral vector using the Agilent Quick Change II or Agilent Quick Change 




Primer Design Program (Agilent), synthesised by the UCT Synthetic DNA lab or Inqaba Biotech, South 
Africa, and PAGE purified, Table 12) to synthesize the mutant strand. Primers SDM1–7 were designed 
to introduce EPHA2 SNVs previously identified in our clinical association study [34] and SDM8 primers 
were designed to introduce a previously described serine phosphorylation deficient mutant, c.G2844A 
[127], (Table 12). As a control, SDM with benign primers identical to the WT sequence (i.e. inducing 
no mutagenesis) was performed so that the Hu-WT-SDM cell line was subjected to the same 
experimental steps as the SDM cell lines, removing the possibility that any functional differences seen 
were due to experimental conditions. This was followed by DpnI digestion of the parental strand. DpnI 
digested DNA was transformed into E.coli XL1-Blue supercompetent cells and spread onto agar plates 
containing 75 μg/ml ampicillin. Plates were incubated at 37°C (or 32°C for the lentiviral vector) 
overnight. The following day, colonies were picked into ampicillin containing LB media and incubated  
Table 12: Primers used for site directed mutagenesis. 
Introduced mutation Primer name Primer sequence (5’–3’) Source 
C915T SDM 1 F CCAATGGGCACCAACCACTCGCCATCC [34] 
R GGATGGCGAGTGGTTGGTGCCCATTGG 
A2257C SDM 2 F CCCGAAGGAACTTGGCCAGGGCCCCATTC [34] 
R GAATGGGGCCCTGGCCAAGTTCCTTCGGG 
T2254C SDM 3 F GAAGGAACTTGTCCGGGGCCCCATTCTCC [34] 
R GGAGAATGGGGCCCCGGACAAGTTCCTTC 
A2257C + T2254C SDM 4 F GGAGAATGGGGCCCCGGCCAAGTTCCTTCGGG [34] 
R CCCGAAGGAACTTGGCCGGGGCCCCATTCTCC 
G2688C SDM 5 F GCTGGTAGATGGGGGAGGGGCAGTC [34] 
R GACTGCCCCTCCCCCATCTACCAGC 
C2727T SDM 6 F GCGGCGGGCACACTCCTGCTGCC [34] 
R GGCAGCAGGAGTGTGCCCGCCGC 
G2990T SDM 7 F GCACCCCAATCCTATTGATGTCGTCGTTGGTC [34] 
R GACCAACGACGACATCAATAGGATTGGGGTGC 




F GCGGCGGGCACGCTCCTGCTGCC Not 
applicable R GGCAGCAGGAGCGTGCCCGCCGC 




shaking at 37°C or 32°C for 16 h. Plasmid DNA was extracted from bacterial cultures using the Wizard®  
Plus SV Miniprep DNA Purification System kit (Promega). DNA quality and quantity were assessed by 
nanodrop (see 2.3.3) and plasmid DNA was sequenced (see 2.9.3) using primers designed to cover the 
EPHA2 gene (Table 13). 
 
Table 13: Sequencing primers for EPHA2 cDNA in EPHA2-pCMV, sEPHA2-RRL.SF.newMCS.i2.Zeo.pre 
lentiviral vector and transduced (and amplified) cell line genomic DNA. 
Primer name Primer sequence (5’–3’) Use/resultant sequences 
Reverse BGH TAGAAGGCACAGTCGAGG EPHA2.pCMV/ Supplementary figure 9  
T7 promotor TAATACGACTCACTATAGGG EPHA2.pCMV/ Supplementary figure 9 
3’LTR of sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ 
Supplementary figure 11 
652F TCTGATGCACCTTCCCTGG EPHA2.pCMV/ Supplementary figure 9   
sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ Supplementary 
figure 12 
Transduced cell lines/Figure 21B 
858R CTTCTCGTAGCCTGCCTGG sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ Supplementary 
figure 12 
Transduced cell lines/Figure 21B 
1296F CAGCATCAACCAGACAGAGC EPHA2.pCMV/ Supplementary figure 9 
sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ Supplementary 
figure 12 
Transduced cell lines/Figure 21B 
2184R AGTTCATGTTGGCCAGGTAC EPHA2.pCMV/ Supplementary figure 9   
sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ Supplementary 
figure 12 
Transduced cell lines/Figure 21B 
2155F GACAAGTTCCTTCGGGAGAA sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ Supplementary 
figure 12 
5’LTR TGCCGATTGGTGGAAGTAAG 5’LTR of sEPHA2-RRL.SF.newMCS.i2.Zeo.pre/ 
Supplementary figure 10 
567R ATGGGTATTCCCACAGTGTTC Transduced cell lines/Figure 21B 




2.15. Lentiviral EPHA2 expression vector construction, production and 
transduction 
2.15.1. Lentiviral vector construction 
To reintroduce EPHA2 to the EPHA2 knockout cells, a sEPHA2 construct was designed and constructed 
by GeneArt, Thermo Fisher Scientific. This sEPHA2 contained silent mutations in the gRNA target site 
so to avoid detection by the CRISPR/Cas9 system already transduced into the Hu-KO cells, and the 
AgeI and BamH1 restriction enzyme sites 5’ and 3’ of sEPHA2 construct, respectively, in a standard 
pMA vector (17ADD7RP_sEPHA2_pMA, see 2.10). 
To generate the sEPHA2-RRL.SF.newMCS.i2.Zeo.pre lentiviral vector, the sEPHA2 construct 
(GeneArt, Thermo Fisher Scientific) was first isolated from the expression vector by restriction enzyme 
digestion using AgeI and BamHI. The segment was then inserted into the lentiviral vector 
RRL.SF.newMCS.i2.Zeo.pre which was pre-digested with AgeI and BamHI restriction enzymes to 
produce compatible ends. Successful ligation was confirmed by restriction enzyme analysis with AgeI, 
BamHI and NdeI and sequencing of the cloned plasmid DNA.  
 
2.15.2. Lentivirus production 
Lentiviruses containing the WT sEPHA2-RRL.SF.newMCS.i2.Zeo.pre, the mutant-sEPHA2-
RRL.SF.newMCS.i2.Zeo.pre or the EV control RRL.SF.newMCS.i2.Zeo.pre were produced in HEK293T 
cells by transfecting the respective vector constructs and the packaging plasmids using the calcium-
phosphate transfection method. Briefly, HEK293T cells were plated at a density of 4x106 cells in a 10 
cm dish. Media was removed 24 h later and replaced with transfection media (DMEM + 10% FBS + 
HEPES (pH 7)) with 0.1 mM chloroquine. In parallel, the packaging vector pCMV-VSV-G, pGag/pol, 
pRev together with the RRL-vectors were combined in separate Eppendorf tubes per transfection and 
mixed with 50 µl of 2.5 M CaCl2. The DNA-CaCl2 mix was added to 2X HEPES buffered saline (HBS) 
buffer dropwise while bubbling air through the HBS. The HBS-DNA-CaCl2 mixture was incubated at 
room temperature for 20 min before being added to the HEK293T cells slowly while swirling. 
Transfected cells were incubated at 37°C, 5% CO2 for 6–12 h before media was removed and replaced 
with transfection media. Transfection media was refreshed 12 h and 24 h later. At the 36 h time-point, 
media containing lentiviruses was removed off HEK293 cells and replaced with fresh media. 




point, media was again removed from the HEK293 cells and filtered before being pooled with the first 
harvest. Lentiviruses were purified by ultracentrifugation at 7500 x g at 4°C for 10 h in an SW40 swing 
rotor (Beckman Coulter Inc.). The supernatant was discarded, and the lentivirus pellet was 
resuspended in the remaining media and stored at -20°C.  
 
2.15.3. Lentivirus titration 
The amount of lentivirus used to transduce cells was determined by titration in control cells. Hu-KO 
cells were plated at a density of 5x106 cells/well in a 6-well plate and transduced with lentiviruses in 
series (1 µl–40 µl). After selection, transduced cells were assessed for EPHA2 expression by flow 
cytometry (see 2.21) relative to EV transduced Hu-Scr cells (representative of endogenous expression).  
 
2.15.4. Determining zeocin sensitivity  
The minimal concentration of zeocin required to kill untransfected HuARLT2 cells was determined 
empirically. Cells were plated in a 96-well plate at a density of 2.5x104 cells/well. The following day, 
media was removed and replaced by fresh media containing zeocin at a range of concentrations (0, 
50, 100, 200, 400, 600, 800 and 1,000 μg/ml). Selection media was replenished every three days for 
ten days at which time live cells were counted. The concentration that killed the majority of cells was 
used for future selection of cells transduced with the RRL.SF.newMCS.i2.Zeo.pre vector containing the 
zeocin resistance gene.  
 
2.15.5. Lentivirus transduction of engineered HuARLT2 cell lines 
For transduction, HuARLT2 cells were plated (5x105) in 6-well plates in duplicate. The next day, media 
was changed to media containing 5 μg/ml of polybrene. The respective lentiviruses (containing 
constructs or EV) were thawed on ice and added to the media above the cells. Cells were transduced 
by spinoculation at 450 x g for 30 min at 30°C. At least 4 h later, fresh media was added containing 
400 mg/ml zeocin. When all the control cells were dead, selected cells were expanded. These 
transduced cell lines were designated Hu-WT-SDM, Hu-SDM1, Hu-SDM2, Hu-SDM3, Hu-SDM4, Hu-
SDM5, Hu-SDM6, Hu-SDM7 and Hu-SDM8 (Table 9). Transduced cells were maintained in media 
containing half the zeocin concentration of the selection media (200 mg/ml). Transduced cells were 




amplified and sequenced using primers designed to amplify the regions where mutations were 
introduced (Table 13). 
 
2.16. Recombinant KSHV production 
BJAB-rKSHV.219 cells were utilised to produce rKSHV virus, as previously described [335,342]. Briefly, 
BJAB-rKSHV.219 cells were inoculated at a density of 6x105 cells/ml in a 500 ml spinner flask (Lasec, 
South Africa) in the presence of 2.5 μg/ml of anti-human IgM antibody (Sigma-Aldrich) to induce the 
KSHV lytic cycle. Induced cells were incubated for five days at 60 rpm agitation. Cells and debris were 
separated from the culture supernatant by low-speed centrifugation at 1125 x g for 10 min and 
discarded. Virus particles in the supernatant were concentrated by ultracentrifugation at 14,000 rpm 
for 5 h in a JA20 rotor (Beckman Coulter Inc.). The pellet-containing virus was resuspended in serum-
free EGM-2MV medium and stored at 4°C for less than one month.  
Infectious virus titre was determined by infection of cells with serial dilutions of the virus. 
HEK293 or HuARLT2 cells were plated at a cell density of 3x104 cells/per well in a 96-well plate and 
infected (see 2.17). Three days after infection, GFP-positive cells were counted by fluorescent 
microscopy (see 2.19) and the infectious virus titre was calculated using the dilution factor. 
 
2.17. Recombinant KSHV infection  
Cells were plated at 5x105 cells per well of a 6-well plate (for flow cytometry) or 1x105 cells per well of 
a 24-well plate (for fluorescent microscopy, fluorometry or Western blot) in duplicate and infected 
with rKSHV (see 2.16) by spinoculation (450 x g for 30 min at 30°C) at a multiplicity of infection (MOI) 
of 2.5 in the presence of 10 μg/ml polybrene (Sigma-Aldrich) unless otherwise indicated. The culture 
medium was changed 1 h post infection unless otherwise indicated. The cells were further incubated 
at 37°C in a 5% CO2 cell culture incubator for 48 h before infection levels were assessed by fluorometry 






2.18. Fluorometry  
Following KSHV infection as indicated (see 2.17), media was removed from cells. Cells were washed 
twice with cold PBS and GFP fluorescence was measured on a microplate reader (Glomax, Promega) 
using an excitation filter of 490 nm and an emission filter of 510–570 nm. Triplicate readings were 
averaged, and the average of the uninfected wells was subtracted. 
 
2.19. Fluorescent microscopy 
Following infection as indicated (see 2.17), media was removed, and cells were washed twice with 
PBS. Cells were visualised immediately in PBS using phase contrast and the Alexa Fluor 488 filter (for 
GFP expression) on a Zeiss inverted fluorescent microscope (Axiovert 200M) using the AxioVision 
software (version 4.8). Photographs were captured using the monochrome Zeiss AxioCam HRm. GFP-
positive cells were counted in five fields of view per well (photographed) and these were averaged.  
 
2.20. Western blot analysis 
2.20.1. Cell lysate preparation 
To analyse protein expression by Western blot, adherent cells were lysed in the cell culture plates 
after washing with PBS with 1X sodium dodecyl sulphate (SDS) sample buffer (see Appendix 7.1) and 
centrifuged at 20,000 x g for 10 min at 4°C. Lysates were either stored at -20°C for later use or 
processed immediately by sonication for 30 s in a frozen block. Sonicated samples were then placed 
in a heating block set at 100°C for 5 min and then back on ice for 5 min. Protein concentration was 
determined by nanodrop (see 2.23.4).  
 
2.20.2. SDS-PAGE and protein transfer 
Cell lysates (see 2.20.1) were loaded into a 12% SDS polyacrylamide gel and the precision Plus Protein 
Standard (Biorad) was loaded as a marker. The gel was run at 20 mA in running buffer (see Appendix 




gel onto 0.45 μm nitrocellulose membranes (Amersham) in transfer buffer (see Appendix 7.1) for 
70 min at 350 mA. 
 
2.20.3. Antibodies  
The following antibodies were used for Western blotting: mouse anti-Eck/EphA2 Antibody, clone D7 
(05-480, 1:500) and mouse anti-β-actin (A5441, 1:1,000) purchased from Sigma Aldrich; rat anti-LANA 
(1:1,000), produced by the Schulz laboratory (MHH, Germany) [343]; HRP-conjugated rabbit anti-
mouse IgG (1:2,000, P0260) secondary antibody purchased from DAKO; and goat anti-rat IgG (1:1,000, 
#3050–05) purchased from Southern Biotech. 
 
2.20.4. Immunoblotting and chemiluminescent visualisation  
Membranes were blocked by incubating them in 5% (w/v) non-fat milk (Carl Roth) in PBS-Tween (see 
Appendix 7.1) for 1 h followed by incubation with the appropriate primary antibody (see 2.20.3) in 
milk-PBS-Tween overnight at 4°C on a tube roller. Membranes were washed three times in PBS-Tween 
for 5 min on a shaker before incubation with the corresponding HRP-conjugated secondary antibody 
in blocking solution for 45 min at room temperature. The membranes were washed three times again 
after which they were visualised in a LAS-3000 Imager (Fujifilm) after signal development using an 
enhanced chemiluminescence (ECL) kit (Thermo Fisher Scientific).  
 
2.21. Flow cytometry analysis 
2.21.1. Experimental setup 
Each experiment included negative controls of unstained and secondary antibody only cells. Controls 
and samples were prepared in duplicate.  
 
2.21.2. Antibodies 
Antibodies used for flow cytometry were mouse anti-human EPHA2 antibody (1:800, MAB3035) 




(1:800, AB_2340867) purchased from Jackson ImmunoResearch.  
 
2.21.3. Secondary antibody titration 
Hu-Scr (which expresses WT EPHA2) and Hu-KO (which is negative for EPHA2, Table 9) were mixed to 
generate a cell population that would stain both positive and negative for EPHA2. These cells were 
stained with primary antibody at the recommended concentration for flow cytometry 
(0.25 µg/106 cells) and a range of concentrations of secondary antibody (recommended range 1:100–
1:800). An unstained and secondary only control were included. Cells were acquired on a BD Fortessa 
using the BD FACSDiva software in the AF647 channel. Histograms of AF647 intensity were gated with 
a bisector gate to discriminate EPHA2-positive and -negative peaks and the median fluorescent 
intensity (MFI) of each was calculated. The ratio of the positive to the negative peak MFI was 
calculated and the secondary antibody concentration which best discriminated between the negative 
and positive populations was selected for further experiments.  
 
2.21.4. Sample preparation 
Following the relevant treatment, engineered HuARLT2 cells were lifted by adding 500 µl accutase 
(Biowest) at 37°C for 5 min and neutralised with the equal amount of EGM-2MV media which was 
used to wash the bottom of the well and ensure all cells were lifted. Lifted cells were centrifuged at 
450 x g for 2 min in an Eppendorf centrifuge 5702 (Merck), the supernatant removed, and 
resuspended in 100 µl flow cytometry block solution (see Appendix 7.1) per stain and transferred to a 
V-shaped 96-well plate. The samples were incubated at 4°C for 30 min. The pellet was resuspended in 
100 µl flow cytometry block solution containing primary antibody (1:800, recommended by the 
manufacturer) by pipetting up and down to mix. Unstained and secondary antibody only controls were 
resuspended in block solution only. The cells were incubated with primary antibody at 4°C for 1 h. The 
plate was centrifuged at 450 x g for 2 min at 4°C and the supernatant removed. The cells were then 
washed three times by resuspending them in 200 µl flow cytometry wash solution (see Appendix 7.1) 
followed by centrifuging at 450 x g for 2 min at 4°C and removal of the supernatant. The cells were 
resuspended in 100 µl flow cytometry block solution containing secondary antibody (1:800, 
determined by titration, see 2.21.3) by pipetting up and down to mix. Unstained control was 
resuspended in block solution only. The cells were incubated with primary antibody at 4°C for 1 h in 




(see Appendix 7.1) and transferred to flow cytometry tubes (BD). Prepared samples were kept at 4°C 
and protected from light until data acquisition (see 2.21.5).  
 
2.21.5. Data acquisition 
Flow cytometry data were acquired on a BD Fortessa using the BD FACSDiva software in the GFP and 
AF647 channels. Acquisition parameters were set up using an unstained negative control and stained 
positive control. To ensure that compensation was not required when acquiring data from both GFP 
and AF647 signals, fluorescence minus one (FMO) controls were included in a pilot experiment. The 
cell population was defined by setting the threshold for forward scatter at 10,000 to exclude cell debris 
and 25,000 events were acquired per sample. 
 
2.21.6. Data analysis 
Flow cytometry data were analysed using FlowJoTM software (v10.6.1). The cell population was gated 
using a dot plot of side scatter (SSC) versus forward scatter (FSC) for the WT cells and the gate was 
applied to all samples. The GFP histogram of stained, uninfected WT cells was used to identify the 
GFP-positive population and this was gated with a bisector gate. This gating strategy was applied to 
all acquisitions providing % GFP+ cells. MFI of the GFP and Alexa Fluor 647 histograms was calculated 
using FlowJoTM.   
 
2.22. MTT assays 
To determine cell viability, 5 mg/ml Thiazolyl Blue Tetrazolium Bromide (MTT reagent), Sigma (see 
Appendix 7.1), was added at a 1:10 dilution to the cell culture media covering adherent cells and 
incubated for 4 h at 37°C 5% CO2. Media was removed and MTT crystals were solubilised in DMSO for 
45 min. MTT absorbance was measured at 600 nm on a microplate reader (GloMax, Promega). 





2.23. EPHA2 phosphorylation 
2.23.1. Determining baseline phosphorylation levels 
Hu-WT-SDM, Hu-SDM 1, Hu-SDM 2, Hu-SDM 3, Hu-SDM 4, Hu-SDM 5, Hu-SDM 6, Hu-SDM 7 and Hu-
SDM 8 cells were plated at a density of 2.5x105 cells/well in 12-well plates in duplicate. The following 
day, cells were lysed (see 2.23.3), protein concentration was quantified (see 2.23.4) and EPHA2 
tyrosine phosphorylation levels were assayed (see 2.23.5). 
 
2.23.2. Determining phosphorylation response to rKSHV  
2.23.2.1. Determining cell line sensitivity to serum starvation 
Hu-WT-SDM cells were plated at a density of 1x104 cells/well in a 96-well plate. The following day, 
cells were subjected to EGM-2MV media containing 0% FBS in a time course (serum-starved) in 
triplicate or serum-containing media (control). At the end of the time course, MTT assays (see 2.22) 
were performed to determine cell viability. Viability of serum-starved cells was expressed as a 
percentage of unstarved cells of the same time-point. The time-point at which no change in viability 
was observed was selected for future experiments.  
2.23.2.2. Determining optimal treatment time 
Hu-WT-SDM cells were plated at a density of 2.5x105 cells/well in 12-well plates in duplicate in the 
morning. In the afternoon, once cells were adhered to the cell culture plate, media was removed, cells 
were washed with PBS and serum starvation media was added. Cells were incubated in the absence 
of serum overnight (16 h, based on sensitivity experiment, see 2.23.2.1). Cells were treated with rKSHV 
at MOI 10 for 10 min, 20 min or 60 min. Cells were lysed (see 2.23.3), protein concentration was 
quantified (see 2.23.4) and EPHA2 tyrosine phosphorylation levels were assayed (see 2.23.5). The 
time-point at which the most pronounced increase in phosphorylation was observed was selected for 
future experiments.  
2.23.2.3. Determining phosphorylation response to rKSHV 
Hu-WT-SDM, Hu-SDM 1, Hu-SDM 2, Hu-SDM 3, Hu-SDM 4, Hu-SDM 5, Hu-SDM 6, Hu-SDM 7 and Hu-
SDM 8 cells were plated at a density of 2.5x105 cells/well in 12-well plates in duplicate in the morning. 
In the afternoon, media was removed and replaced with serum-free EGM-2MV and cells were 
incubated in the absence of serum overnight (16 h). The following morning, media was replaced with 




determined under 2.23.2.2). Cells were lysed (see 2.23.3), protein concentration was quantified (see 
2.23.4) and EPHA2 tyrosine phosphorylation levels were assayed (see 2.23.5). 
 
2.23.3. Sample preparation 
Following the appropriate treatment, media was removed, and the cells were washed twice with PBS. 
Cells were solubilised in 100 µl Lysis buffer (IC Diluent #12 (1% NP-40 Alternative, 20 mM Tris (pH 8.0), 
137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate (R&D Systems®, 
Catalogue # DYC002)) containing 1x cOmplete™, EDTA-free Protease Inhibitor Cocktail (Roche)) in the 
plate and incubated on ice for 15 min. Lysates were centrifuged at 2,000 x g for 5 min at 4°C and the 
supernatant transferred to a clean Eppendorf tube. Protein concentration was determined using 
bicinchoninic acid assay (BCA) assay (see 2.23.4). If necessary, lysates were stored at -80°C.  
 
2.23.4. BCA assay 
Lysate protein concentration was determined using the PierceTM BCA Protein Assay Kit (Thermo Fisher 
Scientific). Protein standards (5 µg/ml–250 µg/ml) were prepared by diluting the provided 2 mg/ml 
albumin standard in IC Diluent #12; the blank standard consisted of IC Diluent #12 only. BCA working 
reagent was prepared as required by combining BCA Reagent A with BCA Reagent B in a 50:1 ratio. 
Each standard and sample (3 µl) was added to 100 µl BCA working reagent and these were incubated 
in a heating block set to 37°C for 30 min. Tubes were cooled to room temperature. Absorbance at 562 
nm was measured on a Nanodrop. Absorbance of the blank standard was subtracted from the other 
measurements. A standard curve was constructed from the absorbance values of the standards and 
the protein concentrations of the samples were determined by interpolating the absorbance values in 
the standard curve.  
 
2.23.5. Human Phospho-EPHA2 ELISA 
ELISA microplates were coated with 100 µl Human Phospho-EphA2 Capture Antibody (Human 
Phospho-EPHA2 kit component, R&D Systems®, part 842422) reconstituted in PBS and diluted to a 
final concentration of 4 µg/ml, sealed and incubated overnight at room temperature. The coated 
plates were washed three times with ELISA Wash Buffer (0.05% Tween® 20 in PBS, pH 7.2-7.4, R&D 




inversion of the plate and blotting against paper towel. Plates were blocked by the addition of 300 µl 
Block Buffer (1% BSA (R&D Systems®, #DY995), 0.05% NaN3 (see Appendix 7.1) in PBS, pH 7.2-7.4) to 
each well and incubation at room temperature for 1–2 h. The plate was washed three times, again.  
Samples were diluted with IC Diluent #12 to 0.5 µg/µl and 100 µl of each sample and control 
was added to the plate. The blank control contained only IC Diluent #12. The positive control was 
Human Phospho-EphA2 Control (Human Phospho-EPHA2 kit component, R&D Systems®, Part 842154) 
reconstituted with IC Diluent #12 and diluted to a final concentration of 800 pg/ml. The plate was 
sealed and incubated for 2 h at room temperature after which the plates were washed three times. 
Anti-pY-HRP (mouse anti-phospho-tyrosine antibody conjugated to HRP, Human Phospho-
EPHA2 kit component, R&D Systems®, Part 841420) was diluted 1:1800 (as recommended by the 
manufacturers) in IC Diluent #14 (20 mM Tris, 137 mM NaCl, 0.05% Tween® 20, 0.1% BSA (R&D 
Systems®, #DY995), pH 7.2-7.4) as needed and 100 µl of this working stock was added per well. The 
plate was sealed and incubated for 2 h in the dark at room temperature after which the plates were 
washed three times. 100 µl Substrate Solution (1:1 mixture of Colour Reagent A (H2O2) and Colour 
Reagent B (Tetramethylbenzidine), R&D Systems®, #DY999) was added per well. The plate was sealed 
and incubated for 20 min at room temperature in the dark at which time 50 µl Stop Solution (2 N 
H2SO4, R&D Systems®, #DY994) was used to halt the reaction. Plates were gently tapped to mix the 
solutions and the absorbance was immediately determined using a microplate reader (GloMax, 
Promega) set to 450 nm with a wavelength correction of 560 nm. The average OD of the blank control 
was subtracted from the other samples. 
 
2.24. KSHV binding and internalisation assay 
2.24.1. Validation of binding and internalisation infection conditions  
RFP is expressed by rKSHV from the KSHV lytic gene PAN promoter [336]. To validate that RFP 
fluorescence measured on the fluorometer was indeed indicative of binding and internalisation (see 
2.24.2), infected cells were visualised using a fluorescent microscope. Cells were plated on sterile 
coverslips in 12-well plates at a density of 1x105 cells/well. The following day, cells were infected with 
rKSHV at MOI 10 in the presence of 10 µg/ml polybrene by centrifuging at 450 x g for 30 min at 4°C 
and either incubated at 4°C (binding) or shifted to 37°C (internalisation) for 1 h. Cells were washed 
twice to remove unbound virus, and the coverslips were mounted on microscope slides on a drop of 




background levels of RFP. Cells were visualised immediately using phase contrast and the Cy-3 filter 
with the 20X objective of a fluorescent microscope (Axiovert 200M) using the AxioVision software. 
 
2.24.2. Quantifying internalisation and binding 
Cells were plated at a density of 1x104 cells/well in six repeats in two 96-well sterile black plates in 
parallel: one to assess binding of rKSHV and the other to assess internalisation. The following day, 
media was replaced with fresh media (for uninfected wells) or media with rKSHV at MOI 10 together 
with 10 µg/ml polybrene (in triplicate) and centrifuged at 450 x g for 30 min at 4°C. To assess KSHV 
binding, one plate was kept at 4°C. To assess internalisation, the other plate was shifted to 37°C for 1 
h. Cells were washed twice with cold PBS and RFP fluorescence was measured on a microplate reader 
(Glomax, Promega) using an excitation filter of 530 nm and an emission filter of 580–640 nm. Triplicate 
readings were averaged, and the average of the uninfected wells was subtracted.  
 
2.25. Statistical analysis of experimental data 
When replicate experiments were combined (as indicated), means and standard errors were pooled. 
When data were normalised, standard errors were propagated accordingly. Statistical testing of 
experimental data was conducted by one-way ANOVA with post hoc Dunnett’s test corrected for 





Despite the high seroprevalence of KSHV in SSA, the contribution of KSHV infection or host KSHV 
receptor variations to disease outcome in HIV-infected South African patients is unknown. To further 
our understanding of KSHV-driven pathology and disease outcome, we first assessed the contribution 
of KSHV infection and KSHV-associated syndromes to mortality in a clinical cohort of patients 
presenting with suspected but not microbiologically confirmed TB, the leading cause of death among 
HIV-positive South Africans. The results presented in 3.1 have recently been published [62]. Secondly, 
in continuation of previous work from our laboratory which formed my MSc thesis and has been 
published [34,35], we investigated EPHA2, the KSHV entry receptor, as a potential genetic 
susceptibility marker for KSHV infection, KS development or KSHV VL (see 3.2). Thirdly, we 
characterised EPHA2 variants of interest in terms of KS development and KSHV infection (see 3.3).  
 
3.1. The contribution of KSHV to mortality in HIV-infected South 
African patients presenting with suspected but unconfirmed TB  
3.1.1. Assessment of parameters relevant for this study 
To assess the role of KSHV and KSHV-associated diseases in HIV-positive patients presenting with 
syndromes compatible with TB, demographic and clinical information was recorded, vital status was 
ascertained at 12-week follow-up and KSHV VL, KSHV serostatus and IL-6 levels were measured. 
Patients were recruited on presentation with a suspected diagnosis of severe HIV-associated TB 
(n=682). Seven patients were excluded (two withdrew, one was HIV-negative, and four had no blood 
samples stored for KSHV assays) and 675 were included in this analysis. The median CD4 count was 62 
cells/μl (range: 0–526 cells/μl) (Table 14). Twelve patients were lost to follow-up and 146 (22%) died 
by 12-weeks follow-up. Ten patients had a clinical diagnosis of cutaneous or oral cavity KS at 
enrolment. All patients were assessed for KSHV seropositivity, of whom 207 (30.7% (95% CI: 27.2, 
34.3) tested positive for the presence of either K8.1 or ORF73 antibodies in the plasma by ELISA (Table 
14 and Figure 6).  
The entire patient cohort was also assessed for KSHV VL by quantitative real-time PCR. Of the 
207 KSHV seropositive patients, 39 (18.8%) showed detectable VL in the blood which is in agreement 
with earlier studies [24,344,345]. VL in the individual seropositive patients displayed a wide range with 




the 468 KSHV seronegative patients were found to have detectable VL with a median of 1084.29 
copies/106 cells (range: 141.4–57054 copies/106 cells). These patients had a particularly low median 
CD4 count of 25.5 cells/μl (range: 20–168 cells/μl) and, assuming they only became infected while 
immunosuppressed, might not have been able to mount a detectable antibody response against KSHV. 
 
 
Table 14: Baseline demographic and clinical characteristics of the study cohort (n=675). Sex, ART, 
anaemia diagnosis, detectable IL-6, TB diagnosis, KSHV status, KS diagnosis and survival are given 







Age (years) 36.1 (18.5-80.8) 
Weight (kg) 53 (30-104) 
Receiving ART 252 (37.3%) 
HIV VL (copies/ml) 104 252 (29-1x107) 
CD4 (cells/μl) 62 (0-526) 




Patients with detectable IL-6 
IL-6 concentration (pg/ml) 
559 (82.8%) 
42.3 (9.8-103.8) 
TB/ infection category 
Patients with proven TB 
Patients with an alternate microbiologically proven 
opportunistic infection 







KSHV status in patients 
Seropositive 
Seropositive with detectable VL; copies/106 cells 
Seropositive with elevated VL (>100 copies/106 cells) 
Seronegative 
Seronegative with detectable VL; copies/106 cells 
Seronegative with elevated VL (>100 copies/106 cells) 
 
207 (30.7%) 
39 (5.8%); 199.05 (13.4-2.2x106) 
29 (4.3%) 
468 (69.3%) 
4 (0.6%); 1084.29 (141.4-57 054) 
4 (0.6%) 
Skin or oral Kaposi’s Sarcoma 10 (1.5%) 
Survival at 12-weeks 
Died 
Survived 









Figure 6: Assessment of KSHV seropositivity in the whole patient cohort (n=675). ELISA results 
indicating 30.7% KSHV seropositivity (207/675) as defined by the OD values for K8.1 and ORF73 above 
the cut-off for either ELISA assay (indicated by cells with shaded background). 
 
Importantly, plasma IL-6 was detected in 559 (82.8%) of all patients with a median 
concentration of 42.3 pg/ml (IQR: 9.8–103.8 pg/ml). This is considered highly elevated compared to a 
reference population of HIV-positive patients (n=9864, median IL-6: 1.80 pg/ml (IQR: 1.20–2.89) 
[346]). Finally, when performing a binomial logistic regression predicting KSHV seropositivity or 
elevated KSHV VL, respectively, by age, sex, CD4 count, haemoglobin levels and ART status, only CD4 
count was significantly associated with KSHV seropositivity (p=0.001, adjusted OR= 1.003 (95% CI: 
1.001, 1.004), Table 15).  Male sex was associated with elevated KSHV VL (p=0.029, adjusted OR=2.367 
(95% CI: 1.093, 5.126), Table 16). 
 
3.1.2. Elevated KSHV VL is associated with mortality in critically ill patients with neither MTB nor other 
microbiologically proven co-infection  
Initially, the entire patient cohort (n=675) was assessed for a possible association of elevated KSHV VL 
(i.e. >100 copies/106 cells) with mortality at the end of the 12-weeks study period. We identified 33 
patients with elevated KSHV VL of whom 9 (27.3%) did not survive until 12-weeks. Meanwhile, 137 
(21.7%) of 630 patients with undetectable KSHV VL or VL <100 copies/106 cells had died by the end of 
the study period. We did not identify a statistical association between elevated KSHV VL and mortality 
in the whole patient cohort (Group 1, Table 17 and Figure 7A). 
   K8.1   
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Table 15: Multivariate logistic regression of factors assessed for association with KSHV seropositivity 
in the entire cohort (n=675). 
 Unadjusted 
Odds Ratio 




95% CI for 
Adjusted OR 
P 
 Lower Upper Lower Upper  
Sex1 0.969 0.698 1.345 1.009 0.713 1.429 0.960 
Haemoglobin2 1.034 0.965 1.109 0.998 0.927 1.075 0.958 
Age3 1.016 1.000 1.033 1.016 1.000 1.033 0.057 

























1Sex is for males compared to females; 2Haemoglobin levels were mean (9.02g/dl) centred; 3Age is per 1-year increase; 4CD4 
count is per 50 cells; 5For ART status, naïve is the reference category. Patients were considered KSHV seropositive if 




Table 16: Multivariate logistic regression of factors assessed for association with elevated KSHV VL 
in the entire cohort (n=675). 
 Unadjusted 
Odds Ratio 




95% CI for 
Adjusted OR 
P 
 Lower Upper Lower Upper  
Sex1 2.309 1.101 4.840 2.367 1.093 5.126 0.029 
Haemoglobin2 1.037 0.895 1.201 0.971 0.833 1.131 0.703 
Age3 1.029 0.997 1.062 1.024 0.991 1.059 0.151 

































1Sex is for males compared to females; 2Haemoglobin levels were mean (9.02g/dl) centred; 3Age is per 1-year increase; 4CD4 
count is per 50 cells; 5For ART status, naïve is the reference category. Patients were considered KSHV seropositive if 







With the rationale that TB illness might be masking an association of KSHV with mortality, four 
overlapping categories based on the presence or absence of microbiologically confirmed infections 
were identified. Group 1 (n=675) consisted of the total patient cohort analysed; Group 2 consisted of 
n=500 patients who had microbiologically proven MTB on a culture or GeneXpert test (on any clinical 
sample) or tested positive for urine LAM, while of the remaining 175 patients without 
microbiologically confirmed TB (Group 3), 16 patients had a microbiologically proven alternative 
opportunistic infection (other than MTB including bacterial bloodstream infection or Cryptococcus 
species). Therefore, 159 patients (Group 4) were defined as patients with neither MTB nor other 
microbiologically proven co-infection, although this group retained ‘clinical’ TB patients who were 
negative for all TB diagnostic tests.  
As in the entire patient cohort, proven TB patients (Group 2) showed no significant association 
of KSHV VL and mortality (Table 17 and Figure 7B). However, in all patients without proven TB (Group 
3, n=175) and particularly in patients without proven TB or other co-infections (Group 4, n=159), 
elevated KSHV VL was detected at a higher frequency, and KSHV VL was significantly higher in patients 
who had died than in patients who had survived at the end of the 12-weeks study period (Table 17 
and Figure 7C and D), indicating an association between KSHV VL and mortality. Binomial logistic 
regression was performed to assess this relationship while adjusting for the effects of age, sex, CD4 
count and ART status in patients without proven TB or proven co-infection (n=159). Of the dependent 
variables, age, CD4 count and elevated KSHV VL (categorical) were statistically significant (Table 18). 
The adjusted OR for elevated KSHV VL was 6.467 (95% CI: 1.290, 32.406). 
Interestingly, we did not find a significant relationship between KSHV seroprevalence and 
mortality (Table 19), in contrast to the above-mentioned significant association between KSHV VL and 
mortality (Table 17). To assess the drivers of KSHV antibody responses among critically ill HIV-positive 
patients without a proven MTB or alternative diagnosis, KSHV seropositive Group 4 patients (n=60) 
were analysed indicating that lower haemoglobin levels were associated with higher K8.1 antibody 
levels (p=0.003, unstandardized coefficient= -0.020) when adjusted for age, sex, CD4 count and ART 










Table 17: Association of KSHV VL with 12-weeks mortality. Frequency of mortality among patients 
with elevated KSHV VL (>100 copies/106 cells) versus those with undetectable KSHV VL or VL<100 
copies/106 cells. Patients were grouped as indicated: Group 1 (n=675, entire patient cohort); Group 2 
(n=500, patients with microbiologically proven TB); Group 3 (n=175, patients without a confirmed TB 
diagnosis); Group 4 (n=159, patients without microbiologically confirmed infections). Twelve patients 
of the total cohort were lost to follow-up. 1P value is by AChi-square test for association if expected 
cell frequencies were >5 or BFisher exact test. 
 






OR (95% CI) 
Group 1: 
Entire patient cohort 
(n=675) 







(95% CI: 0.6, 3.0) 








proven TB (n=500) 







(95% CI: 0.2, 1.7) 







Patients without proven 
TB (n=175) 
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Figure 7: 12-weeks mortality versus KSHV VL in A) the entire patient cohort (Group 1, n=675); B) 
patients with proven TB (Group 2, n=500); C) patients without proven TB (Group 3, n=175); D) patients 












Table 18: Logistic regression of factors assessed for association with mortality based on elevated 








95% CI for 
Adjusted OR P 
Lower Upper Lower Upper 
Elevated KSHV VL1 7.143 1.611 31.671 6.467 1.290 32.406 0.023 
Sex2 0.949 0.433 2.082 0.477 0.187 1.214 0.120 
Age3 1.051 1.014 1.088 1.067 1.022 1.113 0.003 

























1KSHV VL is for elevated (>100 copies/106 cells) compared to non-elevated (<100 copies/106 cells or non-detectable); 2Sex is 










Table 19: Association of KSHV serology with 12-weeks mortality. Frequency of mortality among 
patients with positive or negative K8.1, ORF73 or overall KSHV seropositivity. Patients were grouped 
as indicated: n=675 (entire patient cohort); n=500 (patients with microbiologically proven TB); n=175 
(patients without a confirmed MTB diagnosis); n=159 (patients without microbiologically confirmed 



































Positive 37 (5.5) 126 (18.7) p=0.810 
OR=1.053 
(95% CI: 0.690, 1.609) Negative 109 (16.1) 391 (57.9) 
ORF73 
Positive 28 (4.1) 93 (13.8) p=0.742 
OR=1.082 
(95% CI: 0.677, 1.729) Negative 118 (17.5) 424 (62.8) 
Overall 
Positive 47 (7.0) 156 (23.1) p=0.640 
OR=1.099 




























Positive 21 (4.2) 85 (17.0) p=0.512 
OR=0.837 
(95% CI: 0.491, 1.426) Negative 88 (17.6) 298 (59.6) 
ORF73 
Positive 19 (3.8) 64 (12.8) p=0.859 
OR=1.052 
(95% CI: 0.599, 1.848) Negative 90 (18.0) 319 (63.8) 
Overall 
Positive 29 (5.8) 108 (21.6) p=0.743 
OR=0.923 































Positive 16 (9.1) 41 (23.4) p=0.149 
OR=1.728 
(95% CI: 0.819, 3.648) Negative 21 (12.0) 93 (53.1) 
ORF73 
Positive 9 (5.1) 29 (16.6) p=0.728 
OR=1.164 
(95% CI: 0.494, 2.740) Negative 28 (16.0) 105 (60.0) 
Overall 
Positive 18 (10.1) 48 (27.4) p=0.156 
OR=1.697 











































Positive 14 (8.8) 37 (23.3) p=0.180 
OR=1.713 
(95% CI: 0. 777, 3.776) Negative 19 (11.9) 86 (54.1) 
ORF73 
Positive 8 (5.0) 28 (17.6) p=0.858 
OR=1.086 
(95% CI: 0.441, 2.673) Negative 25 (15.7) 95 (59.7) 
Overall 
Positive 16 (10.1) 44 (27.7) p=0.183 
OR=1.690 





Table 20: Summary of multiple regression analyses for K8.1 and ORF73 OD values in Group 4 patients 
who were KSHV seropositive (n=60). 



































































































Intercept .293 0.425  0.493  0.099 0.949  0.917 
Sex1 -0.060 0.065 -0.126 0.357  -0.002 0.144 -0.002 0.987 
CD4 count2 0.007 0.046 0.020 0.887  0.034 0.102 0.047 0.742 
Age3 -0.039 0.262 -0.019 0.883  0.060 0.585 0.014 0.919 
Haemoglobin 
levels4 
-0.033 0.014 -0.307 0.022  -0.017 0.031 -0.075 0.585 
ART status5 -0.058 0.074 -0.119 0.437  -0.262 0.165 -0.254 0.118 
1Sex is for males compared to females; 2CD4 count is per 50 cells; 3Age is per 1-year increase; 4Haemoglobin levels were 
mean (9.02g/dl) centred; 5ART status is on ART compared to naïve as the reference category. 
 
3.1.3. ‘KICS’ criteria can be used as a surveillance tool for patient mortality 
Since a substantial number of critically ill patients was recruited with suspected TB who, on diagnostic 
examination, turned out to have neither proven TB nor an alternative microbiologically proven 
co-infection (n=159, 23.5% of total cohort, Table 14) and who displayed a significant association of 
KSHV VL with mortality (Table 17, Table 18, Figure 7) we set out to determine whether KSHV-driven 
KICS might have a currently unrecognised contribution to mortality in patients who present with a 
suspected diagnosis of TB.  
The working case definition of KICS requires at least two clinical manifestations from at least 
two of three categories (Table 2, [6]): 1) symptoms (including fever, fatigue, oedema, cachexia, 
respiratory symptoms, gastrointestinal disturbance, arthralgia and myalgia, altered mental state, and 
neuropathy); 2) laboratory abnormalities (anaemia, thrombocytopenia, hypoalbuminemia, and 
hyponatremia); and 3) radiographic abnormalities (lymphadenopathy, splenomegaly, hepatomegaly, 
and body cavity effusions), together with evidence of systemic inflammation (elevated CRP [>10 
mg/l]), evidence of KSHV lytic activity (elevated [>100 copies/106 cells] KSHV VL in peripheral blood), 
and exclusion of MCD. As this analysis was done retrospectively, MCD could not be excluded for all 





We applied the criteria according to the proposed working case definition for KICS [6,7] and 
identified six “possible KICS” patients by exclusion of the study subsets with the caveat that we could 
not exclude MCD in all patients (Figure 8). While most baseline characteristics and selected laboratory 
abnormalities between “possible KICS” subjects (n=6) compared to the remainder of this patient group 
(n=153) did not significantly differ (except for age with “possible KICS” patients being slightly older, 
and platelet count being slightly lower in “possible KICS” patients, Table 21 and Table 22), all “possible 
KICS” patients (100%) displayed abnormally elevated KSHV VL and abnormally elevated K8.1 OD values 
compared to 1% and 30%, respectively, in the remainder of this patient group (Table 22 and Figure 9). 
Abnormally elevated ORF73 OD values were evident in 67% of “possible KICS” patients compared to 
22% of the remainder of the group. Median KSHV VL, K8.1 and ORF73 OD values were also significantly 
higher in the “possible KICS” patients than in the remaining Group 4 patients (Table 22). Interestingly, 
“possible KICS” patients had significantly higher KSHV VL than a cohort of KS patients (recruited 
independently n=100 [34,35], see 3.2.1.1) in which elevated KSHV VL levels were not evident (Figure 
10).  
HIV VL and patient CD4 counts did not differ significantly between “possible KICS” patients 
and the non-proven TB patients without an alternative microbiologically proven co-infection (Table 
21), indicating that HIV infection is not the cause of differences seen between these groups. According 
to the KICS working case definition (Table 2 [6]), evidence of systemic inflammation (i.e. elevated CRP 
levels) is among the criteria defining KICS. Moreover, IL-6 and IL-10 have been found to be elevated in 
KICS patients [6–8]. Although markedly elevated in all (100%) “possible KICS” patients, we found 
neither IL-6 nor CRP to be significantly different in these patients compared to the non-proven TB 
patients without an alternative microbiologically proven co-infection (Table 22 and Figure 9). Other 
laboratory abnormalities reported in KICS subjects such as low haemoglobin and albumin levels [6] 
were also found to be abnormally low in 83% of the herein reported “possible KICS” patients (Table 
22) although not different to the remainder of the group. As mentioned earlier, low haemoglobin was 
found to be associated with increased K8.1 antibody levels in the entire cohort when adjusted for age, 
sex, CD4 count and ART status (Table 20); and in the “possible KICS” group, K8.1 antibody levels were 
significantly higher than in the remainder of the Group 4 patients (Table 22). However, most 
laboratory abnormalities did not significantly differ among these two patient groups, presumably due 
to all these patients being critically ill for reasons other than those that had been microbiologically 
tested for in this study. This is further evidenced by the high proportion of patients in this group with 
abnormally elevated IL-6 and CRP levels (63% and 85%, respectively) which would not be expected in 





Figure 8: Schematic flow chart showing the diagnosis of “possible KICS” by exclusion in the cohort 
of critically ill patients investigated for TB. Patients were excluded if they had microbiologically 
proven TB or other bacterial or fungal infections and those who remained were further evaluated 
according to the criteria previously described in the KICS working case definition [6]. Two patients 
were excluded on the basis of alternative diagnoses (TB meningitis and community-acquired 
pneumonia, respectively). As this analysis was done retrospectively, MCD could not be excluded, 
hence the designation, “possible KICS”. 
 
Table 21: Baseline characteristics of “possible KICS” subjects (n=6) and all other Group 4 patients 
(n=153). Mortality, sex, ART, KSHV seropositivity and KS diagnosis are given as count and percentage; 
other characteristics are median and range. 
 
Possible KICS subjects 
(n=6) 
Remainder of patients 
without microbiologically 
proven co-infection (n=153) 
P value 
Died 5 (83.3%) 28 (18.3%) 0.002 
Males 4 (67%) 61 (39.9%) 0.227 
Age (years) 47 (26-74) 38 (19-81) 0.049 
Weight (kg) 58 (35-71) 53.0 (30-99) 0.912 
Receiving ART 3 (50%) 63 (41.2%) 0.290 
HIV VL (copies/ml) 81 298 (29-3 507 840) 70 363 (29- 7 934 692) 0.978 
CD4 (cells/μl) 106.5 (10-328) 97 (2-519) 0.818 
KSHV seropositive 6 (100%) 55 (35.9%) 0.003 







Table 22: Selected laboratory abnormalities in “possible KICS” subjects (n=6) and all other Group 4 
patients (n=153). 
 
Possible KICS subjects 
(n=6) 
Remainder of patients without 
microbiologically proven co-
















K8.1 OD 6 (100%) 2.1 (1.3-2.3) 46 (30%) 0.48 (0.10-2.57) 0.001 
ORF73 OD 4 (67%) 3.3 (0.32-7.4) 33 (22%) 0.24 (0.03-8.14) 0.003 
IL-6 (pg/ml) 5 (83%) 11.5 (1.6-3 307.4) 97 (63%) 12.5 (1.6-1 045.4) 0.978 
CRP (mg/l) 6 (100%) 71.4 (11.1-304) 131 (85%) 94.0 (0.38-564.9) 0.767 
Haemoglobin (g/dl) 5 (83%) 8.1 (6.9-14.9) 130 (85%) 10 (4.9-17.4) 0.231 
White cell count 1 (17%) 7.6 (3.5-21.6) 25 (16.3%) 6.8 (1.0-43.2) 0.783 
Platelet count 4 (67%) 185 (89.0-305) 29 (19%) 280 (23.0-789) 0.050 
Albumin (g/l) 5 (83%) 24.0 (16.0-39.0) 118 (77%) 28.0 (12.0-43.0) 0.489 
Sodium (mEq/l) 5 (83%) 132 (125-138) 119 (78%) 131 (113-150) 0.692 
1”Abnormal” refers to elevated KSHV VL, >100 copies/106 cells; positive K8.1 and ORF73, OD values >1 (normalised cut-off); 
elevated IL-6, >1.8 pg/ml; elevated CRP, >10 mg/l; low haemoglobin <12 g/dl (female) or <13g/dl (males); low white cell 
count <3.9; low platelet count, <186; low albumin, <35 g/l; and low sodium, <135 mEq/l. P values are by Fisher exact tests or 





Figure 9: Selected KICS-defining parameters in “possible KICS” patients. A) KSHV VL, B) IL-6 levels, C) 
CRP levels, D) platelet count, E) albumin and F) haemoglobin in “possible KICS” patients (n=6) 
compared to the remainder of Group 4 patients (n=153). The dotted lines mark abnormal levels (KSHV 
VL >100 copies/106 cells; IL-6 >1.8 pg/ml [22]; CRP >10 mg/l, platelet count <186, albumin <35 g/l and 
haemoglobin <12 g/dl). P values are by Wilcoxon rank sum test. Data are log transformed where 








Figure 10: Comparison of KSHV VL in “possible KICS” patients with independently recruited KS 
patients. The dotted line marks abnormal levels (KSHV VL >100 copies/106 cells). P values are by 
Wilcoxon rank sum test. Data are log transformed. Each circle represents a patient. 
 
Finally, the overall survival at the end of the 12-weeks study period was significantly worse in 
the identified “possible KICS” patients compared to the remainder of the non-proven TB patients 
without any other microbiologically proven co-infection, with an overall mortality of 83% (5/6) among 
the “possible KICS” patients (compared to 15% for the remainder of the group) and a median time to 
death in the “possible KICS” patients of 11 days ((95% CI: 0.00, 50.61); remainder of the group= 
undefined) (Figure 11), supporting previous reports of markedly elevated risk of death in KICS subjects 
[6]. However, this significant difference between the two survival curves should be interpreted with 
care as the assumption of similar percentage of censored cases between groups is not upheld due to 
the large discrepancy in sample size per group and the relatively short study period. 
Three of the six “possible KICS” patients had KSHV-associated malignancies. One was 
diagnosed with KSHV-associated MCD at autopsy. This patient displayed the highest KSHV VL of the 
entire cohort (2,165,642 copies/106 cells) and was positive for K8.1 but not ORF73, indicating a highly 
lytically active KSHV infection. This patient was empirically treated for TB for six months with no 
improvement prior to admission. He presented with further deterioration after completion of TB 
treatment and died on the day of enrolment. His CD4 count was 328 cells/μl, and HIV VL was 
undetectable. The patient had evidence of systemic inflammation (CRP=304 mg/l) and cytokine 
activation (IL-6=3307 pg/ml), as well as severe anaemia (haemoglobin=0.9 g/dl), thrombocytopenia 




lymphadenopathy and hepatomegaly. KICS-associated symptoms included respiratory symptoms 
(cough), weight loss, nausea, body pain and weakness. Histologic examination of lymph nodes was 
consistent with KSHV-associated MCD (Figure 12). There was no evidence of PEL. Two other “possible 
KICS” patients’ deaths were likely attributable to KICS in the setting of KS. One had biopsy-confirmed 
KS, was re-started on ART but died before assessment for chemotherapy. One patient, after 
deterioration on empiric anti-TB therapy, had skin KS confirmed on biopsy and features of lung KS on 
computed tomography scan two weeks prior to death. The other “possible KICS” patients did not have 
identified KSHV-associated malignancies. One was started on TB treatment empirically, deteriorated 
on treatment and was diagnosed with an invasive keratinising moderately differentiated SCC during 
evaluation of an upper gastrointestinal bleed. The other patient suffered from chronic renal failure 
due to an urethral stricture and was admitted with an episode of acute kidney injury. The patient was 
treated for suspected bacterial sepsis but died within the study period. The sixth patient was treated 




Figure 11: Overall survival at the end of the 12-weeks study period in “possible KICS” patients 








Figure 12: Histopathological assessment of post-mortem lymph node biopsies taken from a 
“possible KICS” patient with the highest KSHV VL of the entire patient cohort. A) Haematoxylin and 
eosin (H&E) stain showing a regressed germinal centre with sheets of plasma cells in the mantle zone 
among prominent capillaries, (20X objective magnification). B) Haematoxylin and eosin (H&E) stain 
showing an infiltrate of numerous benign plasma cells (40X objective magnification). C) 
Immunohistochemical stain of KSHV-ORF73 showing aggregates of KSHV-positive cells in the lymph 
node staining brown (10X objective magnification). D) Immunohistochemical stain showing brown 
granular nuclear KSHV-ORF73 positivity among the numerous background plasma cells (40X objective 
magnification). E) Immunohistochemistry for kappa light chains demonstrates few of the plasma cells 
in an area of ORF73-positive cells are kappa restricted (40X objective magnification). F) 
Immunohistochemistry of lambda light chains in the area ORF73-positive cells demonstrates many 







3.2. The genetic contribution of EPHA2 receptor variants to KSHV 
susceptibility and KS development  
KSHV infection is necessary but insufficient for the development of KS requiring precipitating factors, 
such as HIV infection and related immunosuppression [67]. Even so, patients who are HIV and KSHV-
positive do not strictly develop KS suggestive of a role for host factors in seroconversion after exposure 
to KSHV as well as in KS development [67].  
EPHA2 is a key host receptor utilised by KSHV for cell entry and intracellular trafficking [36]. 
Moreover, EPHA2 has also been implicated in oncogenesis [36,37,307], thus potentially acting at the 
level of both susceptibility to KSHV infection and susceptibility to KS development. These key 
functional roles of EPHA2 render it a promising candidate as a host genetic factor involved in KSHV 
susceptibility and subsequent KS development.   
 
3.2.1. Previously identified genetic association of EPHA2 SNVs with KSHV susceptibility and KS 
development 
Our previous work identified SNVs in EPHA2 that were associated with susceptibility to KSHV infection 
or KS development, which has been published and formed my MSc thesis [34,35]. To frame the context 
of the current results, details of the previous study are given here.  
3.2.1.1. Definition of the patient cohort 
HIV-positive patients from South Africa were recruited (see 2.2) into three groups, namely:  
 
Group 1 (KS+/KSHV+): patients with KS who were KSHV seropositive  
Group 2 (KS-/KSHV+): patients without KS who were KSHV seropositive  
Group 3 (KS-/KSHV-): patients without KS who were KSHV seronegative  
 
KS was clinically diagnosed and KSHV serostatus was determined by ELISAs to KSHV lytic antigen K8.1 




3.2.1.2. Previous identification of EPHA2 SNVs associated with KSHV susceptibility or KS 
development 
In our previous study, we sequenced the entire EPHA2 coding region in 150 HIV-positive patients 
grouped by KS and KSHV status to identify EPHA2 SNVs that were associated with KS development or 
KSHV susceptibility [34,35]. After removing SNVs based on linkage disequilibrium and with MAF <3% 
(calculated within the test group), four individual variants (Supplementary table 1) were assessed 
statistically for association with KSHV susceptibility by comparing their frequency in KSHV-positive 
patients (group 1 and 2, n=100) to KSHV-negative patients (group 3, n=50) resulting in the discovery 
of a novel heterozygous C>T variant in the conserved Pkinase-Tyr domain at mRNA position 2727, 
which was found to be significant (OR=6.4 (95% CI: 1.4, 28.4), adj. p=0.028), occurring in 21 (21%) 
KSHV+ patients (14 in Group 1 and 7 in Group 2) and in only 2 (4%) KSHV- (Group 3) patients. This 
variant was predicted to result in a non-conservative substitution of a cysteine for arginine at AA 
position 858.  
Similarly, after removing SNVs based on linkage disequilibrium and with MAF <3% (calculated 
within the test group), eight individual variants (Supplementary table 2) were assessed statistically for 
association with KS development by comparing occurrence in KS+/KSHV+ (Group 1, n=50) patients 
versus KS-/KSHV+ (Group 2, n=50) patients. The variant at mRNA positions 2254 was predicted to 
result in a novel, non-conservative AA change from leucine to proline at AA position 700 and is in 
linkage disequilibrium with another SNV at mRNA position 2257 predicted to result in an AA 
substitution from Aspartate to alanine at the next AA position, 701, in the conserved Pkinase-Tyr 
domain. These variants were found to co-occur in eight (16%) KS+ patients (Group 1, with an additional 
Group 1 patient showing only the variant at mRNA position 2257) and not to occur at all (0%) in KS- 
patients in Group 2 (OR=1.2 (95% CI: 1.1, 1.3), adj. p=0.04). Additionally, several other variants 
occurring in the Pkinase-Tyr domain (spanning mRNA positions 1990–2766), were found to be 
overrepresented in the KS+ (Group 1) patients (Supplementary table 2); the most marked of these was 
a heterozygous G>C variant at mRNA position 2688, predicted to result in the substitution of alanine 
with proline at position 845 which was found to occur in 6 (12%) of KS+ (Group 1) patients and no KS-
negative (Group 2) patients (OR=1.1 (95% CI: 1.0, 1.3), adj. p=0.16). A previously reported SNP at this 
position (rs765280326) indicated an ‘A’ allele while our data show a ‘C’ allele. Within the SAM domain, 
a heterozygous G>T variant at mRNA position 2990, predicted to result in a substitution of asparagine 
for lysine at AA position 945, was found to be significantly more frequent among KS+/KSHV+ (Group 
1) patients (18%) compared to KS-/KSHV+ (Group 2) patients (0%) (OR=1.2 (95% CI: 1.1, 1.4), adj. 




We further assessed the occurrence of these variants in relation to detectable KSHV VL (not 
previously reported) amongst KSHV-positive patients (Groups 1 and 2, n=100) after removing SNVs 
based on linkage disequilibrium and with MAF <3% (calculated within the test group, Supplementary 
table 3). We discovered that the G>T variant at mRNA position 2990, also associated with KS status 
(Supplementary table 2), was statistically associated with KSHV VL (OR=11.7 (95% CI: 1.4, 97.3), adj. 
p=0.08) occurring in eight patients (18%) with detectable VL and only one patient (2%) with 
undetectable VL. These results are summarised in Table 23. 
 
Table 23: Previously identified variants found to be associated with KSHV susceptibility, KS 
development or KSHV VL [34,35]. In addition to previous analyses (Supplementary table 1 and 
Supplementary table 2), previously identified variants were statistically tested for association with 
KSHV VL (not previously reported, Supplementary table 3). AA position and domain are according to 
the EPHA2 NCBI reference NP_004422.2 and named according to IUPAC standards. Ambiguous base 
notations represent heterozygous variants. P values are adjusted for multiple comparisons. SNVs that 
have a record on the dbSNP are indicated by their rsid numbers.  








2254 T>Y Pkinase-Tyr 700 Leu>Pro KS (0.04) Supplementary table 2 
2257 A>C Pkinase-Tyr 701 Asp>Ala KS (0.04) Supplementary table 2 
2688 G>S 
/rs765280326 
Pkinase-Tyr 845 Ala>Pro KS (0.16) Supplementary table 2 
2727 C>Y Pkinase-Tyr 858 Arg>Cys KSHV (0.028) Supplementary table 1 
2990 G>K SAM 945 Lys>Asn KS (0.021) 
KSHV VL (0.08) 
Supplementary table 2 
Supplementary table 3 
 
3.2.2. Aggregate association analysis of previously identified SNV data with KSHV susceptibility, KS 
development and KSHV VL 
When aggregate variation was considered within each of the functional domains of EPHA2, it was 
observed that having one or more SNV in the Pkinase-Tyr domain or SAM domain was associated with 
increased risk of KS (OR=4.9 (95% CI: 1.9, 12.4), p=0.001 and OR=13.8 (95% CI: 1.7, 111.6), p=0.014, 
respectively, Table 24A). Aggregate tests did not find significant associations between EPHA2 SNVs 
and KSHV status. However, there was a trend indicating that having one or more Pkinase-Tyr domain 




Table 24: Aggregate score associations for SNV domain with A) KS status, B) KSHV status [34] and C) 
KSHV VL status. By-gene tests were restricted to SNVs with MAF <5% and were stratified by the 
domain in which the SNV is located (Pkinase-Tyr, SAM, 3’ or 5’ UTR, Fn-3 or no domain). Each study 
participant and category was scored based on the total number of SNVs that participant carried and 
categorized as having any variants (≥1) versus no variants (0). Associations were assessed using logistic 

















Pkinase-Tyr 42 (84%) 8 (16%) 26 (52%) 24 (48%) 0.001 4.85 (1.9, 12.38) 
SAM 49 (98%) 1 (2%) 39 (78%) 11 (22%) 0.0137 13.82 (1.71, 111.6) 
3’UTR 47 (94%) 3 (6%) 41 (82%) 9 (18%) 0.0777 3.44 (0.87, 13.56) 
None 45 (90%) 5 (10%) 43 (86%) 7 (14%) 0.5399 1.47(0.43, 4.97) 
5’UTR 49 (98%) 1 (2%) 49 (98%) 1 (2%) 1 1 (0.06, 16.44) 













Pkinase-Tyr 41 (82%) 9 (18%) 68 (68%) 32 (32%) 0.0734 2.14 (0.93, 4.94) 
SAM 48 (96%) 2 (4%) 88 (88%) 12 (12%) 0.1307 3.27 (0.7, 15.23) 
3’UTR 46 (92%) 4 (8%) 88 (88%) 12 (12%) 0.4573 1.57 (0.48, 5.14) 
None 43 (86%) 7 (14%) 88 (88%) 12 (12%) 0.7287 0.84 (0.31, 2.28) 
5’UTR 49 (98%) 1 (2%) 98 (98%) 2 (2%) 1 1 (0.09, 11.3) 













SAM 52 (95%) 3 (5%) 36 (80%) 9 (20%) 0.036 4.33 (1.10, 17.12) 
Pkinase-Tyr 42 (76%) 13 (24%) 27 (60%) 18 (40%) 0.081 2.15 (0.91, 5.10) 
3’UTR 51 (93%) 4 (7%) 37 (82%) 8 (18%) 0.118 2.78 (0.77, 9.84) 
None 47 (86%) 8 (14%) 41 (91%) 4 (9%) 0.391 0.57 (0.16, 2.04) 
Fn-3 50 (91%) 5 (9%) 42 (93%) 3 (7%) 0.658 0.71 (0.16, 3.17) 




or more Pkinase-Tyr SNV compared to only 9 (18%) KSHV-negative controls (OR=2.1 (95% CI: 0.93, 
4.9), p=0.07, Table 24B). Aggregate variation in the SAM domain was associated with detectable VL 
among KSHV seropositive patients (OR=4.3 (95% CI: 1.1, 17.1), p=0.036, Table 24C). These aggregate 
analyses indicated that the Pkinase-Tyr and SAM domains were the region of interest on which we 
should focus our further analyses. 
 
3.2.3. Validation of previously identified SNVs in a newly recruited cohort 
Before further analysing the SNVs presented in Table 23 (n=150, 50 patients per group) in functional 
assays, we wanted to increase the power of the statistical analysis by increasing the sample size (see 
2.2.2.1). Sample size calculations based on our previous analyses (see 3.2.1) necessitated that we 
recruit n=100 patients per group (see 3.2.1.1). Due to cost constraints, it was necessary to limit this to 
regions of interest in EPHA2 which were identified by by-gene analysis of aggregate variation [332] 
stratified by EPHA2 domain (see 3.2.2, Table 24). We recruited a further 150 patients (an additional 
50 per group) into our defined patient groups (see 3.2.1.1) from the same clinics.  
3.2.3.1. Demographic and clinical information 
Clinical and demographic information concerning the above-mentioned participant groups (see 
3.2.1.1, total sample size n=300, with n=100 per group) is summarised in Table 25. All patients were 
HIV-infected as determined serologically prior to recruitment. Age did not differ significantly between 
the three groups: median age was 35, 30 and 37 for Groups 1, 2 and 3, respectively. Population group 
distribution was heavily skewed towards black Africans (94%) and included only a minority of mixed 
ancestry (5.4%) and Caucasian (0.7%) individuals which was consistent across the three patient 
groups. The final cohort of patients had a slight overrepresentation of males (52.3%) compared to 
females (47.7%) but that was particularly marked in KS patients (Group 1: males 65%, females 35%) 
which was different to KS-/KSHV+ Group 2 patients (p=0.007); and KSHV+ patients (Groups 1 and 2: 
males 57%, females 43%) vs. KSHV- Group 3 patients (p=0.05). Most recent CD4 counts were recorded 
at the time of patient recruitment. Median CD4 count was highest in Group 1 patients (KS+/KSHV+) 
and lowest in Group 3 patients (KS-/KSHV-) which is most likely a function of the proportion of patients 
on ART at time of recruitment: all KS+ patients (Group 1) were receiving ART or were started on ART 
on the day of enrolment, whereas a significantly smaller number of KS- patients (Groups 2 and 3) were 
on ART medication (p <0.0001) at the time of recruitment. CD4 count and ART status differed 
significantly between KS+/KSHV+ (Group 1) and KS-/KSHV+ (Group 2) patients and between KSHV+ 




between these groups, we considered them suitable for further candidate gene association analysis 
as these variables could not have an effect on the genetic level. Where statistical differences existed 
between groups tested in association analyses (Table 25 and Table 26), we performed logistic 
regression to control for differences in these variables.   
 
Table 25: Clinical and demographic information of the three patient groups making up the entire 
cohort (n=300). Variables are assessed according to comparisons used in statistical association testing: 
* indicates statistical significance (p<0.05) for KS association test comparisons (Group 1 vs. Group 2); 
# for KSHV association test comparisons (Group 1 + Group 2 vs. Group 3). Age and CD4 count were 
assessed by Mann Whitney test. Sex, population group and ART status were assessed by Chi square or 











Sample size 100 100 100 
Age, median in years (IQR)  35 (31–41) 40 (31–47) 37 (31–45) 
Sex, count (%) *# 
    Male  










Population group, number (%) 
    Black 
    Mixed ancestry 
    Caucasian 
















On ART at time of blood draw *# 
    Yes 










CD4 count, median in cells/µl (IQR) *# 181 (53–332) 114 (46–225) 81 (32–204) 
 
 
Table 26: Assessment of KSHV VL in patient groups. KSHV status (KSHV+/KSHV-) was determined by 











Detectable VL, number (%)  66 (66%)  17 (17%) 0 (0%) 
    VL, median in copies/106 cells      
    (Range) 
294 (25–119,760) 199 (25–104,664) NA 
Elevated VL, number (%) 





3.2.3.2. KSHV VL testing  
KSHV VL in the blood was assessed in all patients regardless of their KSHV serostatus by quantitative 
Taqman PCR (Table 26). We detected KSHV in the blood of 66 KS patients (Group 1), 47 of which had 
elevated VL (>100 copies/106 cells), and 17 KS-/KSHV+ patients, 12 of which had elevated levels. We 
did not detect KSHV in the blood of any of the KSHV- patients. Where detectable, VL varied over a 
large range with median VL of 294 copies/106 cells and 199 copies/106 cells in KS+ (Group 1) and KS-
/KSHV+ (Group 2) patients, respectively. Demographic and clinical variables between KSHV VL 
detectable and KSHV VL non-detectable groups did not differ with the exception of sex: there was a 
higher proportion of males (65%) in the VL detectable group compared to the VL non-detectable group 
(50%, p=0.044, Table 27).   
 
Table 27: Clinical and demographic information for patients with detectable VL vs. KSHV 
seropositive patients with non-detectable VL, irrespective of presence of KS (n=200). All participants 
were KSHV seropositive (Groups 1 and 2). * indicates statistical significance (p<0.05). Age and CD4 
count were assessed by Mann Whitney test. Sex, population group and ART status were assessed by 
Chi square or Fisher exact tests. IQR, inter-quartile range; ART, antiretroviral therapy. 
 
Detectable KSHV VL Non-detectable KSHV VL 
Sample size 83 117 
Age, median in years (IQR)  37 (32–42) 37 (31–45) 
Sex, count (%) * 
    Male  







Population group, number (%) 
    Black 
    Mixed ancestry 









On ART at time of blood draw  
    Yes 







CD4 count, median in cells/µl (IQR) 153 (55–274) 128 (44–281) 
 
3.2.3.3. Overview of identified EPHA2 variants in the Pkinase-Tyr and SAM domains  
Our original sequencing study of the entire EPHA2 coding DNA identified a total of 17 variants in the 
region of interest (Pkinase-Tyr and SAM domains, identified by aggregate analysis (see 3.2.2)) [34]. 
Additional sequencing of this region in a further 150 patients (falling into the three categories based 
on KS diagnosis and KSHV serology status as outlined above) resulted in a total of 18 variants, 9 of 
which were previously identified in our original cohort [34] and 9 of which were unique to this 




missense variants and the remaining 6 were synonymous; 14 were previously reported on the SNP 
database while the remaining 12 were novel. For the purposes of our further analysis, we pooled the 
original and validation cohorts to enhance the overall statistical power.  
3.2.3.4. Association testing for identified SNVs and KSHV susceptibility, KS development and 
detectable KSHV VL 
The statistical tests previously done on the original patient cohort (selected after removing SNVs based 
on linkage disequilibrium and with MAF <3%; Supplementary table 1, Supplementary table 2 and 
Supplementary table 3) were repeated including the same SNVs within the region of interest that were 
previously tested as the aim was to validate the previously identified variants. Four individual variants 
(Supplementary table 1) were assessed statistically for association with KSHV susceptibility by 
comparing their frequency in KSHV-positive patients (Group 1 and 2, n=200) to KSHV-negative patients 
(Group 3, n=100) resulting in the validation of the previously identified C>T variant at mRNA position 
2727, which was found to be significant in this larger cohort (OR=8.0 (95% CI: 1.9, 34.2), adj. p=0.004), 
occurring in 28 (14%) KSHV+ patients (21 in Group 1 and 7 in Group 2) and in only 2 (2%) KSHV- (Group 
3) patients (Table 28).  
Seven individual variants (Supplementary table 2, one variant from the original analysis of 
eight was outside of the region of interest) were assessed statistically for association with KS 
development by comparing occurrence in KS+/KSHV+ (Group 1, n=100) patients versus KS-/KSHV+ 
(Group 2, n=100) patients (Table 29). Variant C2727Y, associated with KSHV, was also found to be 
significantly associated with KS (OR=3.5 (95% CI: 1.4, 8.7), adj. p=0.0049). The variant at mRNA 
positions 2254 (which is in linkage disequilibrium with another SNV at mRNA position 2257), previously 
found to be significantly associated with KS, was validated in this larger cohort (OR undefined, adj. 
p=.049). The G>C variant at mRNA position 2688, which was found to be overrepresented in KS+ 
patients in our original analysis but not statistically significant, was found to be significantly associated 
with KS before adjustment for multiple comparisons but not after (OR undefined, adj. p=0.014, adj. 
p=0.098), occurring in 7 (7%) KS+ patients (Group 1) patients and no KS-negative (Group 2) patients. 
The mRNA variant at position 2990 was found to be significantly more frequent among KS+/KSHV+ 
(Group 1) patients (9%) compared to KS-/KSHV+ (Group 2) patients (0%) (OR undefined, adj. p=0.021).  
Similarly, seven variants (Supplementary table 3) were assessed in relation to detectable KSHV 
VL amongst KSHV-positive patients (Groups 1 and 2, n=200, Table 30). The G>T variant at mRNA 
position 2990, also associated with KS status, was significantly associated with KSHV VL (OR=12.4 (95% 
CI: 1.5, 100.9), adj. p=0.028) occurring in 8 patients (10%) with detectable VL and only 1 patient (1%) 




Table 28: Associations between EPHA2 SNVs and KSHV (n=300). 1P values adjusted for multiple 
comparisons. 2OR adjusted for logistic regression controlling for sex, ART status and CD4 count when 











OR (95% CI) 
Adjusted2 OR 
(95% CI) 
Log reg. P 
C2727Y 2 (2%) 28 (14%) 0.001 0.004 8.0 (1.9, 34.2) 6.7 (1.5, 29.2) 0.012 
G2990K 2 (2%) 9 (5%) 0.347 1 2.3 (0.5, 10.9) - - 
A2217M 2 (2%) 8 (4%) 0.505 1 2.0 (0.4, 9.7) - - 
T2047Y 7 (7%) 12 (6%) 0.803 1 0.8 (0.3, 2.2) - - 
 
Table 29: Associations between EPHA2 SNVs and KS (n=200). 1P values adjusted for multiple 
comparisons. 2OR adjusted for logistic regression controlling for sex, ART status and CD4 count when 
SNV is statistically significant in univariate analysis. Undefined OR is due to one group having 0 cases. 











OR (95% CI) 
Adjusted2 OR 
(95% CI) 
Log reg P 
G2990K 0 (0%) 9 (9%) 0.003 0.021 Undefined Undefined Undefined 
T2254Y 0 (0%) 8 (8%) 0.007 0.049 Undefined Undefined Undefined 
C2727Y 7 (7%) 21 (21%) 0.007 0.049 3.5 (1.4, 8.7) 2.7 (0.9, 7.7) 0.074 
G2688S 0 (0%) 7 (7%) 0.014 0.098 Undefined Undefined Undefined 
G2325S 1 (1%) 5 (5%) 0.212 1 5.2 (0.6, 45.4) - - 
A2217M 5 (5%) 3 (3%) 0.721 1 0.6 (0.1, 2.5) - - 
T2047Y 5 (5%) 7 (7%) 0.76 1 1.4 (0.4, 4.7) - - 
 
Table 30: Associations between EPHA2 SNVs and KSHV VL (n=200). 1P values adjusted for multiple 
comparisons. 2OR adjusted for logistic regression controlling for sex, ART status and CD4 count when 
















G2990K 1 (1%) 8 (10%) 0.004 0.028 12.4 (1.5, 100.9) 11.3 (1.4, 92.8) 0.024 
T2254Y 2 (2%) 6 (7%) 0.068 0.476 4.5 (0.9, 228) - - 
G2688S 2 (2%) 5 (6%) 0.129 0.903 3.7 (0.7, 19.5) - - 
C2727Y 13 (11%) 15 (18%) 0.214 1 1.8 (0.8, 3.9) - - 
G2325S 3 (3%) 3 (4%) 0.694 1 1.4 (0.3, 7.2) - - 
A2217M 5 (4%) 3 (4%) 1 1 0.8 (0.2, 3.6) - - 




To account for differences in demographic and clinical variables (Table 25, Table 27) that may 
affect our association analyses (see 3.2.3.1), logistic regression was employed for statistically 
significant SNVs controlling for the clinical and demographic variables that differed between the 
groups analysed. 
3.2.3.5. Validated variants taken forward for functional analysis 
SNVs that were found to be significantly associated or strongly tended toward KSHV serumpositivity 
(Table 28), KS (Table 29) and detectable KSHV VL (Table 30) were assessed in silico with the PolyPhen-
2 prediction tool generating a score on a scale of 0 (benign) to 1 (probably damaging) with regard to 
the impact of an AA substitution on the EPHA2 protein function based on sequence homology, 
conserved family annotations and PDB 3D structures [330]. These scores are reported in Table 31. As 
a control, a conservative missense C>G variant at mRNA position 915 found within our patient cohort 
but not statistically associated with KSHV, KS or KSHV VL, was included and its predicted AA change of 
leucine to valine at position 254 was allocated a ‘0’ score with an annotation of ‘benign’. Four non-
synonymous variants in the Pkinase-Tyr domain were annotated as ‘probably damaging’. The SAM 
variant, lysine to asparagine at AA position 945 (encoded by 2990 G>T), was predicted to be ‘possibly 
damaging’. These variants were selected for further functional assays. 
 
Table 31: Predicted functional consequences of validated variants found to be associated with KSHV 
susceptibility, KS development or KSHV VL [34,35]. AA position and domain are according to the 
EPHA2 NCBI reference NP_004422.2 and named according to IUPAC standards. Ambiguous base 














SDM1 915 C>S -6 EGF-like 254 Leu>Val Benign (0) - 
SDM2 2257 A>M Pkinase-Tyr 701 Asp>Ala 
Probably damaging 
(0.965) 
KS (0.0049, Table 29) 
SDM3 2254 T>Y Pkinase-Tyr 700 Leu>Pro 
Probably damaging 
(0.998) 
KS (0.0049, Table 29) 
SDM4 
2257 A>M 
+ 2254 T>Y 
Pkinase-Tyr 
701 Asp>Ala + 
700 Leu>Pro 
- KS (0.0049, Table 29) 
SDM5 2688 G>S Pkinase-Tyr 845 Ala>Pro 
Probably damaging 
(0.991) 
KS (0.098, Table 29) 
SDM6 2727 C>Y Pkinase-Tyr 858 Arg>Cys 
Probably damaging 
(0.932) 
KSHV (0.004, Table 28) 
KS (0.049, Table 29) 
SDM7 2990 G>K SAM 945 Lys>Asn 
Possibly damaging 
(0.903) 
KS (0.021, Table 29) 






3.3. Determining the consequences of EPHA2 variants on KS 
development and KSHV infection  
3.3.1. Establishing a relevant cell culture system to test the functional consequences of identified 
EPHA2 variants 
To assess the functional consequences of the EPHA2 variants found within our clinical study to be 
associated with KS, KSHV or KSHV VL (Table 31) which were predicted to have significant functional 
effects in silico, we aimed to establish a relevant cell culture system to study the impact of EPHA2 
variants on EPHA2 expression, EPHA2 steady state and KSHV-induced tyrosine phosphorylation and 
KSHV binding, internalisation and infection.  
3.3.1.1. Assessing the EPHA2 variants in an overexpression model 
Initially, we assessed endogenous EPHA2 protein expression in the HEK293 cell line, the conditionally 
immortalised human endothelial cell line HuARLT2 and a HuARLT2 cell line latently infected with 
rKSHV, HuARLT2.rKSHV, by Western blot (Figure 13). While HEK293 cells have a very low endogenous 
EPHA2 level, EPHA2 is expressed at significantly higher levels in HuARLT2 cells. Latent infection with 
rKSHV caused a slight decrease in EPHA2 expression in HuARLT2.rKSHV cells.  
As HEK293 cells have relatively low endogenous expression of EPHA2 and with the rationale 
that the identified EPHA2 variants may have a dominant effect on function, we initially tested the 
identified EPHA2 variants (Table 31) in an overexpression model by transiently transfecting pCMV3-
untagged negative control vector (EV), EPHA2.pCMV (WT) and its mutant EPHA2.pCMV constructs (1–
7) in HEK293 cells. EPHA2 variants were introduced to the pCMV3-EPHA2 (Sino Biological Inc) by SDM, 
confirmed by sequencing to assess the correct mutation was introduced and no undesired changes 
resulted in the entire EPHA2 coding region (Supplementary figure 9). All mutant EPHA2 constructs 
showed EPHA2 expression comparable to that of the transfected WT (Figure 14A) indicating that the 
introduction of the SNVs into the EPHA2 sequence did not affect expression. Transfected cells were 
infected with rKSHV at MOI 10 and GFP-positive cells were counted 48 h later showing that rKSHV 






Figure 13: Endogenous expression of EPHA2 in HEK293 cells and HuARLT2 endothelial cells. HEK293, 
HuARLT2, HuARLT2.rKSHV and A431 (positive control, provided) cell lysates separated by SDS PAGE 
were probed with an anti-EphA2 antibody (clone D7 05-480, 1:500) which detects EPHA2 (140kDa) 
and a nonspecific band between <100 kDa [347]. Probing for actin indicates equal loading.  
 
 
Figure 14: Transfection of WT-EPHA2 or SDM-generated mutant-EPHA2 constructs into HEK293 
cells. HEK293 cells were transfected with pCMV3 negative control vector (EV), EPHA2.pCMV (WT) or 
mutant EPHA2.pCMV constructs 1–7. A) Mutant EPHA2 constructs are expression capable as shown 
by Western blot using an anti-EPHA2 antibody (clone D7 05-480, 1:500). EPHA2 is detected at 140 kDa, 
the band <100 kDa is nonspecific [347]. Actin staining serves as the loading control. B) Transiently 
transfected mutant EPHA2 cells were infected with rKSHV and infection measured by counting GFP-






3.3.1.2. CRISPR/Cas9 knockout of endogenous EPHA2 in HuARLT2 (Hu) cells 
As we did not see any difference in the permissiveness to rKSHV infection upon transfection of the 
mutant EPHA2 constructs in HEK293 cells, we considered that the effects of our mutants may be 
overridden by endogenous EPHA2 expression. Moreover, we turned to HuARLT2 cells, an endothelial 
cell line, which is a more appropriate model system than HEK293 epithelial cells as KS develops from 
KSHV-infected endothelial cells. As HuARLT2 cells express endogenous EPHA2 at levels higher than 
HEK293 (Figure 13) which would likely interfere with our assays, we deleted the endogenous EPHA2 
gene using CRISPR/Cas9. HuARLT2 cells were transduced with CRISPR/Cas9 lentiviruses containing 
either scrambled gRNA (control) or one of three gRNAs designed to target EPHA2 (gRNA 1, 2 and 3). 
Western blot analysis showed that EPHA2 expression was abolished in the cells transduced with gRNA 
1 and gRNA 3 and markedly reduced in the cells transduced with gRNA 2 (Figure 15). We extracted 
genomic DNA from the cell lines transduced with scrambled gRNA and gRNA 1, 2 and 3 CRISPR/Cas9 
lentivirus and subjected it to PCR amplification using primers designed to amplify the respective gRNA 
target sites followed by sequencing to confirm that the CRISPR/Cas9 system has successfully disrupted 
the double-stranded DNA within the expected region (Table 32). As the CRISPR/Cas9 transduced cells 
were not clonal, it was expected to see overlapping peaks starting within the gRNA target site, as is 
the case for gRNA target regions 1 and 2, when compared to the sequences generated from the 
HuARLT2 cells transduced with scrambled gRNA. Hu-G3 shows the introduction of a stop codon (TAA) 
within the gRNA target site.   
We functionally compared our EPHA2 knockout cell lines, Hu-G1, Hu-G2 and Hu-G3 to two 
other EPHA2 knockout cell lines, SLK-KO (of epithelial origin) and LEC-KO (of LEC origin), kindly 
provided by Dr Frank Neipel (Institute of Clinical and Molecular Virology, University Clinic, Erlangen). 
As in the SLK-KO and the LEC-KO, Hu-G1 and Hu-G3 KOs had nil EPHA2 expression by Western blot 
(Figure 16A, top panel). Following infection with rKSHV at MOI 10 for 48 h, infection was largely 
reduced in Hu-G1 and Hu-G3 as well as in the SLK-KO and LEC-KO cell lines as assessed by LANA 
expression by Western blot (Figure 16A, bottom panel), fluorescent microscopy images of GFP+ cells 
(Figure 16B) and MFI of GFP as a measure of infection (Figure 16C). The greatest reduction in infection 
by GFP MFI between the Hu-KO cell lines compared to the control Hu-Scr cell line was seen in Hu-G3 
(38% of Hu-Scr) which is comparable to the infection rates of the SLK-KO (34% of SLK) and LEC-KO (38% 





Figure 15: CRISPR/Cas9 EPHA2 KO in HuARLT2 cells. EPHA2 expression by Western blot in HuARLT2 
cells and cells transduced with Scr.pLentiCRISPR v2 (Hu-Scr), G1.pLentiCRISPR v2 (Hu-G1) 
G2.pLentiCRISPR v2 (Hu-G2) or G3.pLentiCRISPR v2 (Hu-G3) using an anti-EPHA2 antibody (clone D7 
05-480, 1:500). EPHA2 is detected at 140 kDa, while the band <100 kDa is nonspecific [347]; probing 






Table 32: Sequencing of the CRISPR/Cas9 cut sites in transduced cell lines shows CRISPR/Cas9 
induced disruption of the double-stranded DNA. DNA extracted from Hu-Scr or Hu-KO cells was 
amplified and sequenced to visualise the respective gRNA cut sites (shaded in orange). The gRNA 1 
and gRNA 2 cut sites show nonspecific disruption in the non-clonal KO cells while the gRNA 3 cut site 
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Figure 16: Evaluation of HuARLT2-KO cell lines compared to other established EPHA2 KO cell lines, 
SLK and LEC. A, top panel) EPHA2 expression by Western blot in Hu-G1, Hu-G2, Hu-G3, SKL-KO and 
LEC-KO compared to their respective control cell lines using an anti-EPHA2 antibody (clone D7 05-480, 
1:500). EPHA2 is detected at 140 kDa, while the band <100 kDa is nonspecific [347]; probing for actin 
indicates equal loading. Subsequently to EPHA2 KO, WT and KO cells were infected with rKSHV as 
indicated at MOI 10 and assessed for rKSHV infection after 48 h by A, bottom panel) LANA Western 
blot (multiple bands between 100–250 kDa [348,349]) using a rat anti-LANA antibody (1:1,000), B) 











3.3.1.3. Reintroduction of synthetic EPHA2 into Hu-KO cells  
Following endogenous EPHA2 knockout, reintroduction of WT and mutant EPHA2 constructs required 
their transduction into the generated Hu-KO cells (see 3.3.1.2). As the CRISPR/Cas9 system targeting 
EPHA2 was active within these cells, it was necessary to design a synthetic EPHA2 expression construct 
which would be resistant to the EPHA2-targeted CRISPR/Cas9. Therefore, we designed a sEPHA2 with 
silent mutations of the gRNA 3 target site (GeneArt, Thermo Fisher Scientific). This sEPHA2 plasmid 
was cloned into the lentiviral vector plasmid, RRL.SF.newMCS.i2.Zeo.pre by BamHI and AgeI restriction 
enzyme digestion followed by ligation. Cloning success was evaluated by restriction enzyme analysis 
with two sets of restriction enzymes: BamHI/AgeI and BamHI/NdeI which were expected to yield 
fragments of 6564 bp/2937 bp and 9348 bp/1153 bp, respectively (see example Figure 17 in which 
clones 2, 4, 6 and 9 showed the expected fragment pattern on electrophoresis). Transduction of the 
selected clone (e.g. clone 9) into Hu-KO cells showed successful reintroduction of EPHA2 expression 
compared to the absence of EPHA2 in Hu-KO cells and the endogenous only expression in Hu-Scr cells 
(Figure 18, top panel) and further, rescued the phenotype of permissiveness to rKSHV infection as 
shown by Western blot to LANA (Figure 18, bottom panel). Transduced cells were selected with zeocin 
(400 µg/ml, determined by sensitivity experiment, Supplementary figure 13).  
 
 
Figure 17: Restriction enzyme analysis of sEPHA2 cloned into the RRL.SF.newMCS.i2.Zeo.pre 
lentiviral vector. An example agarose gel showing restriction enzyme analysis with BamHI and AgeI 
(RD1) and BamHI and NdeI (RD2). Expected fragments are uncut=10,501 bp (linear, nicked, circular), 
RD 1=6564 bp + 2937 bp; RD 2=9348 bp + 1153 bp. M=GeneRuler 1 kb DNA ladder (250-10,000 bp, 











Figure 18: Transduction of sEPHA2 into control and KO cells. Empty vector (RRL-EV) and/or sEPHA2 
(RRL-sEPHA2) were transduced into control cells (Hu-Scr, endogenous EPHA2 expression) or EPHA2-
KO cells (Hu-KO) as indicated and EPHA2 detected by Western blot using an anti-EPHA2 antibody 
(clone D7 05-480, 1:500, top panel, 140 kDa). Cells were infected with rKSHV at MOI 10 and 48 h later 
rKSHV infection as shown by LANA expression using a rat anti-LANA antibody (1:1,000, bottom panel, 

















In order to determine the optimal amount of lentivirus that would achieve EPHA2 expression 
comparable to that of endogenous expression in Hu-Scr cells, the sEPHA2 (WT) lentivirus was titrated 
in HuARLT2 cells. Flow cytometry with an EPHA2-specific antibody indicated that 40 µl lentivirus 
yielded EPHA2 expression comparable to Hu-Scr cells transduced with EV (Figure 19) and this amount 




Figure 19: Lentiviral titration compared to endogenous EPHA2 expression by flow cytometry. Shown 
are histograms of Alexa Fluor 647 fluorescence (indicating EPHA2 expression) after gating for live cells. 







3.3.1.4. Reintroduction of mutant sEPHA2 
After generating and cloning the sEPHA2 construct for stable transduction in EPHA2 knockout cell lines 
(see 3.3.1.3), SDM was performed on sEPHA2-RRL.SF.newMCS.i2.Zeo.pre to introduce the EPHA2 
variants identified in the association study (SDM1–7, Table 31) producing sEPHA2-SDM1–7-
RRL.SF.newMCS.i2.Zeo.pre lentiviral vectors. Additionally, a previously described serine 
phosphorylation deficient mutant (G2844A, SDM 8 [127]) was generated, producing the sEPHA2-
SDM8-RRL.SF.newMCS.i2.Zeo.pre lentiviral vector. As a control, SDM with primers identical to the WT 
sequence (i.e. inducing no mutagenesis) was performed to generate the 
sEPHA2-SDM.RRL.SF.newMCS.i2.Zeo.pre lentiviral vector. The 5’ LTR (Supplementary figure 10) and 3’ 
LTR (Supplementary figure 11) regions of the lentiviral vector plasmid were sequenced to ensure 
integrity, as well as the sEPHA2 coding sequence to ensure that the intended mutation was introduced 
without any undesired mutations (Supplementary figure 12). Control and mutant EPHA2 lentiviruses 
were transduced in equal amounts as previously determined by titration with sEPHA2-
RRL.SF.newMCS.i2.Zeo.pre (Figure 19), and flow cytometry detecting EPHA2 showed similar EPHA2 
expression levels in each transduced cell line, although, slight variations did exist (Figure 20). DNA was 
extracted from each of these cell lines for PCR-amplification and sequencing of the respective mutated 





Figure 20: EPHA2 WT and mutant 1–8 expression in transduced cell lines assessed by flow cytometry. 
Shown are histograms of Alexa Fluor 647 fluorescence (indicating EPHA2 expression) after gating for 






Figure 21: PCR and sequencing of transduced HuARLT2 cell lines. A) PCR with the indicated primer 
pairs amplified the genomic regions surrounding the introduced variants. M=GeneRuler 1 kb DNA 
ladder (250-10,000 bp, Thermo Fisher Scientific). B) Sequencing followed by alignment to the sEPHA2 
reference sequence allowed for visualisation of the introduced variants. The ambiguous base ‘Y’ refers 
to a C/T as the primer pair 652F/858R amplifies both endogenous and transduced EPHA2. Primer pairs 







3.3.2. Assessing engineered cell lines expressing WT or variant EPHA2 in functional analyses 
We next aimed to assess the functional consequences of the EPHA2 variants by expressing the WT or 
EPHA2 variants in the established, engineered EPHA2 KO cell lines. The expression levels of the 
introduced EPHA2 receptor proteins were at levels similar to endogenous expression (Figure 20). We 
assessed the cell viability (see 3.3.2.1), phosphorylation levels (see 3.3.2.2) and permissiveness to 
KSHV infection (see 3.3.2.3) in these cell lines.   
3.3.2.1. Baseline characteristics of engineered cell lines 
To ascertain if any of the transduced EPHA2 variants had an effect on the viability of the Hu-KO cells 
in which they were expressed, MTT assay was employed and cell viability was compared to that of Hu-
WT-SDM cells. Cell viability in culture was not affected by the presence of any of the variants 
compared to HU-WT-SDM (Figure 22). Cell morphology did not differ between engineered HuARLT2 




Figure 22: Cell viability does not differ between the engineered HuARLT2 cell lines expressing EPHA2 
variants. MTT assay was used to quantify the cell viability of each stably transduced cell line. Presented 
are pooled data from two independent experiments each done in triplicate. Hu-WT-SDM was set as 
100%. Means of each cell line were compared to that of Hu-WT-SDM by one-way ANOVA with post hoc 







3.3.2.2. Tyrosine phosphorylation of EPHA2  
Essential to its downstream functions, tyrosine phosphorylation of EPHA2 is a measure of receptor 
activation. We assessed if the expression of EPHA2 variants has an effect on steady state tyrosine 
phosphorylation levels or the ability of EPHA2 to be phosphorylated in response to rKSHV infection. 
Baseline tyrosine phosphorylation levels (Figure 23), assessed by ELISA, were significantly decreased 
in the Hu-SDM3 and Hu-SDM4 cells lines compared to Hu-WT-SDM. As Hu-SDM4 is a double mutant 
of Hu-SDM2 and Hu-SDM3 (Table 31), it follows that the effect is caused by the introduction of Hu-
SDM3. Conversely, Hu-SDM5 showed enhanced baseline phosphorylation levels compared to Hu-WT-
SDM. The remaining mutant cell lines did not show baseline phosphorylation levels that differed 
significantly from Hu-WT-SDM.  
We next assessed the phosphorylation response of our cell lines to rKSHV stimulation. We 
determined serum starvation conditions (0% FBS, 16 h) that did not affect cell viability (Figure 24A) 
while resulting in a significant decrease of phosphorylation levels from baseline (Figure 24B). We 
determined the rKSHV treatment time (20 min) that resulted in the greatest phosphorylation response 
empirically (Figure 24B). After serum starvation, cells were subjected to rKSHV (MOI 10) for 20 min at 
37°C, before they were lysed and assayed for tyrosine phosphorylation levels. Differences in 
Figure 23: Baseline EPHA2 tyrosine phosphorylation levels among cell lines. EPHA2 tyrosine 
phosphorylation was measured by ELISA quantified by absorbance at 450nm (with reference 
absorbance at 560nm subtracted). Presented are pooled data from two independent experiments 
as a percentage of Hu-WT-SDM, which was set 100%. ** p<0.01 by one-way ANOVA with post hoc 





phosphorylation between untreated and rKSHV-treated cells per cell line were compared between the 
Hu-WT-SDM cells and the mutant cell lines, none of which showed significant differences in rKSHV-
induced phosphorylation (Figure 24C).   
 
 
Figure 24: EPHA2 tyrosine phosphorylation response to rKSHV. A) Hu-WT-SDM cell viability when 
subjected to serum starvation over time was assessed by MTT assay. * p<0.05 was determined in a 
paired two-tailed t test. B) Time course assessing EPHA2 tyrosine phosphorylation in response to 
rKSHV. One-way ANOVA with post hoc Dunnett’s multiple comparison test was done. *<0.05, **<0.01. 
C) EPHA2 tyrosine phosphorylation response to rKSHV in cell lines. Data from two independent 
experiments were pooled. The difference between untreated and rKSHV-treated cell lines per cell line 
was compared by one-way ANOVA between Hu-WT-SDM cells and mutant cell lines and no significant 





3.3.2.3. Recombinant KSHV binding, internalisation and infection 
To assess the early stages of rKSHV infection (binding and internalisation), we established an 
experimental workflow making use of rKSHV-expressed RFP (from the viral PAN promotor) as a proxy 
for lytic virus that would represent these stages of infection: infection with rKHSV at 4°C for 1 h 
followed by two washes with PBS allowed virus to bind but not internalise (Figure 25A, top panel) 
while infection with rKSHV at 37°C for 1 h followed by washing resulted in bound and internalised virus 
(Figure 25A, bottom panel). These same procedures using virus added to empty wells (media but no 
plated cells) showed no visible RFP background (data not shown). 
Binding did not differ significantly between the cell lines although Hu-SDM8 appeared to have 
slightly decreased rKSHV binding (Figure 25B). Similarly, binding and internalisation did not differ 
significantly between cell lines but Hu-SDM5 and Hu-SDM8 had the lowest read-out while Hu-SDM3, 
Hu-SDM4 and Hu-SDM6 appeared to have increased levels of bound/internalised virus (Figure 25B). 
To measure the levels of rKSHV infection, we relied upon the expression of GFP as a proxy as 
rKSHV expresses GFP from the cellular EF-1α promoter. GFP-positive cells quantified by flow 
cytometry were normalised to EPHA2 expression, due to slight differences in the transduced cell lines 
(Figure 20). One-way Welch ANOVA with post hoc simple contrast testing with p-values adjusted for 
multiple comparison (p<0.00625 was considered significant) revealed that there was a significant 
reduction in percentage of GFP-positive cells (normalised to EPHA2 expression) of Hu-SDM3 (28.8 ± 
2.8%, p=0.001, 45% of Hu-WT-SDM) and Hu-SDM4 (30.9 ± 9.9%; p=0.002, 49% of Hu-WT-SDM) 
compared to Hu-WT-SDM cells (63.6 ± 7.6%). In context, KO of EPHA2 resulted in reduced but not 
completely abolished rKSHV infection (38% of Hu-Scr, Figure 16C). The remaining cell lines did not 










Figure 25: Early stages of rKSHV infection are not affected in engineered HuARLT2 cell lines 
expressing EPHA2 variants. A) Fluorescent microscopy was used to validate the conditions of 
internalisation and binding assays by visualising rKSHV expressed RFP (from the KSHV lytic gene PAN 
promoter) in Hu-WT-SDM cells using the experimental conditions for “binding” or “binding and 
internalisation” assays. B) RFP fluorescence was quantified in a fluorometer for each cell line subjected 
to rKSHV infection under the indicated conditions. Presented are pooled data from two independent 
experiments each in triplicate. Means were statistically compared by one-way ANOVA which indicated 








Figure 26: rKSHV infection of mutant-EPHA2 cell lines. Infection was measured by quantifying GFP-
positive cells by flow cytometry. Presented are pooled data from two independent experiments each 
done in duplicate normalised to EPHA2 expression. One-way Welch ANOVA with simple contrasts 
revealed significant differences in the means of WT and SDM3 and 4, respectively when adjusting the 






While AIDS-related deaths have declined from 1.7 million in 2004 to 770,000 in 2018, due to global 
scale-up of ART, the majority of these (61%) occurred in SSA (see 1.1.1) [40]. With the HIV 
epidemiologic shift away from infectious mortality, cancer is an increasingly important cause of 
morbidity and mortality among people living with HIV globally [350]. KS is one of the most common 
AIDS-defining cancers worldwide and there is a particularly high burden of KS disease in SSA (see 1.3.1) 
[1]. The γ-herpesvirus, KSHV is a necessary but insufficient etiological agent of not only KS, but also 
PEL, KSHV-MCD [2], and the recently described KICS [6,8]. KSHV remains one of the most important 
oncogenic viruses in HIV-infected individuals and KSHV-associated malignancies are of particular 
public health significance in South Africa, and much of SSA, where both KSHV (30–50%) and HIV 
seroprevalence (20%) are elevated (see 1.3). Furthermore, incidence and mortality for KSHV-
associated B-cell neoplasms are not well defined and therefore likely underreported. Earlier detection 
of progression from asymptomatic KSHV infection to tumour progression may mitigate KSHV-
associated disease mortality.  
 Symptoms of KSHV-driven malignancies mimic TB which, despite increasing numbers of HIV-
infected South Africans receiving ART, remains the leading cause of mortality [5]. However, a 
significant proportion of patients treated for TB have microbiologically unconfirmed diagnoses (see 
1.1.2) [55]. Although KSHV and HIV co-infection are known to be particularly prevalent in SSA, the 
contribution of KSHV and KICS to patient mortality has not been studied in this context. We 
hypothesized that KSHV infection has a currently unrecognized contribution to mortality in critically ill 
HIV-positive South African patients who present with a suspected diagnosis of TB. 
Further, genetic variants in receptors for KSHV entry and/or KSHV-driven oncogenesis are 
likely to have functional consequences for pathogenicity but have not been investigated in detail (see 
1.6.5). We, therefore, set out to identify sequence variants in EPHA2, being both an entry receptor for 
KSHV [36,117] as well as being upregulated in various tumours, including KS [36,37,307–309], in South 
African HIV-infected patients, and to assess the functional consequences of identified EPHA2 variants 





4.1. KSHV contributes to mortality in HIV-infected South African 
patients presenting with suspected but unconfirmed TB 
4.1.1. Uncontrolled KSHV infection is an important contributor to mortality 
South Africa has one of the highest global rates of both HIV and TB [351]. Not surprisingly, the 
exceptionally high burden of HIV-associated TB in South Africa causes misdiagnosis or delay of 
diagnosis of diseases mimicking TB symptoms (see 1.1.2). Utilising a large, well-characterized patient 
cohort of 682 HIV-positive critically ill patients admitted to Khayelitsha Day Hospital, South Africa, 
investigated for TB, and followed for 12 weeks to ascertain vital status, we retrospectively evaluated 
KSHV as a contributor to mortality. The patient cohort had a median CD4 count of 62 cells/μl (range: 
0–526) and overall, 22% died during the 12-week follow-up period (Table 14). 
In support of the reported disproportionately high KSHV seroprevalence in SSA (30–50%) 
compared to world prevalence rates (<10%), which has not changed significantly since the onset of 
the HIV/AIDS epidemic [70], we found 30.7% (95% CI, 27–34%) KSHV seroprevalence in patients 
presenting in Cape Town (Table 14 and Figure 6), which is in agreement with other South African 
estimates of 30–42% from Soweto, Johannesburg, and Kwa-Zulu Natal [67,72,73,75,98]. This is the 
first assessment of KSHV seroprevalence in the Western Cape Province of South Africa.  
Of KSHV-seropositive patients, 18.8% (5.8% of the entire cohort, Table 14) showed detectable 
virus in the blood, suggestive of poor immune control of KSHV [75]. Focusing on the 33 (5%) patients 
with elevated (>100 copies/106 cells) KSHV VL, we found no higher mortality within the context of 
either the entire patient cohort or the cohort with confirmed TB (Table 17 and Figure 7), suggesting 
that KSHV does not play a significant role in potentiating TB mortality. However, 23.5% of patients had 
neither microbiologically proven TB nor alternative co-infection (Table 14) and, in these patients, 
elevated PBMC-associated KSHV VL was associated with 6.5-times higher odds (p=0.023, adjusted 
OR=6.5 [95% CI: 1.3, 32.4], Table 18) of mortality when adjusted for age, sex, CD4 cell count, and ART 
status. Moreover, KSHV VL was significantly higher in microbiologically unconfirmed TB patients who 
died compared to those who survived at 12-weeks follow-up (p=0.0094, Figure 7). In contrast, KSHV 
seropositivity alone was not associated with mortality (Table 19), suggesting that it is the burden of 
lytic KSHV activity that contributes to the observed association [5,8,75]. Similarly, elevated plasma 
KSHV VL, a marker of circulating tumour DNA, has been noted as a risk factor for death in people with 




Although a strong association between elevated KSHV VL and mortality among 
microbiologically unconfirmed TB patients was identified, additional factors such as KSHV-associated 
malignancies, functional immune dysregulation (cytokine syndromes), or other pathological processes 
(e.g. co-infections or other cancers) likely also contribute to death. However, given the association of 
mortality with lytically active KSHV in critically ill HIV-infected patients with suspected but not 
microbiologically identified TB, KSHV lytic reactivation is an important consideration in the differential 
diagnosis of HIV-infected patients with symptoms of TB. This study is the first systematic evaluation 
of KSHV in HIV-infected patients presenting to hospital as TB in South Africa. Evaluation of KSHV VL in 
this setting is warranted to identify those patients with treatable KSHV-associated diseases [25].  
 
4.1.2. KICS criteria and KSHV VL as biomarkers for treatable, underdiagnosed KSHV-related diseases 
We further investigated whether the application of KICS criteria (Table 2 [6]) identified patients with 
high mortality compared to the remainder of the group and found six “possible KICS” patients, of 
whom five died, with a median survival of eleven days (Table 21). Only one of the six “possible KICS” 
patients had a pathological examination of a lymph node biopsy. While this is a limitation of our study, 
it is representative of a wider lack of diagnostic capacity in the African setting [17]. This was performed 
following death and demonstrated KSHV-MCD (Figure 12). Another had possible pulmonary KS 
diagnosed based on chest radiograph and confirmed cutaneous KS. It is possible that the other 
patients also had undiagnosed KSHV-associated diseases such as KS or MCD. Our data support that 
patients meeting KICS criteria should be evaluated for KSHV-MCD, visceral KS, or PEL, particularly in 
settings with oncology capacity to manage these treatable KSHV-associated malignancies. Although 
we have not definitively established that “possible KICS” patients died of KSHV-associated 
malignancies in most cases, elevated KSHV VL in the peripheral blood represents a parameter 
significantly associated with mortality (see 4.1). Although “possible KICS” patients had elevated IL-6 
and CRP, these were not distinguishing features compared to other patients with TB or other critical 
illnesses (Table 22 and Figure 9), likely due to these patients all being critically ill with cytokine 
activation and systemic inflammation due to causes not investigated here. This suggests that CRP is a 
less useful screening tool than KSHV VL in this population in contrast to other contexts, such as the 
original series of KICS patients described in the USA who were distinguished by elevated CRP [6].  
Previous studies identified PBMC-associated KSHV VL to be significantly higher in KSHV-MCD 
and KICS compared to KS patients without clinical evidence of IL-6 syndromes [25]. Similarly, in our 




undiagnosed KSHV-MCD which was only confirmed in one patient at autopsy), followed by patients 
with KS (Figure 10) who were further distinguishable from KSHV seropositive patients without KS by 
elevated KSHV VL (Table 26).   
KSHV viremia, rather than KSHV seropositivity, has been reported as a marker of advanced 
HIV disease [75]. Similarly, in our study, high KSHV VL and low CD4 count but not KSHV seropositivity 
were associated with mortality (Table 17). The majority of the patient cohort was anaemic (Table 14), 
which was significantly associated with elevated antibody levels to the KSHV lytic antigen K8.1 in KSHV-
seropositive microbiologically unconfirmed TB patients but not with ORF73 (Table 20). This is 
consistent with results from a recent study from Uganda, which reported a link between elevated 
KSHV serumpositivity and anaemia in the setting of malaria [136]. A South African study found that 
patients with detectable KSHV viremia presented with anaemia and WHO Stage-3 or -4 defining 
conditions, indicative of advanced HIV disease, compared to those with undetectable KSHV VL [75]. 
Additional studies are required to evaluate this association. For example, anaemia may lead to 
reactivation of KSHV through relative tissue hypoxia [136], or KSHV reactivation may lead to anaemia 
or chronic inflammation mediated through IL-6. 
In selected patients, KSHV VL has a strong prognostic value (Table 18). KSHV VL has been linked 
to an increased risk of KSHV-associated malignancies [352]; therefore, HIV-infected patients with 
elevated KSHV VL should be evaluated for KSHV-related malignancies. Therapeutic options exist for 
KS, KSHV-MCD and PEL and are most effective when employed earlier in the course of disease. In 
contrast, advanced KS and untreated KSHV-MCD, KICS and PEL have high mortality. Broccolo et al. 
[246] found KSHV VL to be strongly associated with progression of active KS. Jary et al. [25] have 
proposed that KSHV VL in whole blood is a useful biomarker to identify and monitor KSHV-associated 
diseases. Our data is consistent with this proposal and corroborates studies that propose that KSHV 
VL has a place in clinical practice to identify at-risk patients and monitor progression of KSHV-
associated disease [25,26,246,353]. 
To our knowledge, this is the first systematic evaluation of KICS in South Africa and has 
implications for other countries with high prevalence of HIV/KSHV co-infection. In resource-limited 
countries of SSA, correct and timely diagnoses of KSHV-MCD, PEL and KICS are often impossible. A 
study from Uganda reports that three in every ten patients with HIV-associated lymphoma had a 
possible misdiagnosis and were treated for TB before a final diagnosis of lymphoma was made, and 
our data suggest that KSHV-associated diseases are important to include in the differential diagnosis 
of suspected TB [15]. In Malawi, and most of SSA, KSHV-MCD diagnoses is hindered by lack of 




missed or late diagnoses and high mortality [26]. A better understanding of the spectrum of KSHV-
associated diseases in the SSA context will require improved laboratory capacity. In fact, through our 
study, KSHV VL testing in a laboratory setting was established for the first time in South Africa.  
In summary, elevated KSHV VL should be considered as an important pathology in HIV-
infected patients investigated for TB, and that for those meeting other KICS criteria, evaluation for 
KSHV VL should be considered. Increasing implementation of PCR-based TB diagnostics should 
facilitate more rapid TB diagnostic workup, thereby facilitating selection of patients for whom KSHV 
testing may be indicated. In addition to lung cancer and lymphoma, a number of other pathologies 
should form part of the differential diagnosis of TB in HIV-positive patients including Pneumocystis 
jirovecii pneumonia, cytomegalovirus virus infection, Cryptococcosis and KS [58,354] or dysregulated 
lytic KSHV replication [62], to mitigate inappropriate TB treatment and delayed diagnosis. Appropriate 
implementation of KSHV VL testing offers a potential approach to improving diagnostic accuracy in 
HIV-infected populations with competing infectious co-morbidities. Testing for KSHV is not yet 
included in routine diagnostic workup but seems to claim a significant proportion of disease burden 
in high HIV/TB settings. We propose that a simple inexpensive test for KSHV VL could be developed 
and utilised in routine clinical practice throughout SSA in combination with evaluation of KICS 
symptoms and laboratory abnormalities to serve as an effective surveillance tool for KSHV-associated 
diseases in high-risk HIV-infected populations.  
 
4.2. EPHA2 variants are associated with KSHV infection, KSHV VL and 
KS development in HIV-positive patients 
KSHV infection is necessary but insufficient for the development of KS and other KSHV-associated 
pathologies. Factors, such as HIV infection and related immunosuppression precipitate oncogenesis 
(see 1.6.3). Regardless of the mechanism by which HIV co-infection promotes development of KSHV-
associated pathologies, not all co-infected individuals develop a disease, pointing to potential 
underlying risk related to genetic features in KSHV and/or host factors (see 1.5). Furthermore, the 
geographical epidemiology of KSHV seroprevalence and population-specific incidence of KS outside 
the setting of HIV supports a role for genetic factors (see 1.3.1.1) [28–30,248]. The EPHA2 tyrosine 
kinase receptor is a promising candidate for investigation being both one of the key host receptors 
utilised by KSHV for endothelial cell entry and intracellular trafficking and implicated in oncogenesis 
(see 1.6.4 and 1.6.3). Therefore, this protein potentially acts on two levels: susceptibility to KSHV 




To elucidate a potential underlying genetic predisposition due to variants in the EPHA2 
protein, we assessed aggregate variation across the entire EPHA2 coding region in a retrospective 
candidate gene association analysis with KSHV infectivity, KS prevalence and detectable KSHV VL in 
HIV-positive patients. As AIDS-related KS is by far the most common form of the KSHV-associated 
malignancies and particularly affects individuals in SSA due to the HIV/AIDS epidemic [67], we 
restricted the recruitment of patients to HIV-infected individuals within this geographical region, 
presenting at hospitals in the Western Cape province of South Africa. Since mother-to-child 
transmission via saliva is thought to be the primary route of KSHV transmission [9], the extent of later 
sexual transmission that could be confounding for KSHV infection is thought to be minimal [355,356]. 
All patients recruited to this study were adults between 19 and 73 years of age (Interquartile Range: 
31–44, Table 25); therefore, it can be assumed that their exposure to and infection with KSHV has 
been concluded at the time of recruitment. 
A number of variants previously reported on the dbSNP were identified in the entire cohort 
studied (n=300, 14 out of the total 26 in the region of interest including the Pkinase-Tyr and SAM 
domains), with a further 12 novel variants identified in our South African cohort. Large genotyping 
studies, such as the 1000 Genomes project and ExAc, have contributed the majority of the genetic 
variations stored in the dbSNP [49,50]. While these studies include African populations from Nigeria, 
Kenya, Gambia and Sierra Leone and people with African ancestry residing in America and the 
Caribbean, Southern African populations are not well represented [59]. It is thought that Southern 
African populations specifically have exceptionally high levels of genetic diversity due partly to the 
selective pressure of long term exposure to infectious diseases and due to the lack of founder effects 
present in populations that have migrated [357,358]. Therefore, it is expected that we would see 
variants in our South African population that have not yet been recorded in the dbSNP. 
Based on EPHA2 variants identified in the original cohort [34], we have now validated variants 
within the functionally important Pkinase-Tyr and SAM domains through additional recruitment of a 
validation cohort. The aim of this validation was to increase the power of our study not to detect rarer 
variants but to improve confidence in the established associations. Specifically, 2254 T>C (in linkage 
disequilibrium with 2257 A>C), 2727 C>T and 2688 G>C located in the Pkinase-Tyr domain and 2990 
G>T located in the SAM domain were associated with KS (Table 29). The Pkinase-Tyr variant 2727 C>T 
was further associated with KSHV prevalence (Table 28). The SAM domain variant 2990 G>T was also 
associated with having detectable KSHV VL in the blood (Table 30). Each of these variants was 
predicted in silico to result in damaging changes on the protein level when assessed for functional 
impact using the PolyPhen-2 prediction tool (Table 31). Interestingly, in our original analysis of the 




was found in EPHA2′s ligand binding domain [34,35], supporting the hypothesis of the importance of 
the intracellular Pkinase-Tyr and SAM domains for KSHV-driven KS development (Table 24).  
There were several limitations to our EPHA2 association analysis. Selection biases may have 
overestimated the association of EPHA2 variants as only HIV-positive patients presenting at clinics 
were recruited. The overall number of recruited patients in our original cohort was rather small 
(n=150), restricting the power of the analysis to only be able to detect associations of SNVs with MAF 
>3% with KS development and/or KSHV infection. Not all variants detected in the region of interest in 
the original cohort were detected in the validation cohort and vice versa (Supplementary table 4). The 
original cohort of KS (Group 1) patients was recruited from December 2014–February 2016 and the 
validation cohort of KS patients between February 2017–February 2018. The major difference 
between the original and validation KS cohorts was CD4 count which was significantly lower in the 
validation cohort recruited later in time (original: 238 cells/µl (IQR: 122-340.5); validation: 124 cells/µl 
(IQR: 40–232), p=0.024). This may represent KS patients with alternate risk factors or susceptibility 
markers. Nevertheless, the reported EPHA2 variants were statistically validated and deemed 
appropriate for further functional analysis.    
 
4.3. EPHA2 variants have variable functional consequences on KS 
development and KSHV infection 
Based on the possible functional impact of the identified EPHA2 variants (see 4.2), we proceeded to 
functional assessment of six EPHA2 variants associated with KS status, elevated KSHV VL and/or KSHV 
infection in our clinical cohort. We also included one benign variant (negative control) and one serine 
phosphorylation deficient variant expected to be nonpermissive to rKSHV infection [127]. These 
variant EPHA2s, generated by SDM and expressed in endogenous EPHA2-KO endothelial cells were 
compared to cells expressing the WT EPHA2 (that underwent the process of SDM with benign primers, 
see 3.3.1.4).  
All EPHA2 WT and variant cell lines were expression capable (Figure 14), expressed EPHA2 on 
the cell membrane (Figure 20) and were able to bind rKSHV (Figure 25), indicating that any functional 
changes to the structure of the receptor that may result from the introduction of the variants did not 
affect the extracellular domain which was to be expected as the variants were located only in the 
intracellular Pkinase-Tyr and SAM domains. Moreover, neither cell viability (Figure 22) nor 




this basis, functional characterisation of these mutants with regard to tyrosine phosphorylation and 
KSHV infection could be performed.  
 
4.3.1. EPHA2 variants with altered tyrosine phosphorylation may affect KS development 
Initially, we assessed tyrosine phosphorylation at steady state (Figure 23) and in response to rKSHV 
stimulation (Figure 24) as an indication for the receptor variants’ involvement in KS development. 
Expectedly, there was no effect on the benign variant or the serine phosphorylation deficient variant 
SDM8 (p.Ser897Asn) nor SDM7 (p.Lys945Asn), located in the SAM domain. Of the remaining five 
variants (all affecting the Pkinase-Tyr domain), we saw a marked decrease in tyrosine phosphorylation 
in SDM3 (p.Leu700Pro) and SDM4 (double mutant: p.Leu700Pro+p.Asp701Ala) and enhanced tyrosine 
phosphorylation in SDM5 (p.Ala845Pro). We did not see an effect on phosphorylation of SDM2 
(p.Asp701Ala) alone, indicating that while it is in linkage disequilibrium with p.Leu700Pro, it is 
p.Leu700Pro, not p.Asp701Ala, that confers the functional consequence seen in the double variant, 
p.Leu700Pro+p.Asp701Ala. There was also no effect on tyrosine phosphorylation in SDM6 
(p.Arg858Cys) indicating that its association with KS is likely due to an alternative mechanism, 
potentially mediated through KSHV infection (as p.Arg858Cys is also associated with KSHV infection, 
see 4.3.2). Interestingly, KSHV infection did not change the mutants’ baseline phosphorylation pattern 
(Figure 24). The effect of KSHV on EPHA2 phosphorylation as a proxy for receptor activation may be 
very subtle as there is likely a surplus of EPHA2 on the cell surface and in reserve inside the cell and 
additionally, KSHV can bind to other receptors [36,115].  
The tyrosine phosphorylation deficient variant, p.Leu700Pro (which inferred the same effect 
in the double mutant p.Leu700Pro+p.Asp701Ala) was originally identified as being associated with KS 
development in our clinical cohort (Table 29). Since the tumorigenic signature of EPHA2 is defined by 
low levels of tyrosine phosphorylation, particularly at Tyr772, via abrogation of the canonical pathway 
and ligand-independent high levels of serine phosphorylation, particularly Ser897, via the 
noncanonical pathway (Figure 5) [283,313,314], it is likely that p.Leu700Pro promotes KS development 
via abrogation of the ligand- and kinase-dependent canonical EPHA2 pathway. The absence of tyrosine 
phosphorylation (particularly Tyr772) may lead to increased cell proliferation, migration, survival and 
adhesion thereby promoting oncogenesis [274,283,285,310–314]. Similar to our result, Tan et al. [310] 
identified an EPHA2 variant in the Pkinase-Tyr domain, p.Ala859Asp in genomic DNA extracted from 
MPM tissue which exhibited low levels of tyrosine phosphorylation and subsequently enhanced 




simulations identified atomic level impairment caused by the p.Ala859Asp mutant which reduced 
affinity of adenosine triphosphate (ATP) for the mutant, inhibiting phosphoryl transfer [310]. The 
mechanism by which p.Leu700Pro facilitates the lack of tyrosine phosphorylation of EPHA2 is yet to 
be elucidated but we speculate that this is either due to impairment of ATP-mediated cross-
phosphorylation or enhancement of phosphatase activity. It is well established that EPHA2 is 
dephosphorylated at tyrosine residues via the phosphatase LMWPTP in cancer cells [313,315].  
In contrast to p.Leu700Pro (SDM3), the variant p.Ala845Pro (SDM5) also associated with KS in 
our clinical cohort (before adjustment for multiple comparisons, Table 29) showed enhanced tyrosine 
phosphorylation at baseline (Figure 23). This effect of p.Ala845Pro on KS development might be 
mediated through the ligand-independent noncanonical pathway of EPHA2-mediated oncogenesis 
(Figure 5) which is driven predominately but not exclusively by Ser897 phosphorylation 
[285,286,311,316,317]. While we cannot comment of serine phosphorylation levels in this study, 
simultaneously increased tyrosine phosphorylation has been shown to play a kinase-independent role 
in the noncanonical pathway in addition to its role in the canonical pathway of EPHA2 [283]. Enhanced 
tyrosine phosphorylation has also been shown in breast cancer cell lines, potentially preceding a 
molecular switch to a highly metastatic cell programme when EPHA2 is likely dephosphorylated [283]. 
Faoro et al. [286] similarly identified an EPHA2 mutation (p.Gly391Arg) in lung SCC cell lines and 
patient samples that caused constitutive activation of EPHA2 indicated by enhanced baseline tyrosine 
phosphorylation and thereby promoted invasiveness, adhesion and survival.  
Taken together, assessment of the tyrosine phosphorylation statuses of the engineered cells 
expressing EPHA2 variants yielded insight into the oncogenic potential of alteration to EPHA2. 
Particularly the mutant p.Leu700Pro alone and the double mutant p.Leu700Pro+p.Asp701Ala showed 
strongly impaired tyrosine phosphorylation which may have significant functional consequences for 
oncogenesis. 
  
4.3.2. EPHA2 alterations with impact on KSHV infection 
Having determined the effect of the EPHA2 variants on EPHA2 tyrosine phosphorylation as an 
indication of oncogenic potential, we next examined the direct role of EPHA2 in KSHV infection, a 
necessary precursor of KS development. EPHA2 is a major entry receptor for KSHV in endothelial cells, 
however, it is dispensable for viral attachment which is facilitated mainly by HSPGs and integrins 
(Figure 2) [36,105,122]. EPHA2 tyrosine phosphorylation and activation is necessary for KSHV entry 




use of purified rKSHV that expresses RFP from the lytic PAN promoter (indicating early stages of 
infection: binding and internalisation) and GFP from the cellular EF-1α promoter (indicating infection). 
As expected, binding of rKSHV was unaffected by the expression of EPHA2 variants (Figure 25A), likely 
mediated mostly through cellular HSPGs and integrins. Internalisation of rKSHV did not differ strikingly 
between EPHA2 variants compared to WT either but internalization was slightly reduced for 
p.Ala845Pro (SDM5) and p.Ser897Asn (SDM8) although this was not statistically significant (Figure 
25B). Significantly decreased infection levels were evident in p.Leu700Pro (SDM3) and double mutant 
p.Leu700Pro+p.Asp701Ala (SDM4) and slightly increased infection levels were evident in p.Lys945Asn 
(SDM7, Figure 26). Surprisingly, p.Arg858Cys (SDM6), associated with KSHV infection in our clinical 
cohort (Table 28), did not have an effect on rKSHV infection into endothelial cells nor did the serine 
phosphorylation deficient variant (p.Ser897Asn) which had been reported to be deficient for KSHV 
infection in 293T cells [127].   
While binding and internalisation of rKSHV to p.Leu700Pro (SDM3) and 
p.Leu700Pro+p.Asp701Ala (SDM4) expressing cells was unaffected (Figure 25), both cell lines showed 
decreased rKSHV infection (Figure 26) suggestive of non-infectious internalisation. This may be due to 
impaired trafficking of rKSHV to the nucleus requiring signalling pathways activated by the tyrosine 
phosphorylation sites [36] deficient in p.Leu700Pro and p.Leu700Pro+p.Asp701Ala. Alternatively, 
rKSHV may make use of other non-optimal receptors for internalisation to compensate for impaired 
EPHA2 activation, perhaps resulting in endocytosis into a non-permissive subcellular compartment. 
Even so, the remaining low level of infection suggests that other receptors besides EPHA2 such as 
EPHA4 or EPHA5 (as has been described in epithelial cells [119]) and EPHA5 or EPHA7 (as has been 
described in BJAB cells [120]) likely play a role in infectious internalisation, as has been previously 
suggested [107,115,116,119,120]. Both p.Leu700Pro and p.Leu700Pro+p.Asp701Ala were found to be 
associated with KS development in our clinical cohort (Table 29), but not with KSHV infection. While 
the EPHA2 variant p.Leu700Pro likely promotes oncogenesis through lack of EPHA2 phosphorylation 
and subsequent removal of EPHA2’s canonical tumour suppressor effects (see 4.3.1), it is unclear if or 
how reduced rKSHV infection contributes to increased risk of KS development. We hypothesize that 
the lower infection rate in the presence of the tyrosine phosphorylation deficient EPHA2 might favour 
non-cytopathic latent infection and thereby less immune activation and chronic, ongoing KSHV 
infection, favouring carcinogenesis over time. Regardless of how KSHV infection is facilitated in the 
presence of this tyrosine phosphorylation deficient EPHA2, the effect of p.Leu700Pro is primarily on 
downstream oncogenesis subsequent to KSHV infection as the effect on phosphorylation is far more 
striking than the effect on KSHV infection. A similar dual role of a genetic marker was described for 




reportedly decreases the risk of KSHV viremia, while simultaneously increasing the risk of KS 
development [257]. Alternatively, the interaction with HIV may play a more important role in the 
presence of a tyrosine phosphorylation deficient EPHA2. There is evidence that the molecular 
mechanisms of KS development in AIDS-KS and Classic KS differ: a SNP in the IL-8 promoter region 
(A-251T, rs4073) was found to decrease the risk of developing AIDS-KS in an HIV-positive, KSHV-
infected cohort [251] but was overrepresented in a cohort of Classic KS patients [252]. However, given 
the complexity of the system, it is unlikely that the explanation can be narrowed down to a single gene 
effect.  
Of the other variants, only p.Lys945Asn (SDM7) expression resulted in increased 
permissiveness to rKSHV infection (although this was not a drastic enough difference to be statistically 
significant (Figure 26)), although rKSHV binding and internalisation were unaffected. The variant 
p.Lys945Asn is located in the EPHA2 cytoplasmic SAM protein interaction domain and was found to 
be overrepresented among patients with KS and patients with detectable VL with “possibly damaging 
effects” (Table 29 and Table 30). The SAM domain binds adaptor proteins to mediate the downstream 
signalling events triggered by EPHA2 activation and has been reported to play a role in activation itself 
[287–289]. Although likely attenuated by other effects in our cell culture system, we can speculate 
that p.Lys945Asn may contribute to oncogenesis or enhanced KSHV lytic activity by altering the 
coupling of the SAM to an adaptor protein and regulating downstream signalling pathways. It is 
interesting that p.Lys945Asn is overrepresented in males (8/11) in our clinical cohort and of these, the 
majority (7/8) had KS and detectable (6/8), even elevated (5/8), VL. Indeed, males were 
overrepresented in our KS cohort as well as in patients with detectable KSHV VL compared to KSHV-
positive patients in which VL is undetectable. This supports numerous previous reports 
[67,127,185,359] that KS risk is higher in males and gives further evidence suggesting that the 
mechanism for this is mediated via increased KSHV lytic activity (detectable VL in the blood) [360]. 
Wang et al. [127] suggest that this disproportionate risk of KS in males is due to the interaction of 
EPHA2 with the AR which leads to increased phosphorylation on Ser897, essential for KSHV infection 
in epithelial cells. AR recruits Src and RSK1 to mediate this phosphorylation of EPHA2 and thereby 
enhance rKSHV infection [127]. This suggests a potential role for p.Lys945Asn EPHA2 SAM domain 
variant in potentiating the interaction of EPHA2 with AR to enhance KSHV lytic activity.  
Interestingly, p.Ser897Asn (SDM8), reported to abolish rKSHV infection in 293T cells due to a 
loss of function mutation of Ser897 to Asn [127], showed reduced binding and internalisation although 
the reduced levels were not statistically significant (Figure 25). While this mutant was included as a 
KSHV-infection deficient control, we observed infection rates of HuARLT2 cells expressing p.Ser897Asn 




endothelial cells (such as HuARLT2) via actin-dependent macropinocytosis [129] and epithelial cells 
(such as 293T) via clathrin-independent endocytosis [131] (Table 1). Ser897 phosphorylation may 
mediate endocytosis of KSHV in epithelial cells but not affect macropinocytosis of KSHV in endothelial 
cells. 
In contrast to p.Leu700Pro (SDM3) and p.Leu700Pro+p.Asp701Ala (SDM4), p.Ala845Pro 
(SDM5) did not have an effect on rKSHV internalisation (Figure 25) or permissiveness to rKSHV 
infection (Figure 26) despite enhanced tyrosine phosphorylation levels (Figure 23). This is fitting as 
p.Ala845Pro was found to be associated with KS development (although not after adjustment for 
multiple comparisons, Table 29), but not KSHV infection in our clinical cohort.  
The variant p.Arg858Cys (SDM6) was identified as being associated with increased 
susceptibility to KSHV infection (Table 28) and KS development (Table 29) in the clinical cohort. 
However, in functional assays, we did not see an effect of this variant on rKSHV infection (Figure 26). 
This suggests that the effect of this EPHA2 variant is tempered in our cell culture system. Other EPH 
receptors have previously been shown to compensate for EPHA2 in overexpression systems 
[107,115,116,120] and similarly, in our model, EPHA2 KO reduced rKSHV infection (38% of Hu-Scr, 
Figure 16C) but did not abolish it, indicating that other receptors are used in compensation. We can 
speculate that p.Arg858Cys mediates KSHV infection through a mechanism not accounted for in our 
cell culture system. 
  In summary, EPHA2 variants identified within a clinical KS cohort were assessed in functional 
assays to determine their effects in mediating KS oncogenesis and KSHV infection. While the molecular 
mechanisms of some variants are yet to be elucidated, alteration in EPHA2, in particular p.Leu700Pro 
expressed alone or as a double mutant (p.Leu700Pro+p.Asp701Ala), was linked to functional 
outcomes validating their association with KS in the clinical association study. This may have 
consequences for clinical applications and our data supports this claim by linking EPHA2 variants found 
in KS patients with functional roles in oncogenesis which may have implications for treatment 
strategies. EPHA2 inhibitors have been suggested as a potential therapeutic avenue for further 
investigation in patients who have EPHA2 alterations resulting in increased oncogenic potential [310]. 
Studies have shown that EPHA2 mutants can confer differing drug sensitivities. For example, the 
p.Gly391Arg EPHA2 mutant showed increased sensitivity to rapamycin [286,310] and low dose 
resistance to cisplatin [310] in human lung epithelial cells while the p.Ala859Asp mutant showed 
resistance to doxazosin in HEK293 cells [310]. EPHA2 variants in patients with KS warrant further 




However, care should be taken when validating isolated aspects on genetic variations in a cell 
culture model as it cannot capture the complexities of an in vivo biochemical system. We established 
a cell culture model that relevantly approximated the scenario of KSHV infection of endothelial cells, 
the major cell type in KS, however, it is likely that our model does not recapitulate the complex in vivo 
scenario or that an alternative cell line may produce different effects. The signalling pathways 
mediating internalisation and infection after receptor activation are complex to interpret and further 
investigation is warranted. The markedly differing profile of phosphorylation, internalisation and 
infection seen in p.Leu700Pro (and the double mutant p.Leu700Pro+p.Asp701Ala) versus p.Ala845Pro, 
which both are associated with KS in our clinical cohort, indicated that these variants affect different 
downstream pathways to enact their function. To further elucidate the functional effects of EPHA2 
variants, our future work will delve into the signalling pathways induced by rKSHV binding to EPHA2 
and address the trafficking and fusion kinetics of EPHA2 entry through analysis of transport of capsids 
to the nucleus or co-localization of capsid with cellular markers. Moreover, investigation of the serine 
phosphorylation status of the variant-expressing EPHA2 cell lines will better inform the oncogenic 
potential of the cellular microenvironment.  
Taken together, these results link the discovery of EPHA2 variants associated with KS 






The data presented in this thesis provide important and novel findings on 1) the contribution of KSHV 
to mortality in HIV-infected South African patients presenting with suspected but unconfirmed TB, 
and 2) the genetic contribution of EPHA2 receptor variants to KSHV susceptibility, KSHV lytic activity 
and KS development, respectively.  
While KS has been well established as an independent risk factor for death in HIV-infected 
people, a broader and more heterogeneous range of KSHV-associated diseases, particularly in the SSA 
context of high HIV burden, likely plays a yet under-recognized role in HIV-associated morbidity and 
mortality. We have shown that elevated KSHV VL is an important cause of mortality in HIV-infected 
patients presenting with suspected TB that is not microbiologically confirmed. Furthermore, KICS 
criteria identified patients at high risk of mortality with untreated or undiagnosed KSHV-associated 
malignancies. This study is an important first step in describing the clinical spectrum and epidemiology 
of KSHV infection and KICS in the South African context. Based on these data, including tests for KSHV 
lytic reactivation in the diagnostic work-up of hospitalised HIV-infected patients (once TB has been 
ruled out) should be considered. KSHV-associated malignancies are treatable, and earlier diagnosis 
may improve survival. Inclusion of KSHV VL testing in screening, diagnostic and prognostic pathways 
may lead to earlier detection and improved monitoring of KSHV-associated diseases, and ultimately 
more timely and targeted therapeutic intervention in resource-limited countries.  
On a genetic level, we identified sequence variants in the host EPHA2 tyrosine kinase receptor 
pivotal to KSHV infection and KS oncogenesis that are significantly associated with KS development, 
KSHV infection and KSHV lytic activity in the blood and validated their functional impact for KSHV 
infection and/or KS oncogenesis on a molecular level. Importantly, the Pkinase-Tyr domain variant 
p.Leu700Pro, associated with KS development, was found to be deficient in tyrosine phosphorylation, 
known to promote oncogenesis, and resulted in non-infectious internalisation of viral particles likely 
due to impairment of rKSHV trafficking which may interact with downstream signalling pathways and 
immune-modulatory molecules to further promote carcinogenesis. This study provides the basis for 
further investigation into the impact and functional relevance of EPHA2 variants on KSHV infection, 
lytic activity and KS development which may have clinical implications in terms of identifying KSHV-
infected patients who are susceptible to KS development and highlighting EPHA2 as a novel biomarker 
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7.1. Solution recipes 
1X PBS-Tween  
8 g NaCl 
0.2 g KCl 
1.44 g Na2HPO4 
0.24 g KH2PO4 
2 ml Tween 20 
pH 7.2, in 1 l dH2O 
 
1X SDS sample buffer  
62.5 mM Tris-HCl pH 6.8  
2% (w/v) SDS  
10% (v/v) Glycerol  
50 mM Dithiothreitol  
0.01% (v/v) β-Mercaptoethanol  
0.01% (w/v) Bromophenol Blue 
 
10X Electrophoresis buffer 
72 g Glycine 
19 g Trisaminomethane 
Up to 500 ml with dH2O  
 
1X Running buffer 
50 ml 10X Electrophoresis buffer 
10 ml 10% SDS 
Up to 500 ml dH2O 
 
1X Transfer buffer 
700 ml dH2O 
200 ml Methanol 





Luria Bertani Agar 
2.5 g Tryptone 
1.25 g Yeast extract 
2.5 g NaCl 
3.75 g Agar 
 
Luria Bertani media  
5 g Tryptone  
2.5 g Yeast extract  
2.5 g NaCl  
Up to 500 ml dH2O 
 
50X Tris-acetate-EDTA (TAE) 
242 g Trisaminomethane 
57.1 ml Glacial Acetic Acid 
100 ml 0.5M EDTA (pH 8.0) 
In 1 l dH2O 
 
KSHV ELISA Assay buffer 
2.5% Bovine Serum Albumin (BSA) 
2.5% Normal Donor Goat serum (Equitech-Bio cat# SG-0500) 
0.005% Tween 20 
0.005% Triton X-100 (3%) 
In 1X PBS 
 
KSHV ELISA Wash buffer 
0.05% Tween 20 
In 1X PBS 
 








0.1 g MTT 
20 ml 1X PBS 
 
Flow cytometry block solution  
5% BSA  
5 mM EDTA  
2 mM NaN3 
In 1X PBS 
 
Flow cytometry wash solution  
0.5% BSA  
5 mM EDTA  
2 mM NaN3 
In 1X PBS  
 
Flow cytometry fix solution  
0.5% BSA 
1% Formaldehyde  






7.2. Plasmid maps 
 
 
Supplementary figure 1: pLentiCRISPR v2 plasmid map. The plasmid was engineered to carry gRNA 



























Supplementary figure 5: Cloned sEPHA2-RRL-SF.newMCS.i2.Zeo.pre vector. A) Plasmid map showing 
the position of SDM primers indicated as red features; sequencing primers indicated in purple. B) 
Alignment indicating the silent mutations made to the gRNA 3 binding site in sEPHA2 compared to 




































7.3. Additional material  
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SDM_4_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - - 793
SDM_5_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800
SDM_6_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800
SDM_7_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800
EPHA2 CDS G A A G G T G G A G G A T G C C T G C C A G G C C T G C T C G C C T G G A T T T T T T A A G T T T G A G G C A T C T G A G A G C C C C T G C T T G G A G T G C C C T G A G C A C A C G C T G C C A T C C 900
EPHA2_plasmid_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 745
SDM_1_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 731
SDM_2_T7_promoter . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 822
SDM_3_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 788
SDM_4_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 793
SDM_5_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 842
SDM_6_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900
SDM_7_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - - - 880
EPHA2 CDS C C T G A G G G T G C C A C C T C C T G C G A G T G T G A G G A A G G C T T C T T C C G G G C A C C T C A G G A C C C A G C G T C G A T G C C T T G C A C A C G A C C C C C C T C C G C C C C A C A C T 1000
EPHA2_plasmid_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 745
SDM_1_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 731
SDM_2_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 822
SDM_3_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 788
SDM_4_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 793
SDM_5_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 842
SDM_6_T7_promoter . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 932
SDM_7_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 880
EPHA2 CDS A C C T C A C A G C C G T G G G C A T G G G T G C C A A G G T G G A G C T G C G C T G G A C G C C C C C T C A G G A C A G C G G G G G C C G C G A G G A C A T T G T C T A C A G C G T C A C C T G C G A 1100
EPHA2_plasmid_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 745
SDM_1_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 731
SDM_2_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 822
SDM_3_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 788
SDM_4_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 793
SDM_5_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 842
SDM_6_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 932
SDM_7_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 880
EPHA2 CDS A C A G T G C T G G C C C G A G T C T G G G G A A T G C G G G C C G T G T G A G G C C A G T G T G C G C T A C T C G G A G C C T C C T C A C G G A C T G A C C C G C A C C A G T G T G A C A G T G A G C 1200
EPHA2_plasmid_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 745
SDM_1_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 731
SDM_2_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 822
SDM_3_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 788
SDM_4_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 793
SDM_5_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 842
SDM_7_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500
SDM_7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS G C G C T C C G T G G G G C C G C T C A C C C G C A A A G G C T T C T A C C T G G C C T T C C A G G A T A T C G G T G C C T G T G T G G C G C T G C T C T C C G T C C G T G T C T A C T A C A A G A A G 6
EPHA plasmid_T7_promoter 6
EPHA2 plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
1 6
1 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
2 6
2 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600
SDM_3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4 T7_promoter
4 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
5
5 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
6
6 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
7
652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~ - - - - - - - - - - - - - - - - - - - - - - 4
1
1 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2
2
2 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3
3
3 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2
SDM_4_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 700
SDM_4_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . 4
SDM_5 T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
5 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . 3
6 7
6 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . 2
7 . . . . . . . 00
7 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS C C G T G G T G C C A C C G G G G G G T G A A G A G C C C C G T A T G C A C T G T G C A G T G G A T G G C G A G T G G C T G G T G C C C A T T G G G C A G T G C C T G T G C C A G G C A G G C T A C G A
EPHA2_plasmid_T7_promoter . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 745
_plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
SDM_1 T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
4 - - - - - - - 793
4 652F . . . . . . . . . . . . . . . . . . . . 104
SDM_5_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800
SDM_5_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
SDM_6 T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800
6 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
7 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
EPHA2 CDS G A A G G T G G A G G A T G C C T G C C A G G C C T G C T C G C C T G G A T T T T T T A A G T T T G A G G C A T C T G A G A G C C C C T G C T T G G A G T G C C C T G A G C A C A C G C T G C C A T C C 900
EPHA2 plasmid_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 745
EPHA2 plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
SDM_1_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 731
SDM_1_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
SDM_ T7_promoter . . . . . . . . . . . . . . . . . . . . . . 822
2 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
3 788
652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
4 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
5 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
SDM_6_T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900
SDM_6_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
SDM_7 T7_promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880
7 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
EPHA2 CDS C C T G A G G G T G C C A C C T C C T G C G A G T G T G A G G A A G G C T T C T T C C G G G C A C C T C A G G A C C C A G C G T C G A T G C C T T G C A C A C G A C C C C C C T C C G C C C C A C A C T 1000
EPHA2 plasmid_T7_promoter 45
EPHA2 plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304
SDM_1_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 731
SDM_1_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
SDM_2_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 822
SDM_2_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
SDM_3_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 788
SDM_3_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
SDM_4_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 793
SDM_4_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304
SDM_5_T7_promoter - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 842
EPHA2 CDS A T G G A G C T C C A G G C A G C C C G C G C C T G C T T C G C C C T G C T G T G G G G C T G T G C G C T G G C C G C G G C C G C G G C G G C G C A G G G C A A G G A A G T G G T A C T G C T G G A C T 100
EPHA2_plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
1 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
2 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
3 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
4 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
5 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
6 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EP 2 C S T T G C T C A G C T G A G G A G C T C G G C T G G C T C A C A C A C C C T A T G G C A A A G G G T G G G A C C T G A T G C A A A C A T C A T G A A T G A C A T G C C G A T C T A C A T G T A 2
EPHA plas id_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
S _1_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
S _2_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SD _3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SD _4_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS C T C C G T G T G C A A C G T G A T G T C T G G C G A C C A G G A C A A C T G G C T C C G C A C C A A C T G G G T G T A C C G A G G A G A G G C T G A G C G T A T C T T C A T T G A G C T C A A G T T T 300
EPHA2_plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS A C T G T A C G T G A C T G C A A C A G C T T C C C T G G T G G C G C C A G C T C C T G C A A G G A G A C T T T C A A C C T C T A C T A T G C C G A G T C G G A C C T G G A C T A C G G C A C C A A C T 400
EPHA2_plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SD _2_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SD _3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
S _4_ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
5 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA  CDS T C C A G A A G C G C C T G T T C A C C A A G A T T G A C A C C A T T G C G C C C G A T G A G A T C A C C G T C A G C A G C G A C T T C G A G G C A C G C C A C G T G A A G C T G A A C G T G G A G G A 5
EPHA2 plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
1 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
3 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
4 652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SD _7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS G C G C T C C G T G G G G C C G C T C A C C C G C A A A G G C T T C T A C C T G G C C T T C C A G G A T A T C G G T G C C T G T G T G G C G C T G C T C T C C G T C C G T G T C T A C T A C A A G A A G 600
EPHA2_plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS T G C C C C G A G C T G C T G C A G G G C C T G G C C C A C T T C C C T G A G A C C A T C G C C G G C T C T G A T G C A C C T T C C C T G G C C A C T G T G G C C G G C A C C T G T G T G G A C C A T G 700
EPHA2_plasmid_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~ - - - - - - - - - - - - - - - - - - - - - - . . . . 4
SDM_1_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . 2
SDM_2_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . 3
SDM_3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . 2
SDM_4_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . 4
SD _5_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . 3
SD _6_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . 2
SD _7_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS C C G T G G T G C C A C C G G G G G G T G A A G A G C C C C G T A T G C A C T G T G C A G T G G A T G G C G A G T G G C T G G T G C C C A T T G G G C A G T G C C T G T G C C A G G C A G G C T A C G A 8 0
EPHA2 plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2
4 652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
6_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
EP 2 C S G A A G G T G A G A T G C C T G C C A G G C C T G C T C G C C T G A T T T T T T A A T T T G A G G C A T C T G A G A G C C C C T G C T T G G A G T G C C C T G A G C A C A C G C T G C C A T C C 900
EPHA2 plas id_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
S _1_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
SD _2_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
SDM_3_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
SDM_4_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
SDM_5_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
SDM_6_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
SDM_7_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
EPHA2 CDS C C T G A G G G T G C C A C C T C C T G C G A G T G T G A G G A A G G C T T C T T C C G G G C A C C T C A G G A C C C A G C G T C G A T G C C T T G C A C A C G A C C C C C C T C C G C C C C A C A C T 1000
EPHA2_plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304
SDM_1_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
SDM_2_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
SDM_3_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
SDM_4_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304
SDM_5_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
SDM_6_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
SDM_7_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250
EPHA2 CDS A C C T C A C A G C C G T G G G C A T G G G T G C C A A G G T G G A G C T G C G C T G G A C G C C C C C T C A G G A C A G C G G G G G C C G C G A G G A C A T T G T C T A C A G C G T C A C C T G C G A 1100
EPHA2_plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404
SDM_1_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
SDM_2_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403
SDM_3_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
SDM_4_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404
SDM_5_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403
SDM_6_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
SDM_7_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 350
EPHA2 CDS A C A G T G C T G G C C C G A G T C T G G G G A A T G C G G G C C G T G T G A G G C C A G T G T G C G C T A C T C G G A G C C T C C T C A C G G A C T G A C C C G C A C C A G T G T G A C A G T G A G C 1200
EPHA2_plasmid_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504
SDM_1_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502
SDM_2_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503
SDM_3_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502
SDM_4_652F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504
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EPHA2_plasmid_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1038
EPHA2_plasmid_1296F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 962
SDM_1_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 837
SDM_1_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 909
SDM_1_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 798
SDM_2_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 959
SDM_2_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 913
SDM_2_1296F . . . . . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 871
SDM_3_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 838
SDM_3_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 942
SDM_3_1296F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 962
SDM_4_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 840
SDM_4_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 813
SDM_4_1296F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 903
SDM_5_652F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 922









Supplementary figure 9: Sequence alignment of pCMV-EPHA2 WT and SDM vectors showing the 
integrity of the entire EPHA2 cDNA. 
 
 
SDM_7_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS A C C T C A C A G C C G T G G G C A T G G G T G C C A A G G T G G A G C T G C G C T G G A C G C C C C C T C A G G A C A G C G G G G G C C G C G A G G A C A T T G T C T A C A G C G T C A C C T G C G A 1100
EPHA2_plasmid_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2_plasmid_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS A C A G T G C T G G C C C G A G T C T G G G G A A T G C G G G C C G T G T G A G G C C A G T G T G C G C T A C T C G G A G C C T C C T C A C G G A C T G A C C C G C A C C A G T G T G A C A G T G A G C 1200
EPHA2_plasmid_2184R - - - - - - - - - - - - - - - - - - - - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
EPHA2_plasmid_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . . . . . . . . 11
SDM_3_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_5_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_6_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS G A C C T G G A G C C C C A C A T G A A C T A C A C C T T C A C C G T G G A G G C C C G C A A T G G C G T C T C A G G C C T G G T A A C C A G C C G C A G C T T C C G T A C T G C C A G T G T C A G C A 1300
EPHA2_plasmid_2184R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
EPHA2_plasmid_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_1_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
SDM_1_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_2_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
SDM_2_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_3_2184R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
SDM_3_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_4_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
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SDM_6_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
SDM_7_2184R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
SDM_7_1296F - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
EPHA2 CDS T C A A C C A G A C A G A G C C C C C C A A G G T G A G G C T G G A G G G C C G C A G C A C C A C C T C G C T T A G C G T C T C C T G G A G C A T C C C C C C G C C G C A G C A G A G C C G A G T G T G 1400
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Supplementary figure 12: EPHA2 cDNA of lentiviral vectors showing SDM-introduced mutants while 














Supplementary table 1: Associations between EPHA2 SNVs and KSHV (n=150). Ambiguous base 
notations represent heterozygous variants. N=number of cases. 
SNV KSHV- N(%) KSHV+ N(%) OR (95% CI) p adj. p MAF 
C2727Y 2 (4%) 21 (21%) 6.4 (1.4, 28.4) 0.007 0.028 0.077 
G2990K 2 (4%) 9 (9%) 2.4 (0.5, 11.4) 0.338 1 0.037 
A2217M 2 (4%) 7 (7%) 1.8 (0.4, 9) 0.718 1 0.03 
T2047Y 7 (14%) 12 (12%) 0.8 (0.3, 2.3) 0.796 1 0.067 
 
Supplementary table 2: Associations between EPHA2 SNVs and KS (n=100). Ambiguous base 
notations represent heterozygous variants. N=number of cases. 
SNV KS- N(%) KS+ N(%) OR (95% CI) p adj. p MAF 
G2990K 0 (0%) 9 (18%) 1.2 (1.1, 1.4) 0.003 0.021 0.045 
T2254Y 0 (0%) 8 (16%) 1.2 (1.1, 1.3) 0.006 0.04 0.04 
G2688S 0 (0%) 6 (12%) 1.1 (1.0, 1.3) 0.027 0.16 0.03 
C2727Y 7 (14%) 14 (28%) 2.4 (0.9, 6.6) 0.14 0.698 0.105 
G2325S 1 (2%) 5 (10%) 5.4 (0.6, 48.4) 0.204 0.818 0.03 
A2217M 5 (10%) 2 (4%) 0.4 (0.1, 2) 0.436 1 0.035 
C915S 5 (10%) 2 (4%) 0.4 (0.1, 2) 0.436 1 0.035 
T2047Y 5 (10%) 7 (14%) 1.5 (0.4, 5) 0.76 1 0.065 
 
Supplementary table 3: EPHA2 SNVs and KSHV VL (n=100). Ambiguous base notations represent 
heterozygous variants. N=number of cases. 
SNV KSHV VL- N(%) KSHV VL+ N(%) OR (95% CI) P adj. p MAF 
G2990K 1 (2%) 8 (18%) 11.7 (1.4, 97.3) 0.01 0.08 0.05 
T2254Y 2 (4%) 6 (13%) 4.1 (0.8, 21.3) 0.135 1 0.04 
G2688S 2 (4%) 4 (9%) 2.6 (0.5, 14.8) 0.404 1 0.03 
C2727Y 10 (18%) 11 (24%) 1.5 (0.6, 3.8) 0.469 1 0.11 
G2325S 3 (6%) 3 (7%) 1.2 (0.2, 6.5) 1 1 0.03 
A2217M 5 (9%) 2 (4%) 0.6 (0.1, 2.5) 0.453 1 0.04 
T2047Y 8 (15%) 4 (9%) 0.6 (0.2, 2.0) 0.539 1 0.06 







Supplementary table 4: Overview of identified EPHA2 variants in the Pkinase-Tyr and SAM domains in the entire cohort. Variants found to be statistically 












Validation Group 1 
(KS+/KSHV+) 
Validation Group 2 
(KS-/KSHV+) 
Validation Group 3 
(KS-/KSHV-) 
2217 A>C (Het) 2 KS025, KS029 5 MB005, MB007, 
MB008, MB009, 
MB011 































2269 G>A (Het) 0  0  0  8 KS052, KS053, 
KS058, KS059, 
KS060, KS062, 
KS063, KS064  
0  0  
2325 G>C (Het) 5 KS014, KS015, KS-
017, KS018, KS-
021 






2369 T>G (Het) 0   0   0   2 KS052, KS053 1 TB112 0 
 




2397 A>C (Het) 3 KS013, KS014, KS-
015 






2412 T>A (Het) 0  0  0  4 KS087, KS091, 
KS092, KS094 




2472 A>C (Het) 3 KS020, KS045, KS-
046 

















2507 C>T (Het) 1 KS001 0   2 TB044, MB032 2 KS078, KS091 3 TB172, TB178, 
TB192 
2 TB89, TB149 
2529 C>A (Het) 1 KS028 0   1 TB052 0 
 
2 TB154, TB203  1 TB082 
2603 G>C (Het) 1 KS001 0   0   0  1 TB112  2 TB083, TB118 
2627 C>T (Het) 3 KS013, KS042, KS-
043 
3 TB070, TB086, 
MB011 
5 TB052, TB069, 
TB011, TB102, 
MB001 
3 KS056, KS067, 
KS069, KS091 
4 TB042, TB097, 
TB192, TB223,  
0  




5 TB033, TB070, TB-
088, TB105, 
MB026 




7 KS053, KS061, 
KS070, KS072, 
KS073, KS097*  





TB254, TB259,  











2688 G>C (Het) 6 KS015, KS016, KS-
017, KS018, KS-
020, KS021 
0   0   1 KS086 0 
 
1 TB136 
2709 C>A (Het) 0   0   0   3 KS051, KS058, 
KS059 
0  0  



















2737 G>C (Het) 0   0   0   5 KS063, KS060, 
KS059, KS058, 
KS052 
1 TB128 2 TB136, TB056 
2859 G>A (Het) 3 KS014, KS046, KS-
050 
















































  C>T (Hom) 2 KS005, KS047 4 TB028, TB033, 
MB020, MB027 





















Supplementary figure 13: Zeocin sensitivity curve for HuARLT2 cells. Cells were treated with the 
indicated concentrations of zeocin for 10 days at which point live cells were counted after staining 





Supplementary figure 14: Secondary antibody titration with a mixture of Hu-KO (EPHA2-negative) 
and Hu-WT (EPHA2-positive) cells. 
AF647 AF647 AF647 AF647 









































Supplementary figure 15: Compensation study to detect GFP and AF647. Detection of GFP does not 
change when co-stained for AF647 and vice versa therefore compensation is not required when using 
the two channels.  
 
 
 
 
 
 
 
 
